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De novo design of foldamers is a current challenge in chemical biology. Overcoming it is essential 
in order to expand the protein toolbox and access “bionic proteins”, i.e. proteins comprising non-
natural segments, with enhanced biological functions. Since the α-helix represents the most 
abundant motif in protein structure, α-helix mimicry is a key approach to building foldamers and 
a stepping-stone towards generating bionic proteins. The current state-of-the-art on bottom-up 
foldamer synthesis for the mimicry of α-helices is described in Chapter 1. 
The Wilson Group focuses on aromatic oligoamide proteomimetics for the modulation of protein-
protein interactions (PPIs) involved in known diseases. The work presented in this thesis aimed 
at building a basis towards the elaboration of bionic proteins, by proving that such proteomimetics 
can be used to build novel 3-dimensional constructs. 
3-O-alkylated and N-alkylated oligobenzamides with complementary charged side-chains were 
designed to produce self-assembling foldamers. The synthesis and conformational study of 
dimers and trimers is reported in Chapter 2. This forms the groundwork towards generating 
proteomimetic-based coiled coils. 
An Affimer is a non-antibody-based scaffold, used in tandem with phage display. A small library 
of biotinylated N-alkylated proteomimetic inhibitors of p53/hDM2 was screened against an 
Affimer library. The investigation of the Affimer/foldamer interactions are reported in Chapter 3.  
Taken together, these results demonstrate that aromatic oligoamides are suitable building blocks 
for producing non-natural peptide sequences in order to generate bionic proteins.  
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 Expanding Nature’s toolbox 
Nature uses a stunning array of nanoscale molecular level architectures to carry out complex tasks 
essential to life, e.g. maintenance of the cytoskeleton, catalysis and cell signalling.1 Biopolymers 
such as proteins are able to perform those intricate tasks because they self-organise to present 
distinct functional motifs through a precise 3-dimensional orientation that is defined by their 
primary structure alone. The whole human proteome, so far estimated to over 18,000 different 
proteins,2 is the product of the combination of only 20 different amino acids.1 A long-term 
challenge in chemical and synthetic biology is to question whether this astonishing complexity is 
confined to primary sequences of α-amino acids, or whether the protein toolbox can be expanded 
to other building blocks.3 Building “bionic” proteins, i.e. proteins with non-natural constituents, 
is a stepping stone towards generating elaborate bio-macromolecules with enhanced or orthogonal 
properties.4 
 The α-helix 
The 3-dimensional structure of proteins arises from compact conformations of helices, sheets, 
loops and turns, and disordered domains.1 As the α-helix is a major component in protein 
secondary structure, α-helix mimicry is an important angle to approach protein mimicry.5 A first 
step towards generating bionic proteins is to establish to what extent the structural and functional 
role of the α-helix can be reproduced with non-natural molecules in a predictable manner. It is 
therefore imperative to fully understand what parameters play a role in shaping the structural 
folding of an α-helix. 
 Structural analysis 
The three mains types of helices are 310, α, and , which are stabilized by i, i+3; i, i+4; and i, i+5 
hydrogen bonding interactions respectively (Figure 1.1). The α-helix (Figure 1.1a) is the most 
abundant motif in natural proteins, accounting for about 30% of all amino acid secondary 
conformations (310 helix (Figure 1.1b) account for about 4% and -helix (Figure 1.1c) is even 
more rare as it is less stable).6 
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Figure 1.1: Comparison of the three types of helices, based on an alanine peptide. Top and side 
view of a) an α-helix, b) a 310-helix and c) a -helix. Each colour corresponds to one alanine 
amino acid. Stabilising H-bonds are shown in green (for clarity purposes, only selected H-bonds 
are shown). 
Typically, an α-helix has one turn every 3.6 amino acids. The ideal backbone dihedral angles are 
 = -41° and  = -62° (Figure 1.2a), and the helix rises 1.5 Å for each residue and 5.4 Å for each 
turn (Figure 1.2c).7 Interactions between side-chain residues thus occur every 3-4 residues (Figure 
1.2b), resulting in three distinct faces of the helix. 
 
Figure 1.2: Detailed structure of an α-helix showing a) the dihedral angles  and , b) the 
stabilising H-bond between two turns, and c) the side-chains projecting at positions i, i+4 and 
i+7 on one face of the helix. 
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 Mimicking α-helices 
Different approaches for mimicking α-helices have been explored, e.g. using small molecules or 
peptides.5, 8 Three main families of mimetics have been identified to classify these ligand types:9 
 Type I (peptidomimetics) are short oligomers that mimic the local topology of the helix. 
They usually match the peptide backbone atom-for-atom, and additional covalent 
constraints can be used to promote a helical conformation (see paragraph 1.2.1). 
 Type II (functional mimetics) are small non-peptide molecules that bind to a receptor, but 
don’t necessarily mimic the local structure of the protein. Nutlin is a well known example 
of a type II mimetic.10 
 Type III (proteomimetics)11 are topographical mimetics that match the spatial orientation 
and composition of key functional residues of the original α-helix (see paragraphs 1.2.2 
and 1.2.3). 
 α-Helix mimetics as Protein-Protein Interaction modulators 
α-Helices play a fundamental recognition role in Protein-Protein Interactions (PPIs):7, 8 despite 
being large and relatively flat (around 1500-3000 Å),12, 13 PPIs do not require a full coverage of 
the protein-protein contact surface but only interaction with a few amino acids where most of the 
PPI binding energy is localised.14 This portion of protein is called a “hot spot”, and it represents 
a template upon which to design a synthetic ligand to compete with the original protein partner 
of the PPI, resulting in a modulation of the interaction (Figure 1.3).15  
 
Figure 1.3: Recognition and inhibition of PPIs. 
Since 62% of hot spots feature an α-helix,16 α-helix mimicry has been an important approach to 
exploring PPI inhibition for therapeutic purposes.5, 17 Therefore, in the context of generating and 
using non-natural amino acids for mimicking α-helices, it makes sense to look at developments 
of PPIs inhibitors, and this is the outlook chosen for the writing of this manuscript. 
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 Bottom-up design of α-helix mimetics: foldamers 
One main approach to α-helix mimicry is the bottom-up design of molecules that adopt a 3-
dimensional structure replicating the natural α-helix: those molecules belong to the foldamer 
family. More generally, Gellman defined foldamers as non-natural polymers that tend to adopt a 
well-defined compact secondary structure.18 They can be classified into two main groups: biotic 
foldamers, whose design and development are analogous to biopolymers; and abiotic foldamers, 
featuring backbones and folding modes different from those of biopolymers.19 
 Stabilisation of short peptides 
 Overview of the most common stabilisation techniques 
In order to replicate an α-helical segment of a protein, an obvious approach is to use peptides. 
Nevertheless, short peptides have little ordered structure in solution:20 for a peptide to adopt a 
stable helical conformation in aqueous solution, it is often necessary to introduce a stabilising 
group into its backbone. Various stabilisation techniques have been reported,21 including salt 
bridges, metal chelates and covalent linkages such as lactam22 or disulfide bridges23 (Figure 1.4). 
 
Figure 1.4: Common approaches for stabilisation of short peptides. Adapted from Azzarito et 
al.5 
Early studies demonstrated that disulfide bridges could be used to stabilise helical conformations 
in short peptides:24, 25 it has been shown that disulfide-linked peptides can inhibit nuclear receptor 
co-activator interactions.26, 27 Lactam bridges have also been proven to successfully stabilise α-
helical structures28, 29 and were used to obtain a potent inhibitor of the assembly of the hexameric 
gp41 core that leads to HIV virus host-cell fusion.30 
Grubbs and co-workers introduced hydrocarbon stapling by ring-closing metathesis (RCM) with 
O-allyl serine residues,31 and this approach was later improved upon by Verdine and co-workers 
who extended it to unnatural α-methylated amino acids.32 Recent work within the Wilson group 
ascertained that α-alkenyl substituted amino acids are effective for peptide stapling of Bcl-2 
family peptides, and that the staple does not introduce a steric constraint in the binding cleft.33, 34 
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The Hydrogen Bond Surrogate (HBS) approach involves replacing a native i-i+4 hydrogen bond 
by a covalent linkage. One advantage of HBS compared to other stabilisation techniques is that it 
does not compromise the recognition surface of a constrained structure.35 Solid phase peptide 
synthesis (SPPS) of HBS-constrained helical peptides has been described and peptides of 
biologically relevant conformation have been identified.28-36 
 Application to phage display screening 
Generating small peptides by SPPS is limiting in terms of time of synthesis and purification; 
reverse screening methods can be used to avoid such limitations. The general principle of those 
techniques relies on rapidly generating and screening diversified libraries of compounds, and later 
identifying hits to biologically relevant systems. 
Commonly used as a screening technique, phage display37, 38 has been shown to be an efficient 
tool to study PPIs, and has therefore been extensively used for this purpose in the past.39-42 Phage 
display relies on the use of bacteriophage that infect the standard recombinant bacteria host DNA 
and the encoded foreign peptide is expressed as part of a fusion to one of the coat proteins on the 
surface of the phage.43 A phage library can be constituted by a mixture of phage displaying 
different peptides from different DNA inserts. As illustrated in Figure 1.5a, the randomised library 
of phage is screened against an immobilised target of choice. The best binders are isolated using 
affinity purification techniques that require the immobilisation of the receptor.44 Unbound phage 
are washed away, and the binding ones are then eluted and further amplified, and after at least 3 
rounds of selection, the finally eluted phage are individually characterised.43 
Although phage display classically generates a randomised peptide whose conformation cannot 
be predicted, it is possible to tune the genetic code of the phage in order to produce a specific coat 
protein, including exclusively α-helical peptides.45 Diderich et al. have recently combined phage 
display to peptide stapling methods to screen libraries of stabilised α-helical peptides.46 The 
peptides generated by the phage consistently contained two cysteines, respectively positioned at 
i and i+4, to enable stabilisation with thiol-reactive linkers (Figure 1.5b). 
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Figure 1.5: a) Cartoon representation of the principle of phage display. The generated library is 
tested for binding against an immobilised target. Unbound phage are washed away and bound 
phage are eluted, amplified and bound again. After at least three cycles, the amplified phage are 
characterised. b) Chemical stabilisation of peptides for building a library of α-helical peptides 
by phage display. The sequence of the peptide is randomised except for two cysteines at 
respective positions i and i+4 to allow the stabilisation.46 
 Backbone modifications 
In order to improve the folding properties of small peptides without requiring external 
stabilisation, backbone modifications have been investigated. Indeed, it is possible to replace 
natural α-amino acids (Figure 1.6a) by their β- or γ- equivalents (Figure 1.6b and c): Gellman and 
co-workers studied the competition between possible intramolecular H-bonding within β- and ϒ- 
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peptide monomers.47 In the case of β-peptides, nearest neighbour interactions are unfavourable 
(Figure 1.6b, red arrow), which means the only favoured intramolecular H-bonding occurs 
between distant residues leading to compact folding (Figure 1.6b, green arrows). On the other 
hand, their studies highlighted that nearest neighbour interactions within ϒ-peptides via formation 
of a 9-membered hydrogen-bond ring are favoured, which leads to a non-folded conformation of 
the molecule (Figure 1.6c): this results in a competition between the potential conformations 
adopted by the molecule, and suggests that polymers composed exclusively of ϒ-amino acids are 
less likely to adopt compact and specific folding patterns. 
 
Figure 1.6: H-bond interactions within a) α-, b) β- and c) ϒ-peptides. Green arrows show 
favourable interactions whereas red arrows show unfavourable interactions. Adapted from 
Gellman et al.47 
One focus of the group’s work was identifying backbones that favoured helical secondary 
structure,47 and to understand the consequence of altering the nature of the residues in order to 
modulate the β-peptide structure. A first study showed that β-peptides derived from trans-2-
aminocyclohexanecarboxylic acid (trans-ACHC, Figure 1.7a) adopt a 14-helix, i.e. forming a 14-
membered hydrogen-bonding ring (Figure 1.7b and c).48 It was then established that trans-2-
aminocyclopentane-carboxylic acid (trans-ACPC, Figure 1.7d) forms a 12-helix (Figure 1.7e 
and f).49 Recent work has demonstrated that the substitution of an α-amino acid for a β-amino 
acid such as ACPC will not only preserve the helicity of the peptide, but also enhance its resistance 
to proteolysis.50  
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Figure 1.7: Folding properties of trans-ACHC and trans-ACPC. a) Chemical structure of the 
trans-ACHC monomer. b) Top view and c) side view of the 14-helix folding of trans-ACHC.48 
d) Chemical structure of the trans-ACPC monomer. d) Top view and e) side view of the 12-
helix folding of trans-ACPC. Adapted with permission from Appella et al, Nature, 1997, 387, 
381-384. Copyright 1997 Nature Publishing Group. 
It has been established that the introduction of constraints allows β-peptides to adopt a helical 
conformation and retain activity compared to the natural α-peptide.51-53 Yet, no general conclusion 
can be drawn and the design of foldamers needs to be considered on a case by case basis,54 as the 
β-peptide helix does not perfectly reproduce the spatial arrangements of residues found in α-
helices.55 Beck-Sickinger et al. showed the structural difference between α- and β-peptides by  
replacing secondary structure elements of the C-terminal α-helix of human interleukin 8 (hIL-8) 
by artificial segments.56 Modifications were performed on the residues 61-77 of hIL-8 and the 
residues 105-121 of the cationic antimicrobial peptide (CAP18). Using circular dichroism (CD) 
spectroscopy, the β-peptides configurations were determined to be a 314-helix (Figure 1.8c, right), 
which is left-handed as opposed to the α-helix (Figure 1.8c, left). Yet, modelling of the peptides 
showed good agreement between the faces of the native α-peptides (Figure 1.8a and b, left) and 
the β-peptides (Figure 1.8a and b, right), and the activities of the modified proteins were 
comparable to the ones of the native α-peptides. 
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Figure 1.8: Molecular modelling comparing the folding conformations of native α-helices and 
their equivalent β-peptides. a) Top view of the 61-77 residues of hIL8 (left) and its 
corresponding unnatural 314-helical β-peptide (right). b) Top view of the 105-121 residues of 
CAP18 (left) and its corresponding unnatural 314-helical β-peptide (right). c) Comparison 
between natural α-hIL8 highlighting the native right-handed α-helix (left) and the α-hIL81-60-β-
hIL861-77, highlighting the left-handed 314-helix. Adapted with permission from David et. al., 
J. Am. Chem. Soc. 2008, 130, 15311. Copyright 2007 American Chemical Society. 
Although a full change from α- to β-peptide has consequences on the helicity and can also modify 
the handedness, it has been demonstrated that small alterations on an oligoamide backbone can 
have limited influence on the folding behaviour:57 a series of analogues have been prepared from 
the wild-type sequence of the B1 domain of Streptococcal protein G (GB1), applying different 
backbone modifications, such as incorporating β3-residues (carbon insertion), D-α-residues 
(inversion of configuration), and Cα-methyl or N-methyl α-residues (alkylation) as shown in 
Figure 1.9. Results have shown that helix, loop, sheet, and turn secondary structure of GB1 could 
individually be modified with very little alteration of the folding properties, and these 
modifications could be combined with near-additive effects on the overall structure. 
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Figure 1.9: Study of the effect of backbone modification on foldamer folding properties. a) 
Backbone modifications applied included β3-residues, D-α-residues, and Cα/N-methyl α-
residues. b) Tertiary folding topology of GB1 showing where the modifications were introduced 
(corresponding colors).57 
One main challenge concerning β-peptides is to obtain a stable folded structure in aqueous 
solution.58 Schepartz and coworkers have demonstrated that the 14-helix macrodipole plays a 
significant role on β3-peptide stability: minimising this macrodipole by introducing charged side 
chains at relevant positions on the helix enhanced the structural stability in water.59 Using these 
results, stable 14-helical β3-oligopeptides were designed (Figure 1.10a), that self-assemble into a 
well-defined, thermostable, octameric quaternary structure, named Zwit-1F (Figure 1.10b).60, 61 
The spontaneous assembly into the octamer resulted from non-covalent inter-residue interactions, 
and the final structure possessed a hydrophobic core (Figure 1.10c). 
 
Figure 1.10: β3-peptide quaternary structure. a) 14-helical conformation was enhanced by 
minimising the macrodipole by alternating positively (blue) and negatively (red) charged side-
chains. b) X-ray structure of the octameric quaternary structure Zwit-1F. c) Highlight of the 
hydrophobic core (green). Adapted with permission from Daniels et al., J. Am. Chem. Soc., 
2007, 129, 1532. Copyright 2007 American Chemical Society. 
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 De novo design of foldamers: aromatic oligoamides 
Backbone modification through α-amino acid replacement is not the only approach to foldamer 
synthesis: a different way to address the topic is the complete de novo design of structures with 
folding properties. For this purpose, aromatic oligoamides are very attractive, as their folded 
conformations are predictable and tunable, and they demonstrate high conformational stability. 
Indeed, it is possible to control the number of units per turn of the helix, based on the three main 
parameters that have a strong impact on the helix diameter:62 the orientation of the amide 
linkages,63 the size of the units,64 and the position of any hydrogen bond. Moreover, electrostatic 
repulsions, steric effects and intramolecular hydrogen bonding65 cause a restriction to the aryl-
amide bond rotation, which is strong enough to determine the structure of the folded 
conformation. Extra stability is added to this structure from - interactions between aromatic 
rings.62 
Examples of stability and tunability of aromatic oligoamides have been established by Huc and 
co-workers, by studying the racemisation between M and P helices of the 2-quinolinecarboxylic 
acid foldamer.66 Racemisation rate was measured in different solvents, and the foldamer was 
shown to be particularly stable in polar solvents, with a racemisation rate of around 10-4 min-1 in 
methanol-water solutions. Derivatives of the quinolone scaffold were studied, and the design of 
stable conformations for which side chains formed a linear array enabled the synthesis of 
amphiphilic compounds (Figure 1.11).67, 68 This work was later improved to obtain hybrid 
compounds with the capacity to fold in water.69 
 
Figure 1.11: Conformation of oligoaromatic foldamers. a) Chemical structure of the (LQ2)n 
main building block, where two 8-amino-2-quinolinonecarboxylic acid (Q, grey) are linked to a 
Leucine (L, beige). b) Top view and c) side view of the X-ray structure show that extra stability 
is induced by - interactions between the aromatic rings. These interactions allowed 
orientation of the functionalised side chains to form a linear array. Adapted with permission 
from Kudo et al., J. Am. Chem. Soc., 2013, 135, 9628-9631. Copyright 2013 American 
Chemical Society. 
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Quinoline-based foldamers were further studied on the basis that positively charged quinoline-
based oligomers could selectively bind to quadruplex DNA.70 Biotinylated quinoline-based 
octamers were screened against a wide range of DNA targets, and their high selectivity for 
G-quadruplexes was established.71, 72 
The applications linked to aromatic oligoamide foldamers are not only limited to binding to 
biologically relevant targets, and recent work on encapsulation has shown the versatility of that 
scaffold. Initial research on encapsulating water molecules73 has led to diversified targets, such 
as fructose74 and tartaric acid (Figure 1.12a),75 as well as encapsulation driven self-assembly with 
citric acid (Figure 1.12b).76 
 
Figure 1.12: Encapsulation of targets by a) single helix73-75 and b) self-assembling double 
helix76 foldamers. 
Although foldamers replicating full helices have proven their potency in terms of binding or 
encapsulating, smaller molecules are of interest for their ease of synthesis, purification and 
characterisation. The proteomimetic approach for α-helix mimicry focuses not on replicating the 
whole protein structure but only the spatial and angular projections of the side chain features that 
play a key role in PPIs. Proteomimetics are therefore small scaffolds, not necessarily peptidic. 
Amongst the variety of motifs used for building proteomimetics, linear aromatic oligoamides are 
often preferred, as the distance between two monomers matches the distance between two 
consecutive side chains along one face of an -helix (Figure 1.13a).77 Stabilising H-bonding can 
occur on either or both sides of the molecular strand. In the first case, a facial polarity is generated, 
which leads to a slight curvature of the strand which can be used for molecular recognition77 or 
to give rise to facial amphiphilicity.78 The aforementioned properties make proteomimetics an 
important approach for use as inhibitors of PPIs (Figure 1.13b). 
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Figure 1.13: a) Schematic representation of a proteomimetic designed to mimic an -helix, and 
reproducing the spatial disposition of its key functions. b) Inhibition of PPIs with 
proteomimetics. 
Hamilton et al. described the terphenyl scaffold as the first proteomimetic (Figure 1.14),11 which 
mimicked two turns of the smooth muscle myosin light-chain kinase (smMLCK) -helix, in order 
to inhibit its interaction with calmodulin (CaM). The results indicated an accurate functional 
mimicry of smMLCK in binding with high affinity to CaM. Derivatives of this scaffold were 
successfully elaborated to target the gp41 complex79 and the Bcl-xL/BAK interaction.80 
 
Figure 1.14: The terphenyl scaffold was the first described proteomimetic.11 
On the basis of Hamilton’s work, various proteomimetic scaffolds have been described, exhibiting 
different properties. The enaminone scaffold was developed as an improvement to the terphenyl 
scaffold, especially in terms of solubility in polar solvents (Figure 1.15a).81, 82 Aromatic 
oligoamides have also been extensively used to target PPIs such as p53/hDM2,83 or Bcl-xL/BAK.84 
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They are particularly attractive due to their ease of synthesis and also offer the possibility to access 
double-sided scaffolds (Figure 1.15c),85, 86 as many known interactions require binding to more 
than one face of the helix.87 Benzoylurea-based compounds (Figure 1.15d) were also used to 
mimic double sided helices88 and showed good inhibition properties of the Bcl-xL/BAK 
interaction.89 1,2-Diphenylacetylene (Figure 1.15e) was used to mimic the projections on the two 
faces of the helical region of Bim-BH3.90 Recently, a new scaffold based on an imidazole-phenyl-
thiazole combination was elaborated (Figure 1.15f)91 as an inhibitor of the interaction between 
Cdc42 and Dbs, which has been linked to tumour growth, cardiovascular and neurodegenerative 
diseases, and diabetes.92 
 
Figure 1.15: Examples of reported proteomimetic scaffolds such as a) enaminones;82 b) 
aromatic oligoamides83, 84 and their application to c) double sided helical structures85, 86; d) 
benzoylurea88; e) 1,2-diphenylacetylene90 and the latest f) imidazole-phenyl-thiazole 
combination.91 
Nature exhibits many examples of more complex multi-helix proteins. Mimicking two or more 
helices instead of one is therefore of interest for accurately replicating complex biological 
constructs. This was accomplished by Hamilton et al., who developed double α-helix mimetics 
(Figure 1.16) by attaching two 3-O-alkylated oligoamides together with various rigid linkers.93 
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Figure 1.16: a) General structure of the double helix mimetics. b) Example of applied linkers. 
The approaches for designing α-helix mimetics are varied and enable access to many different 
types of mimetics. Nevertheless, the design and synthesis of such molecules can be limiting in 
terms of time consumed by design, synthesis, troubleshooting and optimisation, compound 
characterisation, and testing. 
 Incorporation of unnatural building blocks into proteins 
In order to use non-natural amino acids to build a bionic protein, it is necessary to incorporate a 
foldamer sequence into a protein. Different approaches can be undertaken depending on the size 
of the protein and the required type of modifications. 
SPPS allows a complete freedom of the choice of amino acids, and therefore opens the door to a 
great variety of new proteins. However, it is limited in size to peptides and small proteins, given 
that the ease of synthesis, yield and purity decrease as the size of the protein increases.94, 95 
Currently, the easiest way of artificially preparing a full protein is by chemical ligation of a 
synthesised peptide to an expressed fragment of protein.96 For the purpose of modifying existing 
proteins in an easy and rapid manner, another approach is desirable. 
Although challenging, the expansion of the genetic code to new unnatural amino acids (UAAs) 
has already yielded several successes.97-99 A common way of doing so is site-directed 
mutagenesis, which permits a single mutation of an amino acid residue located at any site within 
a protein to be performed.100 Using adequate primers, this technique involves the generation of an 
oligodeoxyribonucleotide complementary to the desired methylated wild-type sequence, except 
for the altered residue. Rounds of denaturation followed by annealing synthetic nucleotides and 
DNA synthesis yield the mutant plasmid (Figure 1.17), and the parent wild type templates are 
digested with DpnI so that only the desired mutant plasmid is further transformed.101 
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Figure 1.17: Principle of site-directed mutagenesis. The wild-type plasmid is denatured and a 
primer with the corresponding sequence but for one residue is used to synthesise 
complementary DNA. Several rounds are performed until the desired mutant is obtained. 
A common application of this technique is the mutation of a chosen residue to an alanine group, 
which has minimal contribution to the free energy of a PPI, in order to determine the importance 
of that residue.102 Site directed mutagenesis is also essential in order to use the Amber Suppression 
method (Figure 1.18).103, 104 In this method, Amber suppressor tRNAs are aminoacylated with the 
desired non-natural amino acids through chemical aminoacylation, and the obtained aminoacyl-
tRNAs (aa-tRNAs) are added to an in vitro translation system with a mRNA or DNA containing 
an Amber stop codon (UAG) at a desired position. The incorporation of the non-natural amino 
acid at the desired position results from the suppression of the Amber codon, which occurs on the 
mRNA.105 
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Figure 1.18: Amber suppression method for incorporation of unnatural amino acids into a 
protein.103, 104 
The Amber Suppression method has been applied to Escherichia Coli106 and Saccharomyces 
cerevisiae.107 Applications include incorporation of fluorescent labels into proteins in order to 
study their folding and ligand binding108 and protein therapeutics.109 Recent studies aimed at 
multiple unnatural amino acid insertions into mammalian cells in order to potentially combine 
those two applications.110 Indeed, by varying the codon combinations with 4-base codons, it is 
possible to insert more than one different UAA in a protein.111, 112  
Though, theoretically, any insertion is possible, the size of the UAA is a limiting parameter as the 
peptide sequence must be small enough to get out of the ribosome. It is therefore most likely to 
be possible to produce bionic proteins by replacing sequences of amino acids with proteomimetic 
equivalents. 
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 Previous work from the Wilson group 
The Wilson group has focused on designing aromatic oligoamide scaffolds as α-helix mimetics 
for PPI modulation. Inhibitors of the p53/hDM2 interaction with micromolar activity were 
identified from libraries of the 2-O-, 3-O-113 and N-alkylated114 series (Figure 1.19). Further work 
from the group aimed at improving water solubility of the 3-O-alkylated inhibitors by introducing 
a “wet-edge” on the non-binding face of the compound.115 Fluorescence anisotropy titration 
showed that this “wet-edge” led to very little decrease of activity, with values of IC50 remaining 
in the micromolar range, while improvement of solubility was observed (Figure 1.19). 
  
Figure 1.19: Potent inhibitors of the p53/hDM2 interactions and their IC50 values, from left to 
right: 3-O-alkylated series, 3-O-alkylated compound improved with a “wet-edge”, 2-O-
alkylated series, and N-alkylated series. 
The projection of the side chains along one side of the helix relies on the rigidity of the scaffold, 
which is mainly ensured, for the O-alkylated scaffolds, by the hydrogen bonds between the 2-O 
and the amide below, or 3-O and the amide above (Figure 1.19, green bonds). In the case of the 
N-alkylated scaffold, no such interaction is possible due to the functionalization of the amine and 
the cis-conformation is known to be preferred.116 While the rigidity enables the projection of the 
side chains on one face, it can also account for poor affinity in some cases, as a very rigid structure 
could be restricted in fitting into a binding pocket. In order to break the rigidity of the O-alkylated 
compounds, a new hybrid scaffold substituting the middle aryl-unit with an α-amino acid has 
recently been designed (Figure 1.20a).117 A library of 35 hybrids was prepared using SPPS, and 
tested against p53/hDM2. For equivalent side chains, three combinations of compounds were 
compared (Figure 1.20b): 2-O-alkylated, α-amino acid, 3-O-alkylated (left); 3-O-alkylated, α-
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amino acid, 3-O-alkylated (middle); N-alkylated, α-amino acid, 3-O-alkylated (right). Out of 
those three combinations, the first scaffold exhibited the best inhibition potency, as well as high 
selectivity over the Mcl-1/NOXA B interaction.117 
 
Figure 1.20: a) General design of hybrid mimetics, replacing the central aryl group by a more 
flexible amino acid (blue). Stabilising hydrogen bonds are highlighted in green.117 b) Example 
of potent hybrid inhibitors of the p53/hDM2 interaction. Adapted from Azzarito.117 
The versatility of proteomimetics was established in cell assays. A library of N-alkylated 
oligoamide mimetics of p53 was prepared and tested in a High-Content imaging Screen in U2OS 
osteosarcoma cells, where four endpoints were assessed after 48 hours of incubation: cell count, 
identification of apoptotic cells, autophagy, and arrangement of actin filaments.118 The results 
highlighted that the interplay between biophysical and cellular potency is complex and that not 
all in vitro hits are potent in cells: out of 77 compounds screened, 2 exhibited potency in all 
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biophysical and cellular assays. This is nevertheless proof that proteomimetics can effectively 
inhibit a PPI in cells. 
The Wilson group also reported the first peptide-proteomimetic hybrid. Based on preliminary 
work that demonstrated the ability for a HIF-1α proteomimetic to bind to p300,119 a truncated 
HIF-1α protein was synthesised where HIF-1α816-826 was replaced by the corresponding 
proteomimetic (Figure 1.21).120 The obtained bionic peptide bound to p300 with micromolar 
activity, which is comparable to the original protein, but 10 fold less than the proteomimetic alone. 
It was further shown that the proteomimetic on its own had limited selectivity, as it exhibited 
micromolar activity towards hDM2, whereas the hybrid peptide was selective towards p300.120 
 
Figure 1.21: First peptide-helix mimetic hybrid.120 a) Truncated wild type sequence of HIF-1α. 
b) Structure of the proteomimetic of HIF-1α816-826. c) Bionic peptide of the truncated HIF-1α 
where residues 816-826 were replaced by the proteomimetic illustrated in b). 
 Project Aims 
Proteomimetics can accurately mimic the spatial projection of the side chains of an α-helix. Their 
viability in cellular environment (Figure 1.22a) and insertion as part of a longer peptide was 
established (Figure 1.22b). However, proteomimetic design and synthesis is, as yet, insufficiently 
advanced to conceive of re-engineering nature to the extent of replacing whole segments of 
protein backbone with non-natural prostheses as proposed here (Figure 1.22c). 
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Figure 1.22: Recent developments and future aims on proteomimetics: a) proteomimetics can 
be designed based on natural α-helices to generate binders for specific proteins and b) can be 
incorporated to a peptide to form a functional bionic peptide. c) The replacement of protein 
segments with proteomimetics is yet to be achieved in order to expand Nature’s toolbox and 
generate functional hybrids with enhanced properties. 
The aim of this project was to investigate novel applications using proteomimetics, leading to 
new 3-dimensional assemblies, in the framework of further developing bionic proteins. Two 
approaches were explored: 
1) Design and synthesis of coiled coil mimetics (Chapter 2) 
Coiled coils are an essential motif in protein assemblies involved in many biological pathways. 
Attempting to design coiled coils with proteomimetics is therefore interesting in order to establish 
the ability of proteomimetics to mimic α-helical supramolecular assemblies. Indeed, although 
double-sided single α-helices,85-90, 121 or double single-sided α-helices93 were studied, no coiled 
coil mimetic was ever reported. Succeeding in this exercise would prove the versatility of 
proteomimetics as building block for the construction of bigger, protein-sized complexes. 
The synthesis of proteomimetics equipped with polar hydrophilic side chains, designed to enable 
side-chain/side-chain interactions leading to self-assembly into a coiled coil mimetic, will be 
described. 
2) Identifying high affinity binders to proteomimetics using Affimer display (Chapter 3) 
Affimers are a novel artificial binding protein scaffold developed within the Astbury Centre.122 
Phage display screening using Affimers has been successfully used on protein targets,123 although 
so far, attempts to screen against non-stabilised natural short peptides failed, due to their lack of 
structure. By using this technique on proteomimetics, it will be possible to prove their ability to 
replicate native α-helices in a broader application than previous studies, i.e. specific design against 
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one chosen interaction. This will further validate the value of proteomimetics as potential protein 
prosthesis building block. 
23 
 
 
 Introduction 
 Coiled coils 
The coiled coil is a naturally abundant protein motif, characterised by the distinctive packing of 
amino acid sidechains in a heptad repeat, meaning that two turns comprise exactly seven residues 
forming an a-b-c-d-e-f-g pattern, where a and d are hydrophobic and b, c, e, f, g are polar residues 
(Figure 2.1a).124, 125 This structure enables the assembly of the helices into bundles, in which one 
side chain from one helix is surrounded by side-chains from another helix, to achieve a “knobs-
into-holes” packing (Figure 2.1b).126, 127 
 
Figure 2.1: Structural characteristics of coiled-coils. a) Cartoon representation of the heptad 
repeat. b) Knobs-into-holes packing as observed in the heterodimeric bZIP transcription factor 
c-fos-c-jun leucine zipper (PDB ID: 1FOS). 
Coiled coil motifs vary widely, depending on their orientation, length and spatial projection of 
side-chains. As 3D structure is a central feature of protein function, the coil coiled assembly is 
key to overall protein folding and mode of action. Examples of protein functions associated with 
coiled coil structures include DNA-binding,128-133 ion-channel assembly,134, 135 and 
proteasomes.136 Complex assembly of coiled coils can also lead to architectures such as tentacles 
(Figure 2.2a, b)137-139 tubes (Figure 2.2c, d),140, 141 or stalks (Figure 2.2e).142, 143  
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Figure 2.2: Examples of complex assemblies of coiled coils. a) Proteasome-activating 
nucleotidase N- domain fused to GCNA (PDB ID: 2wg5), b) Archaeal Prefoldin (PDB ID: 
1FXK), c) Bacteriophage φX174 tail protein (PDB ID: 4JPP), d) Bacteriophage Pf1 coat protein 
B (PDB ID: 1QL2), and e) Hamp(AF1503)-Tsr fusion (PDB ID: 3zx6). 
Examples of coiled coil mediated membrane-fusion complexes,144-146 e.g. Influenza 
Hemagglutinin (HA),147-150 Ebola Virus (EBOV) GP2,151-153 and Human Immunodeficiency Virus 
(HIV-1) GP41154-157 have underscore the therapeutic relevance of such structures (Figure 2.3).158 
 
Figure 2.3: Coiled coils involved in viral membrane fusion, top and side view of: a) HIV-GP41 
(PDB ID: 1AIK), b) HA (PDB ID: 1HGF) and c) EBOV-GP2 (PDB ID: 2EBO). 
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 The proteomimetic approach 
In the last two decades, efforts have focused on understanding the fundamental principles of de 
novo coiled coil design.159-162 Successful design has so far led to assembly of fractal structures,163 
nanotubes164, 165 and nanofibers,166, 167 and biochemically active barrels.168, 169 From a foldamer 
point of view, it has been shown that it is possible to produce coiled coils with peptides containing 
β and γ amino acids.170-172 This exercise was successfully extended to the replacement of two 
successive α-amino acids by one non-natural 1,2,3-triazole ε2-amino acid.173 Arora reported the 
first short coiled coil mimetic by covalent linking of short dimers consisting of heptad repeats.174 
Though lots of work has been done on the modification and de novo design of coiled coils and 
foldamers, little is known about the properties of aromatic oligomers as coiled coil mimetics. 
Furthermore, very little synthetic work has been reported on proteomimetics bearing hydrophilic 
side chains.175 If it is known that proteomimetics can inhibit a coiled coil mediated interaction,79 
it is worth considering if forming proteomimetic-based coiled coils is possible. In this work, 
proteomimetics with complementary charged side-chains in order to generate self-assembling 
foldamers were designed and synthesised. The targets comprised both dimers and trimers as a 
starting point, to be later extrapolated to longer oligoamides (Figure 2.4). 
 
Figure 2.4: Cartoon representation of self-assembling dimers as precursors for designing full 
coiled coil mimetics. Complementary polar side chains are shown in red and blue. Homo-dimers 
are expected to self-assemble, and an equilibrium with hetero-dimer formation is expected upon 
addition of the reverse foldamer sequence. 
 Synthesis of self-assembling foldamers 
Amongst the proteomimetic scaffolds developed in the Wilson group, the O-alkylated83, 176, 177 and 
N-alkylated series114, 178 were chosen. The foldamers were synthesised on solid phase on a CEM 
Liberty Blue® automated microwave assisted peptide synthesizer (Scheme 2.1). The Fmoc-
strategy was employed, and Wang resin was chosen following previously optimised synthetic 
methods.178 
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Scheme 2.1: General scheme for the solid phase synthesis of O- alkylated oligomers. A similar 
strategy is applicable for N-alkylated oligomer synthesis. 
The foldamers were designed using a combination of three types of side chains: a carboxylic acid, 
an amine, and a neutral group. The synthesis of the building blocks was planned accordingly. 
 Building block synthesis 
The general building block synthesis is described in Scheme 2.2. 
 
Scheme 2.2: General synthesis for N- and O-Alkylated monomers.  
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Typically, N-alkylated monomers were built by reductive amination of an aldehyde on 4-
aminobenzoic acid 37 followed by Fmoc protection, and O-alkylated monomers required 
alkylation on methyl 3-hydroxy-4-nitrobenzoate 20 followed by nitro reduction or saponification 
of the ester (or the other way round, depending on the nature of the side chain), and, finally Fmoc 
protection. Aldehydes (N-alkylated) or bromides (O-alkylated) were synthesised when not 
commercially available. 
 Preparation of the side chains 
The synthesis of the tert-butyl ester monomer 3 was originally described using tert-butyl 2-
bromoacetate 1, for direct coupling onto O-alkylated monomers and as a starting material to make 
the aldehyde for the N-alkylated scaffold (Scheme 2.3).178 Unfortunately, the formation of the 
aldehyde from the nitro-compound 2 was unpredictably irreproducible, as the final yield obtained 
only reached up to 26% and the reaction would often yield no product. Troubleshooting of the 
reaction (conditions, quality of the reagents and solvents) did not provide any information as to 
the origin of this result.  
 
Scheme 2.3: Synthesis of the tert-butyl ester aldehyde 3 as previously described in the Wilson 
group.178 
Other methods to obtain the same aldehyde were investigated (Scheme 2.4). Direct 
esterification179 of 2-oxoacetic acid 9 or L-tartaric acid 4 were ineffective; the formation of the 
ester was observed with the use of CuCl,180 but the metal salt could not be removed. Then, the 
aim was shifted towards obtaining di-tert-butyl fumarate 8 in order to form the aldehyde 3 by 
ozonolysis. Metathesis on tert-butyl acrylate was successful,181 but the obtained yields (between 
2 and 8%) were limiting. Finally, fumaryl chloride 7 in the presence of n-butyl lithium and tert-
butyl alcohol formed di-tert-butyl fumarate 8 with 38% yield,182 which was further ozonolysed to 
obtain the desired aldehyde.183 
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Scheme 2.4: Alternative synthetic ways to obtain the tBu ester aldehyde. 
Considering the low overall yield, the synthesis of a tert-butyl ester monomer with a slightly 
longer side chain was investigated. The synthesis described in Scheme 2.5 illustrates how both 
bromide 14 and aldehyde 13 required for coupling on respectively O- and N-alkylated scaffolds 
were obtained in a cheaper and safer manner, in only 4 steps from succinic anhydride. Forming 
the bromide was preferred to using the alcohol directly for Mitsunobu coupling on methyl 3-
hydroxy-4-nitrobenzoate 20, as the purification of the Mitsunobu mixture was difficult and time-
consuming because of the presence of an excess of triphenylphosphine. 
 
Scheme 2.5: Synthesis of bromide 14 and aldehyde 13 side-chains for incorporation on 
respectively O- and N- alkylated monomers from succinic anhydride 10. 
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The amine side-chain monomer 16 was prepared following the previously described procedure 
(Scheme 2.6): 3-bromopropylamine was boc-protected in one step; 3-aminopropan-1-ol was boc-
protected and oxidized into the aldehyde 19 using Swern conditions. 
 
Scheme 2.6: Synthesis of the bromide 16 (top) and aldehyde 19 (bottom) boc-amine side-chains.  
 Synthesis of the monomers 
The O-alkylated monomer synthesis (Scheme 2.7) started with the alkylation of methyl-4-nitro-
3-hydroxybenzoate 20 with the relevant bromide. For isobutyl and amine functionalised groups, 
the hydrogenation was performed first, followed by the hydrolysis of the methyl ester under basic 
conditions and Fmoc protection (Scheme 2.7). 
 
Scheme 2.7: Formation of amine (24) and isobutyl (28) O-alkylated monomers. 
For the tert-butyl ester side-chain, the saponification was performed first: in order to avoid 
hydrolysing the tert-butyl ester, it was necessary to tune the conditions and use a weaker base 
than with the other side-chains. Such bases are not strong enough to hydrolyse the methyl ester if 
the nitro group is reduced to an amine, because of its electron donating properties: indeed, 
combined with the electron withdrawing properties of the methyl ester, the overall electron 
density is shifted towards the ester, making it less likely for the negative HO- group to attack there 
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(Scheme 2.8). Instead, the hydrolysis happened in the presence of the nitro group, which is 
electron withdrawing. 
 
Scheme 2.8: The electron density shifted towards the ester makes it harder for the base to attack 
the methyl ester, favouring the deprotection of the tert-butyl ester. 
Following the method previously described in the group, lithium hydroxide was used for n = 1; 
for n = 3, a 0.25 M solution of NaOH in ice was used (Scheme 2.9). 
 
Scheme 2.9: Formation carboxylic acid O-alkylated monomers. 
Full conversion of the starting material was never reached and any attempt to improve it 
inexorably lead to the deprotection of the tert-butyl group. Ultimately, using a diluted NaOH 
solution in ice gave a better yield. The ester and the carboxylic acid could in either case be 
separated by column chromatography, and the ester could be hydrolysed again. The 
hydrogenation was in both cases high-yielding, and finally, the Fmoc protection gave 5% yield 
for n = 1, compared to 62% for n = 3. Further investigation by Dr Ludwig Pilsl on the preparation 
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of 32 established that the formation of the Fmoc-product was effective after 2 hours, but longer 
reflux led to a degradation of the product and formation of an unidentified by-product. 
In the case of the N-alkylated monomers, the length of the side chain had no impact on the yield 
and the protected monomers were obtained in two steps: reductive amination of 4-aminobenzoic 
acid 37, followed by Fmoc protection (Scheme 2.10). 
 
Scheme 2.10: Synthesis N-alkylated monomers in two steps. 
 Dimer and trimer synthesis 
Dimers and trimers were prepared by SPPS following Scheme 2.1. The solvent of choice for the 
synthesis of the trimers was N-methyl-2-pyrrolidone. Indeed, in the case of the O-alkylated 
scaffold, it was previously observed that the monomers were poorly soluble in chloroform, and 
N,N-dimethylformamide reversibly reacts on the acyl chloride to generate a Vilsmeier 
intermediate which can irreversibly cap the aniline (Scheme 2.11).177  
 
Scheme 2.11: Mechanism for capping of anilines during solid phase synthesis via a Vilsmeier 
intermediate. 
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On acquisition of a CEM Liberty Blue Peptide Synthesizer, it was also decided to switch from 
chloroform to N-methyl-2-pyrrolidone for the N-alkylated scaffolds: despite optimisation efforts, 
the chloroform would partially evaporate upon heating and nitrogen bubbling, which resulted in 
a non-homogeneous distribution of the resin in the reaction vessel and therefore non-
homogeneous coupling. Inconsistent deprotections were also observed, which were attributed to 
the partial recondensation of the chloroform in the tubes, leading to an involuntary addition of a 
small amount of piperidine in the reaction vessel during the coupling steps. Using N-methyl-2-
pyrrolidone, no evaporation occurred, allowing a homogeneous distribution of the resin, and the 
deprotections were consistent, suggesting the problem was indeed linked to the use of chloroform. 
After synthesis using the optimised parameters, the trimers were cleaved off the resin with a 50% 
trifluoroacetic acid solution in dichloromethane and purified on semi-preparative HPLC using 
acetonitrile and water. 
Two series of molecules, O-alkylated dimers and N-alkylated dimers and trimers (Figure 2.6), 
were synthesised, for two purposes: 
1) Conformational analysis:  
 Previous studies on 3-O-alkylated dimers have shown that the side chain 
orientation in the solid phase depends mainly on the packing of the molecules in 
the crystal lattice,184, 185 and that rotation around the ArNH bond is possible 
depending on the nature of the side chains. In solution phase, both anti and syn 
conformations were shown to coexist (Figure 2.5a).184  
 N-alkylated trimers were shown to prefer adopting a cis conformation (Figure 
2.5b)116 and were hypothesised to change to a trans conformation upon protein 
binding.186 
 
Figure 2.5: Conformational analyses on aromatic oligoamides showed a) the coexistence of syn 
and anti conformations for O-alkylated series and b) a preference for the cis conformation 
N-alkylated series. 
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The first objective was to determine the effect of the nature of the side chain on the conformation 
of the O-alkylated dimers and N-alkylated dimers and trimers, and establish whether it is possible 
to control the conformation of the foldamer by designing hydrophilic side chains that can form a 
stabilising intramolecular interaction. 
2) Observe self-assembly of polar O-alkylated dimers and N-alkylated dimers and trimers 
as a precursor for coiled coil proteomimetics. 
The nomenclature for the molecules is given from top to bottom, where each monomer is 
numbered and the nature of the side chain is indicated in subscript, considering A = carboxylic 
acid, and B = base (amine), and any non-polar side chain is denominated by its name (in this case 
iBu). The molecule names start by the letter O or N depending whether it is O- or N- alkylated, 
and end with the letter G to denominate the amino acid obtained from the resin (in that instance, 
Glycine). In the case of same side-chain with different lengths, the long chain is considered as the 
default size and the shorter chain is indicated with an “s”. The list of target molecules is presented 
in Figure 2.6. 
 
Figure 2.6: Synthetic targets for conformational analyses and self-assembly. 
Because of the hydrophilic nature of the side-chains, some of the foldamers prepared degraded. 
In a few cases, the difference of mass corresponded to a cyclisation, supposedly of the carboxylic 
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acid monomer on the top alanine (Scheme 2.12), O-alkylated cyclisation observed by Dr Ludwig 
Pilsl). In other instances, the reason for the degradation was not clear.  
 
Scheme 2.12: Cyclisation of the top acid monomer a) for N- and b) for O-alkylated series. 
Attempts at synthesising N-1As2iBu3BG (52) led to a dimer/trimer mixture that co-eluted and 
required several rounds of purification. Cyclisation of the top monomer happened during 
purification, leading to a mixture of dimer, trimer and cyclised dimer that could not be further 
purified (Figure 2.7). The cyclisation was considered to be caused by the presence of 0.1% of 
formic acid in the purification gradient. Once this was established, the purification procedure was 
changed to a gradient of water and acetonitrile only, without using any acid. The synthesis of 
N-1As2iBu3BG (52) was not repeated due to insufficient amounts of monomer available. The 
synthesis efforts were thus focused on the n = 3 monomer (A) as it was easier to prepare in greater 
amounts. 
 
Figure 2.7: HRMS traces of N-1As2iBu3BG (52) before purification, as a mixture with dimer 
N-1iBu2BG (left) and observed cyclisation after purification (right). 
O-1B2BG (47) and O-1B2AG (49) degraded respectively after or during purification (Figure 2.8). 
By-products could not be identified.  
Attempts to synthesise N-alkylated dimers afforded N-1B2AG (55) but N-1A2BG (56) could not be 
synthesised (not observed by test-cleavage of the crude product). Finally, the control dimer 
O-1iBu2iBu (46) was prepared, and although it did not degrade, several impurities appeared after 
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purification, which led to an insufficient amount of product to obtain a clean NMR spectra. While 
it is understandable that charged dimers or trimers could degrade, for example due to the observed 
cyclisation, it is unclear why any trouble would arise from purification of a dimer containing only 
isobutyl side-chains. It is therefore believed that the semi-preparative column used on the HPLC 
might have been contaminated with residual traces of acid. 
Dimers O-1A2BG (50), O-1A2AG (48), N-1A2BG (55) and trimers N-1B2iBu3AG (53) and N-
1A2iBu3BG (54) were obtained. For O-alkylated dimers, the observations linked to compound 
degradation showed a correlation with the presence of an amine group at the top position. There 
is no obvious explanation why these molecules would be more prone to degradation than the 
others, but an answer could lie in the fact that the amine monomer did not always couple fully 
during the synthesis, even with efforts to increase the yield (longer reaction time or triple 
couplings were attempted with little improvement). Because of this, the amount of product in the 
crude mixture was limited, making the purification more difficult and leading to no or too little 
final product to be isolated and used. 
 
Figure 2.8: LC-MS traces showing the degradation of O-1B2BG (47) and O-1B2AG (49) 
respectively after or during purification. 
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Due to time restrictions, further efforts to understand the problems better and repeat those 
syntheses were not accomplished, and the NMR analyses were focused on the obtained molecules: 
O-1A2AG (48), O-1A2BG (50), N-1A2BG (55), N-1A2iBu3BG (54), and N-1B2iBu3AG (53). Instead of 
O-1iBu2iBu (46), a readily available dimer, O-1sBu2sBuG (57), prepared previously by Dr Sίlvia 
Rodriguez-Marin, was used. 
 Molecular modelling predictions 
Molecular modelling was carried out in order to generate ideas as to the behaviour of the dimers 
and the trimers. A Monte Carlo Multiple Minima (MCMM) molecular mechanics conformational 
search was carried out using MacroModel (Schrödinger) and the Merck Molecular Force Field 
(MMFF) forcefield, without restraints and with a cutoff of 1Å in octanol. Considering the pKa of 
the relevant groups (Table 2.1), it was established that the carboxylic acid would be deprotonated, 
and the amine protonated, and this was taken into account for the modelling.  
Table 2.1: pKa and ionisation states of the hydrophilic side-chains. 
Group pKa Ionisation state 
Primary amine (ammonium) 11-12 NH3+ 
Carboxylic acid (including Gly) 4-5 CO2- 
Aromatic amine 5 NH2 
 
 
The conformational landscapes were largely dominated by the structures shown in Figure 2.9. For 
clarity, only the compounds that were obtained are discussed in this section: the modelling of the 
molecules that degraded or could not be synthesised are presented in Appendix I. For O-alkylated 
dimers (Figure 2.9a), the conformations obtained depended on the nature of the side-chains. For 
sBu groups (O-1sBu2sBuG, 57), an equal distribution of syn and anti conformations was observed; 
for O-1A2AG (48), the anti conformation was predominant; for O-1A2BG (50), a syn conformation 
was preferred, stabilised by side-chain/side-chain H-bonding. In the case of N-alkylated dimer N-
1B2AG (55) (Figure 2.9b), a mixture of trans and cis conformations was obtained, each stabilised 
by a ammonium/carboxylate H-bond respectively between side-chains or with the bottom glycine. 
Finally, N-alkylated trimers N-1B2iBu3AG (53) and N-1A2iBu3BG (54) (Figure 2.9c) exhibited a 
preference for the cis conformation at each amide bond, with a bridge between the amine side-
chain and both carboxylic acids. 
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Figure 2.9: Molecular modelling predictions for a) O-alkylated dimers, b) N-alkylated dimers 
and c) N-alkylated trimers. 
Self-assembly was also studied by modelling the interactions between pairs of oligoamides 
(Figure 2.10). In the cases of O-1A2BG (50) and N-1B2AG (55), a change of conformation 
happened upon dimerization: O-1A2BG (50) adopted an anti conformation, whereas N-1B2AG (55) 
adopted a cis conformation. The self-assembling predictions suggest the following assemblies: 
O-1A2BG(1) – O-1A2BG(2) (Figure 2.10a): the complex was symmetrical: the amine of residue 2 
on dimer 1 (O-1A2BG(1)) bound to the carboxylic acid of residue 1 on dimer 2 (O-1A2BG(2)) as 
well as the glycine of dimer 1 (O-1A2BG(1)). The carboxylic acid of residue 1 of dimer 2 
(O-1A2BG(2)) also bound to the bottom amide of dimer 1 (O-1A2B-CONH-G(1)). 
N-1B2AG(1) – N-1B2AG(2) (Figure 2.10b): the complex was symmetrical: the amine of residue 1 
on dimer 1 (N-1B2AG(1)) bound to the carboxylic acid of residue 2 on dimer 2 (N-1B2AG(2)). The 
glycine group was not involved in the complex. 
Although the trimers did not undergo a complete conformational change, some extent of self-
assembly was observed (Figure 2.10c). 
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Figure 2.10: Modelling of the self-assembly of pairs of oligoamides: a) O-alkylated dimer 
O-1A2BG (50), b) N-alkylated dimer N-1B2AG (55) and c) N-alkylated trimers (53 and 54). 
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The following hydrogen bonding profiles were obtained: 
N-1B2iBu3AG(1) (grey) – N-1B2iBu3AG(2) (black): the amine side-chain of residue 1 on trimer 1 
(N-1B2iBu3AG(1)) bound to the carboxylic acid of residue 3 from trimer 1 (N-1B2iBu3AG(1)) as well 
as the glycine on trimer 2 (N-1B2iBu3AG(2)). That later bond was stabilised by an interaction 
between that glycine (N-1B2iBu3AG(2)) and the top amine of trimer 1 (N-NH-1B2iBu3AG(1)). The 
amine side-chain from residue 1 on trimer 2 (N-1B2iBu3AG(2)) bound to the carboxylic acid from 
residue 3, and amide bond from trimer 2 (N-1B2iBu-CONH-2AG(2)), as well as the glycine from 
trimer 1 (N-1B2iBu3AG(1)). The amide bond from the glycine of trimer 1 (N-1B2iBu3A-CONH-
G(1)) also bound to carboxylic acid side-chain on residue 3 of trimer 2 (N-1B2iBu3AG(2)). 
N-1B2iBu3AG(1) (black) – N-1A2iBu3BG(2) (grey): The amine of residue 1 on trimer 1 (N-
1B2iBu3AG(1)) bound to the glycine from trimer 1 (N-1B2iBu3AG(1)) and carboxylic acid from 
residue 1 on trimer 2 (N-1A2iBu3BG(2)). The amine on residue 3 of trimer 2 (N-1A2iBu3BG(2)) 
bound the carboxylic acid side-chain of residue 1 on trimer 2 (N-1A2iBu3BG(2)) and the glycine 
trimer 1 (N-1B2iBu3AG(1)), which bridged with the top amine on trimer 1 (N-NH-1B2iBu3AG(1)). 
The carboxylic acid from residue 1 on trimer 2 (N-1A2iBu3BG(2)) also bound to the top amine on 
trimer 2 (N-NH-1A2iBu3BG(2)). The glycine on trimer 2 (N-1A2iBu3BG(2)) bound to the bottom 
amide bond on trimer 2 (N-1B2iBu3A-CONH-G(1)). 
N-1A2iBu3BG(1) (grey) – N-1A2iBu3BG(2) (black): The carboxylic acid from the residue 1 of trimer 
1 (N-1A2iBu3BG(1)) bound to the amine groups on residues 3 of both trimers (N-1A2iBu3BG(1) and 
N-1A2iBu3BG(2)). The carboxylic acid from the residue 1 on trimer 2 (N-1A2iBu3BG(2)) also bound 
to both amine groups on residues 3 (N-1A2iBu3BG(1) and N-1A2iBu3BG(2)) and had an extra 
stabilisation by binding to the nearest amide bond (N-1A-CONH-2iBu3BG(2)). The amine group 
on residue 3 from trimer 2 (N-1A2iBu3BG(2)) bound to the nearest amide (N-1A2iBu-CONH-
3BG(2)). The glycine from trimer 1 (N-1A2iBu3BG(1)) bound to the top amine from trimer 1 (N-
NH-1A2iBu3BG(1)). 
The summary of all interactions observed by molecular modelling is presented in Table 2.2. 
Taking those calculations into account, NMR experiments were carried out in order to assess the 
conformation of the molecules and their potential self-assembly. 
 
 
 
 
 
40 
 
Table 2.2: Summary of all interactions observed in molecular modelling. The group involved in 
an interaction are denoted in bold, → symbolises a H-bond, & means “binds to both”. 
Complex Interactions 
O-1A2BG(1) –      
O-1A2BG(2) 
O-1A2BG(1) → O-1A2BG(1) → O-1A2BG(2) → O-1A2B-CONH-G(1); 
O-1A2BG(2) → O-1A2BG(2) → O-1A2BG(1) → O-1A2B-CONH-G(2). 
N-1B2AG(1) –      
N-1B2AG(2) 
N-1B2AG(1) → N-1B2AG(2); 
N-1B2AG(2) → N-1B2AG(1). 
N-1B2iBu3AG(1) – 
N-1B2iBu3AG(2) 
N-1B2iBu3AG(1) → N-1B2iBu3AG(1) → N-1B2iBu3AG(2) → N-NH-
1B2iBu3AG(1); 
N-1B2iBu3AG(1) → N-1B2iBu3AG(2) → N-1B2iBu-CONH-3AG(2); 
N-1B2iBu3A-CONH-G(1) → N-1B2iBu3AG(2). 
N-1B2iBu3AG(1) – 
N-1A2iBu3BG(2) 
N-1B2iBu3AG(1) → N-NH-1B2iBu3AG(1); 
N-1B2iBu3AG(1) → N-1A2iBu3BG(2) → N-1A2iBu3BG(2) → N-1B2iBu3AG(1) → 
N-1B2iBu3AG(1); 
N-1A2iBu3BG(2) → N-NH-1A2iBu3BG(2); 
N-1A2iBu3BG(2) → N-1B2iBu3A-CONH-G(1). 
N-1A2iBu3BG(1) – 
N-1A2iBu3BG(2) 
N-1A2iBu3BG(1) & N-1A-CONH-2iBu3BG(2) → N-1A2iBu-CONH-3BG(2) → 
N-1A2iBu3BG(2) → N-1A2iBu3BG(1) → N-1A2iBu3BG(1); 
N-1A-CONH-2iBu3BG(2) → N-1A2iBu3BG(2) 
N-1A2iBu3BG(1) → N-NH-1A2iBu3BG(1). 
 
 NMR studies 
 General considerations 
Choice of solvent. Solvents commonly used for H-bonding studies are chloroform184 or 
acetonitrile.187 The limited solubility of the dimers and trimers in such solvents made the study 
impossible in those conditions. It was first decided to use pyridine-d5 as it has been proven to 
replicate results obtained in polar solvents such as MeOD without disrupting the interactions.188 
Unfortunately the precipitation of O-alkylated compounds was observed in pyridine-d5 on a few 
hours timescale, which meant it was not possible to acquire a good quality 2D spectra. For this 
reason, DMSO-d6 was chosen for O-alkylated dimers as it was shown to be pertinent for H-
bonding studies.189 Although some aggregation was observed for O-1A2BG (50) at the highest 
concentrations (40 mM and 30 mM) even in DMSO-d6, it did not affect the results (this was 
checked by comparing two protons spectra performed after a few minutes or after 24 hours). By 
extension, DMSO-d6 was also the solvent of choice for N-alkylated oligomers in order to compare 
the behaviour of the different series of compounds.  
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Nomenclature of the molecules. In order to describe the NMR spectra, the same nomenclature 
as for characterisation is used. Any relevant hydrogen is annotated, and the full nomenclature is 
further explained in Chapter 5. 
 Conformational analysis 
The first objective of the study was to establish a conformational analysis of the compounds. 
NOESY and/or ROESY NMR experiments were performed at 500 MHz (Figure 2.11). Although 
no correlation was observed between the two side-chains of O-1B2AG (50, Figure 2.11a), the 
ROESY showed an interaction between 2-NH and 1-H2, but not 2-NH and 1-H6 (Figure 2.11d), 
showing that the conformation of the dimer was syn. 
 
Figure 2.11: 2D NMR at 40 mM in DMSO-d6, 500 MHz, showing a) the absence of correlation 
between O-1A2BG (50) side-chains by ROESY, b) the correlation between 2-NH and 1-H2 only 
for O-1A2BG (50), and c) the correlation between 2-NH and both 1-H2 and 1-H6 by NOESY for 
O-1A2AG (48, left) and O-1sBu2sBuG (57, right). d) Zoom on the relevant peaks. 
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Interestingly, the same correlation for O-1A2AG (48) and O-1sBu2sBuG (57) is observed between 2-
NH and both 1-H2 and 1-H6, showing a free rotation around the amide bond (Figure 2.11c and 
d). 
2D NMR were also performed to establish the conformation of N-1B2AG (55, Figure 2.12). 
N-alkylated compounds are known to prefer a cis conformation,116 and this was observed by 
correlation between 2-H3 and 1-H2 (Figure 2.12, purple circles), only possible in cis. A 
correlation between 1-H2 and 2-Hα was also observed (Figure 2.12, orange circles): this 
correlation is possible in the trans conformation, suggesting the dimer could be in equilibrium 
between the two states. Nevertheless, this signal could also be observed in a cis conformation, as 
the two aromatic rings slightly overlap. The only conclusion that can be drawn from this data is 
that the cis conformation is preferred. 
In the case of N-1B2AG (55), the cis conformation is stabilised by the possible H-bond between 
the amine side-chain and the glycine: this interaction would not be possible in the case of N-1A2BG 
(56), and could make the trans conformation more stable, as suggested by the molecular 
modelling (Appendix I). 
 
Figure 2.12: NOESY of N-1B2AG (55) 40 mM in DMSO-d6, 500 MHz, highlighting the 
preference for a cis conformation. 
For the N-alkylated trimers, the NOESY experiments showed a large predominance of the cis 
conformation (Figure 2.13). Indeed, although the aromatic region was quite noisy, the correlation 
between 3-H2 and 1-H3 was clear and out of the noise. In particular, no correlation was observed 
43 
 
between 3-Hα and 2-H2, or 2-Hα and 1-H2 (Appendix II), suggesting the conformation was fully 
cis. 
 
Figure 2.13: NOESY of a) N-1A2iBu3BG (54) and b) N-1B2iBu3AG (53), 40 mM in DMSO-d6, 
500 MHz, showing the preferred cis conformation (purple circle), as shown by c) the chemical 
structure. 
 Study of the self-assembly 
 Solution phase 
In order to evaluate whether the designed foldamers were capable of self-assembling, NMR 
experiments were performed on a dilution scale from 40 mM to 1 mM. Several shifts were 
observed for O-1A2BG (50, Figure 2.14a), indicating changes in the electron density and therefore 
nuclear shielding of the compound. In particular, 1-Hγ shifted from 2.29 ppm to 2.23 ppm upon 
dilution from 40 mM to 1 mM (Figure 2.14a, red), showing a shielding effect therefore an increase 
in the local electron density, correlating with a case where the carboxylate ion is involved in a H-
bonds at high concentration but not at low concentration. This matches the modelling predictions 
that showed the carboxylate group involved in one intramolecular H-bond on its own, and two 
intermolecular H-bond when self-assembled. The shift from 2-Hγ from 2.99 ppm to 2.97 ppm 
upon dilution (Figure 2.14a, red) also followed the prediction: in the dimeric state, the ammonium 
ion was surrounded by two carboxylate groups, one of which was also involved in another H-
bond with 3-NH, whereas in a monomeric state, the ammonium was bound to two carboxylate 
groups in an exclusive manner, providing a plausible explanation for the shielding effect. The 
opposite shift trends observed for 3-NH, from 8.48 ppm to 8.51 ppm (Figure 2.14a, purple), was 
in accordance with that reasoning, as a de-shielding effect would occur upon binding with the 
carboxylate. 
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Figure 2.14: NMR dilutions in DMSO-d6, at 500 MHz, of compounds a) O-1A2BG, 
b) O-1A2AG, and c) N-1B2AG, from 40 mM to 1 mM. Shifting signals are indicated. 
While diluting the samples, the concentration of water in DMSO-d6 remains constant, and 
therefore the ratio water:dimer increased. As a shift in the water peak was also observed during 
the dilutions, it was possible that the results could be due to interactions with water and thus not 
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be related to self-assembly. To assess the situation, the dilutions were also performed on O-1A2AG 
(48, Figure 2.14b), which cannot self-assemble, but can interact with water due to the nature of 
the side-chains, and O-1sBu2sBuG (57, Appendix III), whose hydrophobic side-chains cannot 
interact with water. In both cases, no peak shifted, proving the shifts observed for O-1A2BG (50) 
were not due to the change of water:dimer ratio. Moreover, the water peak did not move for the 
controls, whereas a shift and a broadening was observed for O-1A2BG (50). A possible explanation 
for this change is that the self-assembly happening at higher concentration modifies the available 
surface for hydrogen exchange between the dimers and the water, whereas without self-assembly, 
this surface is constant, hence the sharp peak for O-1A2AG (48) and O-1sBu2sBuG (57). 
To confirm this hypothesis, DOSY NMR was performed on O-1A2BG (50) at concentrations 
above and below the shifts, i.e. 25 mM and 2.5 mM (Figure 2.15). Changes in diffusion were 
observed for the signals corresponding to the side-chains, and not for the aromatic peaks: this also 
suggested a change in behaviour in the side-chain upon dilution, although the error was too 
significant to extrapolate any numerical values. 
 
Figure 2.15: DOSY of O-1A2BG (50) at a) 25 mM and b) 2.5 mM, in DMSO-d6. Shifting peaks 
are highlighted in red. 
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The dilution experiments were performed on N-1B2AG (55, Figure 2.14c). Several shifts were 
observed again, suggesting the same behaviour as for O-1A2BG (50). 
Considering the conformational results for trimers N-1B2iBu3AG (53) and N-1A2iBu3BG (54), 
dilution experiments were not performed. Nevertheless, the compounds were mixed in a 1:1 ratio 
in order to establish a possible interaction between the trimers (Appendix II). As both trimers had 
very similar spectra, the mixture did not involve changes significant enough to draw any 
conclusion. It is possible that both trimers co-exist in solution without interacting with each other. 
To confirm this hypothesis, it would be necessary to synthesize different trimers, such as 
N-1A2A3AG and N-1B2B3BG, or N-1A2iBu3AG and N-1B2iBu3BG, which was not done here due to 
time considerations. 
 Solid phase-state conformation 
Attempts to grow crystals were performed in order to study the solid-state conformation of the 
compounds. Out of all, only O-1A2BG (50), prone to precipitate even in DMSO, formed a cloudy 
crystal-like solid from dimethyl sulfoxide to chloroform. Several solvent systems were used, and 
either mixing or slow evaporation were attempted. The conditions are described on Table 2.3. 
Table 2.3: Different conditions attempted for growing crystals of O-1A2BG (50). 
Solvent Method Result 
Methanol 
Mixing (heating) Nothing observed – fully soluble compound 
Slow Evaporation Nothing observed – fully soluble compound 
Ethyl Acetate 
Mixing 
Solidification/crystallisation on the glass– no 
single crystal obtained 
Slow evaporation 
Solidification/crystallisation on the glass– no 
single crystal obtained 
Diethyl Ether 
Mixing 
Solidification/crystallisation on the glass– no 
single crystal obtained 
Slow evaporation 
Solidification/crystallisation on the glass – no 
single crystal obtained 
Hexane 
Mixing Precipitate – could not be solubilised 
Slow evaporation 
Solidification/crystallisation on the glass– no 
single crystal obtained 
Chloroform 
Mixing Cloudy crystal-like solid, no single crystal 
Slow Evaporation Small cloudy crystal-like solid 
 
From these attempts, chloroform use was the most promising. Although all these setups were 
done from the NMR samples in DMSO, another solvent for the starting material can be used. 
Amongst all systems used, it was possible to solubilise the dimer upon gentle heating in methanol 
(water bath), and no precipitation or crystallisation was observed: a methanol/chloroform system 
will therefore be investigated for further attempts to growing crystals. 
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 Conclusions and future work 
A library of O- and N-alkylated hydrophilic oligomers was designed. The building blocks were 
prepared, involving the design and synthesis of a new carboxylic acid functionalised building 
block for each series of compounds. Because of the nature of the side-chains, the synthesis and 
purification was less trivial than for usual hydrophobic compounds, and therefore some 
cyclisation or degradation of the molecules were observed. Finally, 6 compounds were obtained: 
3 O-alkylated dimers, 1 N-alkylated dimer, and 2 N-alkylated trimers. NMR studies lead to the 
following conclusions: 
- The conformation of O-alkylated dimers can be controlled by carefully designing the 
side-chains: the free rotation around the amide bond can be stopped if a stabilising bridge 
happens between the side-chains of the compound. 
- The N-alkylated compounds synthesised preferred the cis conformation, regardless of the 
nature of the side chains. In particular, for N-alkylated trimers equipped with a central 
hydrophobic group, the stabilising bridge cannot happen in a trans conformation because 
the distance between side-chains is smaller in the cis conformation. Although some 
combinations might generate an equilibrium, as suggested by molecular modelling, this 
scaffold is generally believed to be too flexible to impose a full trans conformation. 
- Dilution experiments were performed on the dimers: only the ones designed to self-
assemble exhibited shifts during the dilution, in particular the protons near the side-chain 
groups. The dilutions were performed on control molecules  in order to assess that none 
of those results were due to unspecific interaction with the water present in the DMSO-
d6, proving that the molecules change state while diluting, suggesting some self-assembly 
happened at high concentration. 
The following work will enable the completion of the results obtained in this chapter: 
- Complete the initial library of oligoamides and perform the same NMR experiment in 
order to get more information and confirm the obtained results. In particular, the 
modelling for N-1A2BG (56) suggested a preference for a trans conformation, which could 
easily be determined by NMR and would confirm whether the cis conformation is always 
preferred or it is possible to force a trans conformation upon that class of compounds. 
- Design and synthesise N-alkylated trimers equipped with the same charge, such as 
N-1A2A3AG and N-1B2B3BG, or N-1A2iBu3AG and N-1B2iBu3BG, which should not allow 
stabilising interactions in the cis conformation, as well as alternating side-chains to enable 
closer side-chain/side-chain interaction stabilising the trans conformation, such as 
N-1A2B3AG or N-1B2A3BG. Investigating different types of resins to have an amine at the 
bottom of the oligomers will also enable to avoid any kind of interaction between a side-
chain and the resin. 
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- New crystal growth assays will be performed, changing the combinations of solvents, and 
varying the temperatures. 
- Finally, longer molecules will be prepared in order to mimic a full coiled coil. 
Considering the high flexibility of N-alkylated series, it is more likely to achieve this goal 
with O-alkylated oligomers equipped with alternated charges on the side-chains in order 
to conserve a cis conformation.
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The work reported in this chapter formed the basis of the following publication: 
I. Arrata, A. Barnard, D. C. Tomlinson, A. J. Wilson, Chem. Commun., 2017, 53, 2834-2837190 
 Introduction 
 Building proteins with non-natural foldamers 
Inspired by the three dimensional compact conformations adopted by proteins (helices, sheets, 
loops, turns and disordered domains),1 foldamers are non-natural polymers designed to adopt well 
defined secondary and tertiary or quaternary structures. The ultimate aim of foldamer synthesis 
is to generate 3-dimensional architectures with novel, enhanced or emergent function (Chapter 1 
and Figure 3.1).18, 19, 191 This goal aligns closely with efforts to build functional proteins de novo 
in synthetic biology.192-198 
 
Figure 3.1: Bottom-up design of foldamers, and examples of biologically relevant applications: 
building tertiary structure, PPI modulation, foldamer-protein hybrid capable of retaining a 
functional site, or immobilisation for use in screening protocols. 
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Although a major challenge in supramolecular chemical biology,199 considerable progress has 
been made in the de novo or bottom-up design of tertiary foldamers74, 200, 201 whilst efforts to 
understand and control their dynamic topology have broadened potential applications.50, 201-210 
“Protein prosthesis”,211-213 which consists in replacing segments of protein sequence with non-
natural foldamer,57, 210-215 is an alternative strategy to the design of functional foldamers, leading 
to bionic proteins.120 
A third related approach would be to exploit the potential of combinatorial biology to identify 
natural biomacromolecule sequences (comprised of amino-acid or nucleotide building blocks) 
that recognise a single synthetic foldamer.214 In identifying compatible natural and non-natural 
components driven by complementary molecular recognition, such an approach could be used to 
identify potential biological targets of a given foldamer,214 a potentially more rapid route to ligand 
discovery than the painstaking construction of libraries using synthetic foldamer assembly 
strategies.  
 Investigating foldamer/Affimer interactions 
The Wilson group extensively explored the use of proteomimetic scaffolds to inhibit the 
p53/hDM2 interaction, using libraries of 2-O-, 3-O-113 and N-alkylated114 series (in vitro and in 
cells),118 as well as hybrid scaffolds117 (further discussed in Chapter 1). Given the established 
ability of those proteomimetics to bind to hDM2, the basis of the work described in this chapter 
was to explore the extent to which biological selection methods can generate peptide sequences 
for future exploitation in construction of foldamer-peptide hybrids. For this purpose, a small 
library of N-alkylated trimers, including p53 mimetics, was used in phage display screening with 
a non-antibody-based scaffold, termed an Affimer.122 
 Phage display screening against a small foldamer library 
 Synthesis 
The current work focuses on a series of six N-alkylated trimers 58-63 and their biotinylated 
equivalents Biotin-58 to Biotin-63 (Figure 3.2). 59 to 63 were originally designed as p53 
mimetics.118 Trimers 58-63 and Biotin-58-63 were previously synthesised by Dr. Anna 
Barnard,118, 178, 215 whilst the general synthesis of N-alkylated building blocks is described in 
Chapter 2. The orthogonal functionalisation of the trimers was developed in the group by Dr Anna 
Barnard.215 Equipping trimers with biotin groups had previously enabled a streptavidin-biotin 
interaction for biological applications, such as pull down assays.118 On this basis, the trimers were 
equipped with biotin tags for immobilisation on streptavidin. 
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Figure 3.2: Details of the small library of N-alkylated trimers used for phage display. 
To enable a later click-chemistry reaction, the O-alkyne N-alkylated monomer 69 (Scheme 3.1) 
was prepared from methyl 3-hydroxy-4-nitrobenzoate 20. Quantitative propargylation of the 
phenol was followed by selective reduction of the nitro group from 65 to an amine, using tin (II) 
chloride. Saponification of the ester 66 led to the O-alkyne amino acid 67. N-alkylation by 
reductive amination and Fmoc protection gave 69, following the previously described 
procedure.215 
 
Scheme 3.1: Synthesis of the O-alkyne N-alkylated monomer 69. 
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The trimers were prepared by SPPS on a CEM Liberty® automated microwave assisted peptide 
synthesizer, following the procedure previously described in the group (see Chapter 2 for 
discussion on trimer synthesis).178 The samples were collected on resin after coupling: the biotin 
was installed on the relevant trimers by Cu(I) catalysed ‘click’-chemistry using biotin azide 72, 
previously synthesised in the group by Dr. Anna Barnard following the conditions described in 
Scheme 3.2.118 The trimers were cleaved manually using a 50% TFA solution in dichloromethane. 
 
Scheme 3.2: Synthesis of the azidiobiotin 72 (top) used to introduce a biotin moiety on the 
trimers by click chemistry (bottom).118 
 Phage Display Screening using Affimers 
Affimers were used in the phage display screening setting. An Affimer (Figure 3.3) is a highly 
thermostable artificial binding protein scaffold, based on the consensus optimisation216, 217 of 
plant-derived phytocystatins,218 comprising four β-strands, one α-helix, and two loops connecting 
each pairs of β-strands.122  
 
Figure 3.3: Structure of an Affimer (PDB ID: 4N6U). Insertion loops are highlighted in red.122 
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The randomisation of 9 amino acids occurs at each loop (Figure 3.3, red). Affimers have been 
successfully used in a number of discovery settings.123, 219-221 
An Affimer library with a complexity of 3x1010 was generated and screened against the 
N-alkylated trimers Biotin-58 to Biotin-63, which were immobilised on alternatively streptavidin-
coated wells, neutravidin-coated wells, and streptavidin-coated magnetic beads. The phage were 
incubated in the presence of the foldamers, non-binding Affimers were washed away, binding 
Affimers were eluted and amplified. Four panning rounds were performed, and bound phage were 
detected by phage ELISA (Figure 3.4) using Anti-Fd-Bacteriophage-horse radish peroxidase 
(HRP) and SeramunBlau® fast TMB. 
 
Figure 3.4: Cartoon representation of an ELISA experiment. The oxidation of TMB with 
hydrogen peroxide is catalysed by the HRP group covalently linked to the anti-phage. 
For each trimer, 48 monoclonal Affimers were tested by ELISA against all six biotinylated trimer, 
in order to assess their cross-selectivity (Figure 3.5). For Biotin-58, there were 25 binders, 12 of 
which were fully selective for Biotin-58; for Biotin-59, 41 Affimers, 30 of which were selective; 
7 Affimers for Biotin-60, 2 of which were selective; 19 Affimers for Biotin-61, none of which 
were selective; 18 Affimers for Biotin-62, none of which were selective; and 25 Affimers for 
Biotin-63, 4 of which were selective. 
The results thus yielded high numbers of selective binders for Biotin-58 and Biotin-59, while 
Biotin-60 and -61 generated fewer binders and exhibited very poor selectivity. In comparison to 
Biotin-58, Biotin-62 and -63 raised a good number of Affimers, nevertheless the selectivity was 
not as good. This is not completely unsurprising, considering the high similarities between the 
structures, as 59 to 63 were all designed as p53 mimetics. In particular, Biotin-62 and Biotin-63 
only differ by one Ar to Cl replacement. The fact that all the structures are highly hydrophobic is 
also a possible reason for cross-binding. Although the exact reasons for the difference in results 
observed for each compound are unclear, it is believed that the absence of any aromatic side-chain 
on Biotin-58, and the presence of a cyclohexane side chain on Biotin-59 may account for the 
higher cross-selectivity. On those considerations, it was decided to focus on the Affimers raised 
against Biotin-58 and Biotin-59 for the rest of the study. 
54 
 
 
Figure 3.5: ELISA readings for 48 monoclonal Affimers for Biotin-58 to Biotin-63 
For Biotin-58 and -59, Affimers showing differential values between test and negative control by 
ELISA were sequenced using a T7P primer – mixed colonies were removed from the list. Each 
Affimer was named using the format X-AFY, where X is the number of the trimer and Y the 
number of the Affimer out of 48. The data obtained is summarised in Table 3.1. 
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Interestingly, no pattern of amino acids stands out. Nevertheless, on average, non-polar or polar 
neutral amino acids tends to be predominant in the Affimer sequences, and polar positive 
outnumber polar negative amino acids. This may be explained by the presence of the carboxylic 
acid at the bottom of the foldamer, which is deprotonated in the conditions of the selection (pH 7). 
Table 3.1: Summary of the Affimer sequences obtained from screening against Biotin-58 and 
Biotin-59 (red: non-selective, green: selective). The amino acids are colour-coded according to 
the following principle: blue: polar positive, red: polar negative, green: polar neutral, grey: non-
polar aliphatic, purple: non-polar aromatic, orange: proline and glycine. 
Biotin-58 
AF Sequence 1 Sequence 2 
26, 27, 29 P H R N S L V S D Y R M A Y G F S W 
28 H P V K P Q Y P T Y K R W G I Y S W 
10, 19, 32, 47 V D W Y G P V Q A S M M T A R H N I 
43 H S Q W F M Y P G P A T V D E I M A 
46 H W A H W S G D A T Y M E E M N L N 
5, 6, 39 M D Q P W W G H I E N E G W P H L W 
7 Q A W V H V H Y I Y N G P A Y K I V 
8, 14, 41 Q W V H F S G D A Q P P Q T Y N M R 
17, 36 Y V Q N E D Y F Y Q F L R Y F P H H Y 
20, 45, 48 Y Y E A W W F P I H N E K S D H N E 
35 R V Q D I Y P T Y N A T G T T W M Q 
Biotin-59 
AF Sequence 1 Sequence 2 
1 T V S T W G G D F A N I K Q D L E M 
24 S V Y T W G G P F P I S E Q R F L P 
4, 5, 25, 42 F G P R Q Y F H H N G V P H M S M L 
13, 19, 23, 29, 30, 33-35 S G Y H K D T F A N V Y Y H N M Q I 
6, 12 R G I R E W T H H P S Q P H L H L Y 
11, 45 P D K S Q P W W P A N M K Q L Y H E 
15 N G P G R H H R H P T Y S Q W Y M M 
18 W N N V G S T L M Y K W I P W P Y I 
46 R A E T W D G P W N R S T P W D G F 
 
For each trimer, two selective and one non-selective Affimer were selected for further study: 58-
AF8, 58-AF17, 58-AF26 and 59-AF1, 59-AF23, 59-AF25. The choice was motivated by high 
occurrence (the most occurring binders were likely to be the best binders since they were selected 
relatively more than the others) and difference in sequences (the more varied the sequences, the 
more likely they were to exhibit different behaviour and deliver different results). In particular, 
the choice of 58-AF17 was motivated by the fact that its first loop counts 10 amino acids instead 
of 9 due to an insertion, which occurs naturally but is still a relatively rare phenomenon. The 
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selected Affimers were subcloned and expressed as his-tagged proteins as follows:122 from the 
phagemid vector, the Affimer DNA was PCR-amplified, digested with NheI and NotI restriction 
enzymes and ligated into a pET11a vector. The DNA was then transformed into XL1-Blue 
supercompetent E.Coli cells and the plasmid DNA was extracted and transformed into BL21 Star 
(DE3) E.Coli cells for expression. The Affimers were finally purified on a Ni-NTA resin. SDS-
Page gel was performed to assess the purity of the proteins before using in assays. 
To establish the affinity of interaction between foldamer and Affimer, a direct ELISA based 
titration of the Affimers was performed against immobilised trimer; here, anti-6X his-tag HRP 
and SeramunBlau® fast TMB were used for detection. The dose-response curves were fitted using 
a logistic model on Origin 7 to obtain EC50 values of: 58-AF8: 3.8 ± 0.9 µM; 58-AF17: 5 ± 1 µM; 
58-AF26: 0.19 ± 0.02 µM; 59-AF1: 9 ± 1 µM; 59-AF23: 3.3 ± 0.8 µM; 59-AF25: 0.98 ± 0.08 µM. 
The results are summarised in Figure 3.6. 
 
Figure 3.6: Normalised absorbance and EC50 values extrapolated from the ELISA direct 
titration for 58-AF8 (black), 58-AF17 (red), 58-AF26 (green), 59-AF1 (blue), 59-AF23 (cyan), 
and 59-AF25 (magenta), n = 3.  
Based on the results of the direct ELISA, concentrations corresponding to the beginning of the 
top plateau were chosen for further analysis: 10 M for 58-AF8 and 58-AF17, 0.3 M for 58-
AF26, 20 M for 59-AF1, 2 M for 59-AF23 and 5 M for 59-AF25. First, an equimolar 
competition assay was realised where the competitors were the non-biotinylated trimer (58 or 59), 
the biotinylated trimer (Biotin-58 or Biotin-59), streptavidin only (Str.), or a complex of 
streptavidin and biotinylated compound (Str-Biotin-58 or Str-Biotin-59). The normalised average 
of four measurements (n = 3 for each) are shown in Figure 3.7. 
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Figure 3.7: Competition ELISA on a 1:1 ratio of Affimer and competitor. The results are shown 
as a normalised average of four different measurements, with n = 3. Concentrations of the 
Affimers: [58-AF8] = 10 M, [58-AF17] = 10 M, [58-AF26] = 0.3 M, [59-AF1] = 20 M, 
[59-AF23] = 2 M and [59-AF25] = 5 M. 
The general trend observed for all the Affimers was a decrease of signal from non-biotinylated 
competition to biotinylated competition. Even though the positive controls did not allow 
determination of a proper reference for 58-AF8 and 59-AF1 despite several repeats and for a 
reason that could not be identified, the presence of the biotin on the foldamer seemed to enhance 
the binding affinity towards the Affimer compared to a foldamer without biotin. The same 
observation was made in the case of 59-AF23 and 59-AF25. The data for 58-AF17 and 58-AF26 
did not allow any conclusion to be drawn although streptavidin also appeared to compete for 
58-AF26 indicating strong binding between the two, which correlates well with the initial 
screening results where 58-AF26 showed high binding affinity but no selectivity. 
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When competing with biotinylated trimer, an increase of the blank signal was observed for most 
Affimers: this is believed to be the result of some Affimer-trimer sticking to the plate during the 
incubation, despite pre-blocking the blank wells with excess of biotin. 
Further analyses using 10 and 100-fold excess of competitor, focused only on 58, 59, Biotin-58 
and Biotin-59 (Figure 3.8). The concentrations were adjusted in order to reduce the error bars, so 
that [59-AF23] = 5 M and [59-AF25] = 10 M. 
 
Figure 3.8: Single-point competition assay using 10- and 100-fold excess of competitor, with 
n = 3. Concentrations of the Affimers: [58-AF8] = 10 M, [58-AF17] = 5 M, 
[58-AF26] = 0.3 M, [59-AF1] = 20 M, [59-AF23] = 5 M and [59-AF25] = 10 M. 
In this assay, the results showed that increasing the excess of competitor enhanced the competitive 
binding, and suggested the Affimers had more affinity for a biotinylated than a non-biotinylated 
compound. For all three Affimers screened against Biotin-59, the observed increase of signal upon 
59 
 
competition of Biotin-59 at the ratio 1:100 can be explained by precipitation of the trimer in the 
assay – attempts to avoid this phenomenon by increasing the percentage of DMSO in the buffer 
were infructuous as the maximum quantity needed to be kept under 10% and ideally under 5%. 
Finally, a competitive experiment was performed in a serial dilution assay, starting from 100-fold 
excess of competitor compared to the Affimer (Figure 3.9).  
 
Figure 3.9: Serial dilution competitive ELISA, n = 3. The following concentrations were used: 
[58-AF8] = 10 M, [58-AF17] = 10 M, [58-AF26] = 1 M, [59-AF1] = 20 M, 
[59-AF23] = 5 M and [59-AF25] = 10 M. 
Here again, the measurements were always prone to a high error, and data such as of 59-AF1 and 
59-AF23 could not be interpreted. The curves corresponding to 58-AF17 could be partially fitted 
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and a weak affinity for either competitor 58 or Biotin-58 is observed (IC50 > 100 M). In 
accordance with the single-concentrations experiments, streptavidin could compete for 58-AF26 
with similar IC50 values to 58 and Biotin-58. Data for 58-AF8 and 59-AF25 were more promising; 
58-AF8 had weak affinity for 58 (IC50 > 100 M), but using Biotin-58, IC50 = 2.5  0.6 M was 
obtained. This implied that trimer 58 on its own is insufficient for recognition of 58-AF8 and that 
the panning process selected for an Affimer that recognises both the three helix mimicking side 
chains of the foldamer and the forth biotin side-chain. In contrast, for 59-AF25 an 
IC50 = 56  2 M was obtained upon competition with 59, whereas a comparable 
IC50 = 28  10 M was obtained for competition with Biotin-59, suggesting the biotin had no 
significant effect on binding and indicating Affimer selection only for the three helix mimicking 
side-chains of 59. 
To further confirm this binding, it was decided to use an orthogonal method Fluorescence 
Anisotropy was chosen (FA, Figure 3.10). FA requires the introduction of a fluorescent tag on the 
trimer (Scheme 3.3): unbound, the tracer is free to rotate and therefore, upon radiation with 
polarised light, the emitted light will not be polarised and the anisotropy will be low; upon 
binding, the complex formed by the tracer and the protein is much bigger and will rotate more 
slowly than the free tracer, therefore the emitted light will be polarised, which is observed by an 
increase of anisotropy. 
 
Figure 3.10: Cartoon representation of the principles of Fluorescence Anisotropy (FA). 
The synthesis of Fluorescein-tagged analogues of 58 and 59 (respectively Flu-58 and Flu-59, as 
well as Flu-59rev, which is the reverse sequence of building blocks of Flu-59) was conducted 
following the same procedure as for the biotinylated trimers: Flu-azide 73 was synthesized as 
described in Scheme 3.3 and clicked to the trimer on solid phase.215 The yields of this coupling 
decreased compared to the click reaction to introduce the biotin: this was accounted for by poor 
solubility of 73 in water and N,N-dimethylformamide. Several solvents systems were tested to 
increase the solubility, and a mixture of water, dimethylsulfoxide and N,N-dimethylformamide 
was the only solvent system with which the product formation was observed. 
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Scheme 3.3: Synthesis of Flu-azide 73 and coupling on resin to form Flu-58, -59 and -59rev.215 
In agreement with the data obtained during the ELISA assays, Flu-59 was recognised by 59-AF25, 
and a binding constant was measured: Kd = 146  11 nM (Figure 3.11a). Gratifyingly, binding 
was not observed for Flu-59rev (Figure 3.11b, blue triangles). Because the values observed gave 
a straight line around an anisotropy of 1, it was suggested that there could be some non-selective 
interactions with the plate; for this reason, repeats of the same assay were performed in a special 
non-stick plate (Figure 3.11b, yellow lozenges), but still no binding curve could be obtained from 
this assay. This result attests of the high selectivity of the Affimer for the exact sequence order 
and composition of side-chains. The direct titration of Flu-58 against 58-AF8 (Figure 3.11b, green 
circles) was also carried out, but did not yield a binding curve either; this confirms the previously 
observed recognition of the biotin as well as the proteomimetic side-chains, as the introduction of 
the fluorescein motif would not be recognised by the Affimer 58-AF8. 
 
Figure 3.11: Fluorescence Anisotropy assays: a) binding curve of Flu-59 with 59-AF25 and 
b) results of Flu-59rev against 59-AF25 and Flu-58 against 58-AF8, showing no binding 
occurred. 
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 Synthesis of biotinylated trimers equipped with a longer 
linker 
It was proven that the biotin group can interfere in the recognition of the Affimer, with the 
example of 58-AF8 binding with micromolar affinity to Biotin-58, but not to 58. Although some 
results indicated that the biotin is not systematically recognised by the Affimers, a way of 
optimising the selection by limiting this non-specific interaction may be to introduce a longer 
linker between the trimer and the biotin moiety. To do so, a new orthogonally functionalised 
scaffold involving the presence of PEG units to act as elongated linkers was designed (Figure 
3.12).  
 
Figure 3.12: New scaffold for orthogonally-functionalised foldamers. 
The synthesis of the new scaffold required the preparation of a new azide, called Biotin-PEG-
Azide 76 (Scheme 3.4), as well as a new alkyne-equipped monomeric building block (Scheme 
3.5). The azide synthesis started off using the acid chloride salt 71 and coupling on 8-(Fmoc-
amino)-3,6-dioxaoctanoic acid. Attempts to achieve this coupling using EDC and HOBT, and 
HCTU were conducted but neither of them were conclusive. Finally, PyBOP was chosen as it led 
to 74 with 82% yield. The Fmoc group was removed using triethylamine and the biotin 
functionalisation was performed using HCTU and DIPEA in N,N-dimethylformamide. 
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Scheme 3.4: Synthesis of Biotin-PEG-Azide 76. 
The new monomeric building block was prepared in a similar manner as previously (Scheme 3.5). 
3-(2-(2-(2-chloroethoxy)ethoxy)ethoxy)prop-1-yne 77 was obtained from the Bon group at the 
University of Leeds, and prepared as a 4:1 mixture of Cl:Br group from a published procedure.222 
The first coupling required the presence of potassium iodide and heating to 70°C, to afford 78 
with a 51% yield. Tin (II) chloride reduction followed by saponification, reductive amination with 
isobutyraldehyde and Fmoc protection led to the final monomer 82. 
 
Scheme 3.5: Preparation of the PEG-equipped alkyne monomer 82. 
For time considerations and considering the final amount obtained of final monomer (40 mg) 82, 
trimer synthesised was not attempted.  
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 Conclusions and future work 
A library of six biotinylated N-alkylated trimers was screened in phage display experiment using 
Affimers. Out of the six, two exhibited few binders with little selectivity (Biotin-60 and -61), two 
exhibited a moderate number of binders and little selectivity (Biotin-62 and -63), one exhibited a 
moderate number of binders with good selectivity (Biotin-58) and one exhibited a good number 
of binders with strong selectivity (Biotin-59). The Affimer hits obtained for Biotin-58 and -59 
were sequenced, and amongst them, three were selected for each trimer (two selective and one 
non-selective), to be subcloned, expressed and purified. Preliminary direct titration ELISA assay 
were performed to assess the strength of the binding of each Affimer towards their corresponding 
trimer. Further single point competition assays were carried out to evaluate the degree of binding 
to the following competitors: non-biotinylated trimer, biotinylated trimer, streptavidin, 
streptavidin-biotinylated trimer. Finally, serial dilution competition assays were performed to 
obtain, when possible, full competition curves and IC50 values. In particular, three cases showed 
three different binding behaviours: 58-AF8 recognises Biotin-58 (IC50 = 2.5  0.6 M), but its 
affinity for 58 without biotin is very weak (IC50 > 100 M); 59-AF25 recognises the side-chains 
of 59, independently of the presence of a biotin or streptavidin group (IC50 = 56  2 M for 
competition with 59, IC50 = 28  10 M for competition with Biotin-59, IC50 = 44  8 M for 
competition with Str.-Biotin-59); 1-AF26 is non-selective, and recognises all the tested 
competitors with similar affinities. Finally, FA assays were conducted: for this purpose, FITC 
tagged trimers Flu-58, Flu-59 and Flu-59rev were prepared and tested against the Affimers in 
direct titrations assays. The binding curves obtained confirmed the results from the ELISA tests: 
Flu-59 bound to 59-AF25, proving its ability to recognise the side-chains independently of the 
orthogonal group; and no binding curve could be obtained against Flu-59rev, confirming the 
strong selectivity obtained for this Affimer and the importance of the sequence order and 
composition of side-chains. 
On those results, a new scaffold was designed, in order to add space between the trimer and the 
biotin group. A new azide and a new alkyne building block were prepared, both including PEG 
units to lengthen the linker. The full synthesis of each compound was described and optimised.  
Future work includes preparing new biotinylated trimers equipped with the new linker and 
screening them against Affimers. Comparing the new selection of hits with the previous ones will 
give important information towards the recognition during the assay. Similar ELISA and FA 
experiments should be conducted to assess the ability of the new hits to recognise exclusively the 
side-chains of the trimers. 
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Only 20 different amino acids are at the origin of a stunning array of over 18,000 proteins,1, 2 
responsible for complex and selective tasks essential for life. The complex 3-dimensional 
structures that enables such complexity, involving helices, sheets, loops, turns, and disordered 
domains, arise from a precise self-organisation of proteins, which is defined by their primary 
structure alone. Although great progress has been made in de novo design of foldamers,50, 76, 79, 93, 
200, 206, 214, 223 chemical and synthetic biologists are facing the long-term challenge to expand the 
genetic toolbox to generate functional bionic proteins that are not limited to sequences of α-amino 
acids only.3, 199 
Considering the importance of α-helices in protein function, α-helix mimicry is a promising 
approach to replicating segments of proteins.5 The previous research conducted in the Wilson 
Group has extensively investigated type III α-helix mimetics (proteomimetics), i.e. structures that 
match the topography of the original helix motif by mimicking the spatial orientation of its key 
functional residues.11 2-O-, 3-O- and N-alkylated oligoamides were designed and successfully 
used as PPI inhibitors113, 114, 119 in vitro as well as in cells.118 Preliminary work towards generating 
bionic proteins was also conducted with a bionic peptide.120 
This project aimed at using proteomimetics to generate novel 3-dimensional assemblies and 
therefore advance towards engineering bionic proteins. The first part of the project attempted to 
design coiled coil mimetics with proteomimetics in order to establish the ability of proteomimetics 
to mimic α-helical supramolecular assemblies.  
In that regard, N- and O-alkylated oligomers bearing hydrophilic side-chains, designed to self-
assemble, were prepared (Chapter 2). The small library obtained was studied by NMR, which 
proved that the conformation of dimers can be, to some extent, controlled by careful design of the 
side-chains: for O-alkylated dimers, a strictly syn conformation was generated, while free rotation 
around the amide bond usually allows a syn/anti equilibrium (Figure 4.1a); for N-alkylated 
dimers, a preference for the cis conformation was observed (Figure 4.1b); N-alkylated trimers 
bearing central hydrophobic side-chains also proved to be too flexible to generate any trans 
conformation. The potential for self-assembly of those compounds was tested by dilution 
experiments. Significant shifts in the NMR were observed in the molecules designed to self-
assemble, while the spectra of the control molecules were unchanged upon dilution, suggesting 
that self-assembly was indeed observed. Further efforts to confirm this hypothesis are 
nevertheless still required. 
To complete this study, the synthesis of a larger library, including different patterns of side-chains, 
and different lengths of oligomers will be necessary. Since modelling suggested that the 
carboxylic acid issued from the resin was involved in different patterns of interactions, it will be 
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interesting to investigate the use of other resins in order to obtain an oligomer equipped with a C-
terminal amine or amide group.  
 
Figure 4.1: Results from chapter 2 suggest that it is possible to a) lock an O-alkylated dimer in 
the cis conformation, but b) no trans conformation was observed for the N-alkylated series. 
Once evidence of self-assembly with dimers and trimers is observed, efforts to construct longer 
oligoamides will be conducted to generate a proteomimetic equivalent of a stalk. Further work 
will aim to diversify the types of coiled coils mimicked, and obtained a biologically functional 
coiled coil mimetic. 
The second part of the project focused on a novel artificial binding protein scaffold developed 
within the Astbury Centre termed Affimer,122 to be screened against proteomimetics in phage 
display so as to assess the ability for proteomimetics to act as native α-helices. 
A library of 6 biotinylated N-alkylated trimers was screened against a library of Affimers. Two 
of them, Biotin-58 and Biotin-59, generated an important number of hits with good selectivity. 
The binding affinities of the foldamers towards a small selection of Affimers were assessed by 
direct titration ELISA assay. Competition assays were further carried out to assess whether the 
Affimers recognised only the side-chains of the proteomimetics, or the full biotin-trimer 
assembly. Several cases were observed, where only the side-chains were recognised (59-AF25, 
Figure 4.2a); where the side-chain and the biotin were recognised (58-AF8, Figure 4.2b); or where 
the Affimer bound to any compound in solution, including the streptavidin on its own (58-AF26). 
Finally, the different patterns of selectivity observed by ELISA were confirmed by FA assays. 
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To improve the screening process, improvements were made to the design of the scaffold, in order 
to lengthen the linker between the recognition face of the foldamer and the biotin moiety. To do 
so, a new azide and a new alkyne building block were prepared, both including PEG units, 
although no trimer was prepared for time considerations. Future work should focus on preparing 
a new library of trimers equipped with this new linkers, and screening them again in an Affimer 
phage display setting in order to maximise the recognition of the side-chains only. 
 
Figure 4.2: Schematic examples of an Affimer recognition a) the side-chains of a foldamer, and 
b) the side-chains and the streptavidin tag (orange). 
Long-term efforts will focus on the binding sequence from the loops (Figure 4.3). Firstly, it is 
possible to express Affimers with one of the two loops mutated: this will allow to establish 
whether both or only one loop is required for binding. Then, excision of the binding peptide(s) 
will allow direct study of the binding between the trimer and the peptide, and enable to obtain 
more information on the 3-dimensional structure of the loop. Finally, the Affimer phage display 
will be used as a reverse screening method for biologically relevant targets: the binding sequences 
will be compared to literature databases in order to identify known sequences corresponding to a 
PPI, therefore allowing to discover interactions to which existing trimers have inhibitory potency. 
 
Figure 4.3: Summary of the future work concerning the Affimers. 
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 Synthesis 
 General considerations 
Solvents. Unless stated otherwise, solvents and reagents were used as received from major 
suppliers without prior purification. Anhydrous acetonitrile, chloroform, dichloromethane were 
obtained from the in-house solvent purification system from Innovative Technology Inc. 
PureSolv®. Anhydrous dimethylsulfoxide was obtained from major chemical suppliers equipped 
with a SureSeal or equivalent. Non-anhydrous solvents were of HPLC quality and provided by 
Fisher or Sigma-Aldrich. Water used for formation of aqueous solutions and quenching was 
deionised. 
Chromatograhy. Thin Layer Chromatography (TLC) was performed on Merck Kieselgel 60 F24 
0.25 mm precoated aluminium plates. Product spots were visualised under UV light 
(λmax = 254 nm) and/or staining with anisaldehyde. Purifications were performed with either silica 
gel 60 (0.043-0.063 mm VWR) using head bellows or by flash chromatography using an Isolera 
Four Biotage®. Ion-exchange columns were performed using Supleco Discovery SPE DSC-SAX 
columns. HPLC experiments were run on an Agilent 1290 Infinity Analytical Preparative system 
spectrometer. 
NMR. 1H NMR spectra were recorded on Bruker DPX 300 (300 MHz) or Advance 500 (500 
MHz) spectrometers and referenced to residual non-deuterated solvent peaks. 13C NMR were 
recorded on a Bruker Advance 500 (125 MHz) and referenced to the solvent peak. Chemical shifts 
(δ) are expressed in part per million (ppm) and coupling constants are expressed in hertz (Hz). 
Assignments of spectra were assisted by the results of COSY, NOESY, TOCSY, ROESY, HMQC 
and HMBC experiments when appropriate. 
Mass. HPLC LC-MS were recorded on a Bruker HCT ultra under the conditions of electrospray 
ionisation (ESI). HPLC separation was performed on an Agilent 1200 series instrument equipped 
with a Phenomenex C18 column (50 x 2 mm) using acetonitrile/water as the eluent for positive 
ion spectra. HRMS were performed using a Bruker Maxis impact mass spectrometer, using ESI. 
Values are reported as a ratio of mass to charge.  
IR. Infrared spectra were recorded on a Perkin Elmer Fourier-Transfer spectrometer. Spectra were 
analysed neat and only structurally important absorptions are quoted. Absorption maxima (νmax) 
are quoted in wavenumbers (cm-1). 
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Characterisation. For compounds previously published in the group, LC-MS and 1H NMR were 
used to confirm the structure and purity. New compounds were either partially characterised (side 
chain intermediates or instable compounds: 1H NMR, 13C NMR) or fully characterised (1H NMR, 
13C NMR, HRMS and IR are reported). 
 Foldamer building block side chain syntheses 
tert-Butoxycarbonylmethyl nitrate (2)178 
 
Tert-butyl bromoacetate 1 (3.0 mL, 20.3 mmol) and silver nitrate (4.5 g, 26.4 mmol) were stirred 
in anhydrous acetonitrile (40 mL) under a nitrogen atmosphere for 16 hours, in the dark. The 
reaction mixture was filtered, and the filtrate was concentrated under vacuum. The residue was 
washed with water (100 mL) and extracted with diethyl ether (100 mL). The organic layer was 
dried over magnesium sulphate, filtered and the filtrate concentrated under vacuum to afford 2 as 
a colourless oil, which was used without further purification (2.9 g, 81%). δH (500 MHz, CDCl3) 
4.79 (s, 2H, CH2), 1.52 (s, 9H, C(CH3)3). 
di-tert-Butyl fumarate (8) 
 
First method:181 tert-Butyl acrylate 6 (4.0 mL, 27.6 mmol) was added to a solution of Grubbs 
second generation catalyst (24 mg, 0.028 mmol) in anhydrous dichloromethane (1 mL) under a 
nitrogen atmosphere. The solution was stirred and heated to reflux for 16 hours. The solution was 
cooled down to room temperature and the solvent was evaporated under vacuum. The residue was 
purified by column chromatography (eluent: ethyl acetate/hexane: 1/10) to give the target material 
8 as a white crystalline solid (245 mg, 8%). Second method:182 n-Butyl lithium (37.5 mL of 1.6 
M in hexane, 60.0 mmol) was added over 10 minutes to anhydrous tert-butyl alcohol (10.0 mL, 
105.0 mmol) at 0°C, under a nitrogen atmosphere, and the suspension was stirred at 0°C for 40 
minutes. Fumaryl chloride 7 (6.5 mL, 60.0 mmol) was added over 40 minutes at room temperature 
and the solution was stirred at room temperature for 4 hours. The reaction was then quenched 
with water (50 mL) and the organic layer was washed with saturated sodium hydrogen carbonate 
(50 mL) and dried over magnesium sulphate, filtered and the filtrate was concentrated under 
vacuum. The crude product was purified by column chromatography (eluent: ethyl 
acetate/hexane: 1/9) to afford 8 as a white crystalline solid (5.13 g, 38%). H (500 MHz, CDCl3) 
6.67 (s, 2H, CH=CH); 1.50 (s, 18H, C(CH3)3). 
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tert-Butyl glyoxylate (3)  
 
First Method:178 tert-Butoxycarbonylmethyl nitrate 2 (2.9 g, 16.5 mmol) and sodium acetate (1.3 
g, 16.5 mmol) were stirred in anhydrous dimethyl sulfoxide (20 mL) under a nitrogen atmosphere 
for 30 minutes. The mixture was poured into brine (100 mL) and extracted with dichloromethane 
(3 x 30 mL). The organic layer was washed with sodium hydrogen carbonate (50 mL) and brine 
(50 mL), then dried over magnesium sulphate, filtered and the filtrate concentrated under vacuum 
to give 3 as a dark yellow oil (containing some residual dimethyl sulfoxide, 560 mg, < 26%) used 
without further purification. Second method:183 Ozone was passed through a solution of di-tert-
butyl fumarate 8 (5.6 g, 24.6 mmol) in dichloromethane (20 mL) at -78°C over 30 minutes, after 
which a blue coloration of the solution was observed. Excess ozone was swept out by a stream of 
oxygen and further bubbled with nitrogen, until the solution became clear again. Dimethyl sulfide 
(9.0 mL, 123.0 mmol) was added and the solution was allowed to reach room temperature and 
stirred for 16 hours. The residue was stirred with magnesium sulfate for 30 minutes, filtered and 
the filtrate evaporated under vacuum to give 3 as a dark yellow oil (containing some residual 
dimethyl sulfoxide, 3.54 g, 13% estimated by NMR) used without further purification. 
H (500 MHz, CDCl3) 9.30 (s, 1H, C(O)H), 1.57 (s, 9H, C(CH3)3). 
4-(tert-butoxy)-4-oxobutanoic acid (11)224  
 
Succinic anhydride (5.0 g, 50.0 mmol) 10, N-hydroxysuccinimide (1.7 g, 15.0 mmol) and 4-
dimethylaminopyridine (610 mg, 5.0 mmol) were dissolved in toluene (25 mL). tert-Butanol 
(5.9 mL, 62.5 mmol) and triethylamine (2.1 mL, 15 mmol) were added sequentially and the 
mixture was refluxed for 16 hours. The solution was cooled down to room temperature and poured 
into ethyl acetate (25 mL) and washed with a 10%w citric acid solution (50 mL) and brine 
(50 mL). The organic layer was dried over magnesium sulfate, filtered, and the filtrate was 
concentrated and purified by column chromatography (eluent: dichloromethane). Product 11 was 
collected as a white solid (3.67 g, 42%). H (CDCl3, 500 Mz) 2.65 (t, 2H, J = 6.8, -CH2CO2H), 
2.56 (t, 2H, J = 6.8 Hz, -CH2CO2C(CH3)3), 1.45 (s, 9H, C(CH3)3). C (CDCl3, 125 Mz): 178.0, 
171.4, 81.0, 30.0, 29.1, 27.9. 
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tert-Butyl 4-hydroxybutanoate (12)224 
 
4-(tert-Butoxy)-4-oxobutanoic acid 11 (2.1 g, 11.8 mmol) was dissolved in anhydrous 
tetrahydrofuran (20 mL) and borane dimethylsulfide complex 2 M in tetrahydrofuran (6.5 mL, 
13.0 mmol) was added dropwise to the mixture. The solution was stirred at room temperature for 
16 hours, and poured into ethyl acetate (100 mL), then washed with water (50 mL) and brine (100 
mL). The organic layer was dried over magnesium sulphate, filtered, and the filtrate was 
concentrated under vacuum and purified by column chromatography (eluent: 
dichloromethane/methanol: 9.5/0.5). 12 was collected as a colourless oil (862 mg, 46%). H 
(CDCl3, 500 Mz) 3.66 (t, 2H, J = 6.2, -CH2OH), 2.35 (t, 2H, J = 7.1 Hz, -CH2CO2C(CH3)3), 2.20 
(s, 1H, OH), 1.85 (quint., 2H, J = 6.2 Hz –CH2-), 1.43 (s, 9H, C(CH3)3). C (CDCl3, 125 Mz): 
173.4, 80.4, 62.1, 32.4, 28.0, 27.8. 
tert-Butyl 4-oxobutanoate (13) 
 
A solution of oxalyl chloride (1.1 mL, 12.7 mmol) in dichloromethane (200 mL) was cooled 
to -78°C. Dimethyl sulfoxide (1.0 mL, 24.1 mmol) was added and the mixture was stirred at -78°C 
for 1 hour. tert-Butyl 4-hydroxybutanoate 12 (1.13 g, 7.1 mmol) was added and the mixture was 
stirred at -78°C for 1 hour. Triethylamine (4.9 mL, 35.3 mmol) was added dropwise and the 
mixture was allowed to reach room temperature and stirred at room temperature for 16 hours. The 
reaction mixture was then poured into water (200 mL) and extracted with dichloromethane 
(2 x 150 mL). The organic layer was dried over magnesium sulphate and the solvent was removed 
under vacuum to give 13 as a colourless oil (326 mg, 30%). H (CDCl3, 500 Mz) 9.80 (s, 1H, -
CHO), 2.74 (t, 2H, J = 6.6 Hz, -CH2CHO), 2.56 (t, 2H, J = 6.6 Hz, -CH2CO2C(CH3)3), 1.44 (s, 
9H, C(CH3)3). C (CDCl3, 125 Mz): 200.5, 171.7, 81.1, 38.9, 28.3, 28.1. 
tert-Butyl 4-bromobutanoate (14)225 
 
Tert-Butyl 4-hydroxybutanoate 12 (250 mg, 1.6 mmol) and carbon tetrabromide (1.0 g, 3.1 mmol) 
were dissolved in tetrahydrofuran (5 mL), in an ice bath. A solution of triphenylphosphine (817 
mg, 3.1 mmol) in tetrahydrofuran (5 mL) was slowly added and the mixture was allowed to reach 
room temperature and then stirred for 16 hours. The residue was filtered off, the solvent was 
removed under vacuum, and the obtained oil was purified by column chromatography (eluent: 
ethyl acetate/hexane: 5/95) to give 14 as a yellow oil (247 mg, 71%). H (CDCl3, 500 Mz) 3.47 
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(t, 2H, J = 6.8 Hz, -CH2Br), 2.42 (t, 2H, J = 6.8 Hz, -CH2CO2C(CH3)3), 2.17 (quint., 2H, J = 6.8 
Hz, –CH2-), 1.44 (s, 9H, C(CH3)3). 
3-(N-boc-amino)-1-propanol (18)178 
 
di-tert-Butyl dicarbonate (32.0 g, 146.5 mmol) in dichloromethane (100 mL) was added dropwise 
to a solution of 3-aminopropan-1-ol 17 (10.0 mL, 133.2 mmol) in dichloromethane (70 mL). The 
solution was stirred for 16 hours at room temperature. The reaction was quenched with saturated 
aqueous sodium hydrogen carbonate (100 mL) and the mixture was washed with water (50 mL) 
and brine (50 mL). The organic layer was dried over magnesium sulfate, filtered, and the filtrate 
was concentrated under vacuum to afford compound 18 as a colorless oil (18.6 g, 80%). H (500 
MHz, CDCl3) 4.84 (s, 1H, N-H), 3.67 (q, 2H, J = 5.9 Hz, HOCH2CH2-), 3.29 (q, 2H, J = 5.9 Hz, 
CH-2CH2NH-), 3.09 (s broad, 1H, OH) 1.68 (qu., 2H, J = 5.9 Hz, -CH2CH2CH2-), 1.44 (s, 9H, 
(CH3)3). 
tert-Butyl (3-oxopropyl)carbamate (19)178 
 
Dimethyl sulfoxide (1.6 mL, 23.4 mmol) was added at -78⁰C to a solution of oxalyl chloride 
(1.7 mL, 21.0 mmol) in anhydrous dichloromethane (20 mL) under a nitrogen atmosphere and 
the solution was stirred for 1 hour at -78⁰C. 3-(N-Boc-amino)-1-propanol 18 (1.4 mL, 8.3 mmol) 
was then added and the resulting mixture was further stirred for 1 hour at -78⁰C. Triethylamine 
(7.9 mL, 57.0 mmol) was added and the mixture was allowed to reach room temperature and 
further stirred for 16 hours. The reaction was quenched with water (30 mL) and the mixture 
extracted with dichloromethane (2 x 30 mL) and concentrated under vaccum. The residue was 
purified by column chromatography (eluent: dichloromethane/methanol: 9.8/0.2) to afford the 
desired product 19 as a dark yellow viscous oil (960 mg, 67%). H (500 MHz, CDCl3) 9.81 (s, 
1H, C(O)H), 4.90 (s, 1H, N-H), 3.44 (q, 2H, J = 5.9 Hz -CH2CH2NH-), 2.72 (t, 2H, J = 5.9 Hz, -
CH2CH2CH2-), 1.43 (s, 9H, (CH3)3). C (125 MHz, CDCl3) 200.6, 171.7, 81.1, 38.9, 28.3, 28.1. 
tert-Butyl (3-bromopropyl)carbamate (16)177 
 
A suspension of 3-bromopropylamine 15 (18.0 g, 83.0 mmol) and di-tert-butyl dicarbonate (18.0 
g, 83.0 mmol) in chloroform (40 mL) was stirred at 0ᵒC. Triethylamine (18.0 mL, 165.0 mmol) 
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was added dropwise over 1 hour and the mixture was stirred at room temperature for 16 hours. 
Chloroform (20 mL) was added, and the solution was washed with a 1M hydrochloric acid 
solution (2 x 20 mL) and water (2 x 20 mL). The organic layer was dried over magnesium sulfate, 
filtered and the filtrate was evaporated to dryness to afford the desired compound 16 as a yellow 
oil (14.4 g, 73%). H (CDCl3, 500 Mz) 4.75 (s, 1H, NH), 3.45 (t, 2H, J = 6.4 Hz, BrCH2-), 3.29 
(q, 2H, J = 6.4 Hz -CH2NH-), 2.08 (quint., 2H, J = 6.4 Hz, -CH2-), 1.44 (s, 9H, OC(CH3)3). 
 Monomer synthesis 
 General procedures 
a) Procedure for O-alkylation 
The phenol (1 eq.), alkyl halide (1.5 eq.), and potassium carbonate (3 eq.) were stirred in N,N-
dimethylformamide (4 mL/mmol) and heated to 50°C for 16 hours. The mixture was cooled down 
to room temperature and poured into water (3 mL/mmol), extracted with ethyl acetate (3 
mL/mmol) and the organic layer was then washed with brine (40 mL/mmol). The organic layer 
was dried over magnesium sulfate, filtered, and the filtrate was evaporated under vacuum and 
purified by column chromatography as required. 
b) Procedure for nitro reduction – hydrogenation 
The nitro compound (1 eq.) was dissolved in methanol:tetrahydrofuran or methanol:ethyl acetate 
(1:1, 5 mL/mmol) and the solution was bubbled with nitrogen for 5 minutes. Palladium 10% on 
carbon (10%w) was added and the solution was further bubbled with nitrogen for 5 minutes. 
Hydrogen was passed through the reaction mixture at room temperature for 16 hours, using a 
balloon. The mixture was filtered through a pad of celite, washed with methanol, and the filtrate 
was evaporated. 
c) Procedure for nitro reduction – tin chloride 
Tin (II) chloride dihydrate (5 eq.) was added to a solution of nitro compound (1 eq.) in ethyl 
acetate (12 mL/mmol), and the reaction mixture was stirred at 50⁰C for 16 hours under a 
nitrogen atmosphere and with a drying tube. The solution was poured into iced water 
(4 mL/mmol) and basified with sodium hydrogen carbonate. The product was extracted with ethyl 
acetate (4 mL/mmol) and the organic layer was washed with sodium hydroxide 1M (2 mL/mmol), 
water (2 mL/mmol) and brine (2 mL/mmol). The organic layer was dried over magnesium sulfate, 
filtered, and the filtrate was evaporated under vacuum. 
d) Procedure for ester hydrolysis 
Sodium hydroxide (6 eq., 10% aqueous solution) was added to a solution of ester (1 eq.) in a 1:1 
mixture of methanol and tetrahydrofuran (4 mL/mmol), and the solution was stirred at room 
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temperature for 16 hours. The mixture was poured into dichloromethane (3 mL/mmol) and the 
organic layer was washed with water (5 mL/mmol). The aqueous layer was acidified to pH 4 with 
a 1M aqueous hydrochloric acid solution and extracted with dichloromethane (9 mL/mmol). The 
organic layer was dried over magnesium sulfate, filtered, and the filtrate was concentrated under 
vacuum. 
e) Procedure for reductive amination 
The amino benzoic acid (1 eq.), aldehyde (1 eq.) and picoline borane (1.2 eq.) were stirred in 
methanol (2 mL/mmol) at room temperature for 3-16 hours. The solvent was removed and the 
residue diluted in ethyl acetate (4 mL/mmol), and washed with a 1M aqueous HCl solution 
(4 mL/mmol). The organic layer was dried over magnesium sulphate, filtered, and the filtrate was 
concentrated under vacuum. 
f) Procedure for Fmoc protection 
The amine (1 eq.) and fluorenylmethyl chloroformate (1 eq.) and sodium carbonate (2 eq. for 
Boc-protected groups) or sodium hydrogen carbonate (1.1 eq. for tert-butyl esters) were refluxed 
for 16 hours in anhydrous chloroform (4 mL/mmol). The residue was evaporated and purified 
either by precipitation or column chromatography. 
 O-alkylated monomers (Chapter 2) 
Methyl 3-isobutoxy-4-nitrobenzoate (21)177 
 
Using the general procedure for O-alkylation a). Methyl-4-amino-3-hydroxybenzoate 20 (3.0 g, 
15.2 mmol); isobutyl bromide (2.9 mL, 26.9 mmol); potassium carbonate (7.4 g, 53.7 mmol); 
N,N-dimethylformamide (60 mL). Orange solid (2.9 g, 75%). H (500 MHz, CDCl3) 7.84 (d, 1H, 
J = 8.5 Hz, Ar-H), 7.74 (d, 1H, J = 1.6 Hz, Ar-H), 7.69 (dd, 1H, J = 8.5 Hz, 1.6 Hz, Ar-H), 3.99 
(s, 3H, O-CH3), 3.96 (d, 2H, J = 6.4 Hz, CH2CH(CH3)2), 2.21-2.16 (m, 1H, CH2CH(CH3)2), 1.09 
(d, 6H, J = 6.8 Hz, CH2CH(CH3)2). 
Methyl 4-amino-3-isobutoxybenzoate (22)177 
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Using the general procedure for nitro reduction b). Methyl-3-isobutoxy-4-nitrobenzoate 21 (2.9 
g, 11.4 mmol); methanol:tetrahydrofuran 1:1 (60 mL); palladium 10% on carbon (300 mg). Red 
solid (2.22 g, 86%). H (500 MHz, CDCl3) 7.54 (dd, 1H, J = 8.3, 0.5 Hz, Ar-H), 7.43 (s, 1H, 
Ar-H), 6.68 (d, 1H, J = 8.3 Hz, Ar-H), 4.23 (s (broad), 2H, NH2), 3.86 (s, 3H, OCH3), 3.83 (d, 
2H, J = 6.4 Hz, CH2CH(CH3)2), 2.16-2.11 (m, 1H, CH2CH(CH3)2), 1.06 (d, 6H, J = 6.8 Hz, 
CH2CH(CH3)2). 
4-amino-3-isobutoxybenzoic acid (23)177 
 
Using the general procedure for ester hydrolysis d). Methyl-4-amino-3-isobutoxybenzoate 22 
(2.2 g, 9.9 mmol); sodium hydroxide (22.0 mL, 59.4 mmol); methanol:tetrahydrofuran (1:1, 
40 mL). Yellow solid (1.7 g, 83%). H (500 MHz, CDCl3) 7.63 (d, 1H, J = 8.0 Hz, Ar-H), 7.48 
(s, 1H, Ar-H), 6.70 (d, 1H, J = 8.0 Hz, Ar-H), 3.85 (d, 2H, J = 6.4 Hz, CH2CH(CH3)2), 2.18-2.12 
(m, 1H, CH2CH(CH3)2), 1.07 (d, 6H, J = 6.6 Hz, CH2CH(CH3)2). 
4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-isobutoxybenzoic acid (24)177 
 
Using the general procedure for Fmoc protection f). 4-amino-3-isobutoxybenzoic acid 23 (1.6 g, 
7.8 mmol); fluorenylmethyl chloroformate (2.0 g, 7.8 mmol); anhydrous chloroform (30 mL). 
The residue was filtered, taken up in chloroform and precipitated with hexane. The procedure was 
repeated three times, until a pale cream solid, 24, was obtained (2.2 g, 65%). H (500 MHz, CDCl3) 
8.15 (s (broad), 1H, N-H) 7.81 (d, 2H, J = 7.5 Hz, Ar-H), 7.76 (d, 1H, J = 7.3 Hz, Ar-H), 7.64 (d, 
2H, 7.5 Hz, Ar-H), 7.58 (s, 1H, Ar-H), 7.54 (s, 1H, Ar-H), 7.45 (t, 2H, J = 7.5 Hz, Ar-H), 7.35 (t, 
2H, J = 7.3 Hz, Ar-H), 4.54 (d, 2H, J = 6.4 Hz, CH2(Fmoc)), 4.34 (t, 1H, J = 6.8 Hz, CH(Fmoc)), 
3.92 (d, 2H, J = 6.4 Hz, CH2CH(CH3)2), 2.26-2.18 (m, 1H, CH2CH(CH3)2), 1.12 (d, 6H, J = 6.6 
Hz, CH2CH(CH3)2). 
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Methyl 3-(3-((tert-butoxycarbonyl)amino)propoxy)-4-nitrobenzoate (25)177 
 
Using the general procedure for O-alkylation a). Methyl-4-amino-3-hydroxybenzoate 20 (5.2 g, 
26.4 mmol); tert-butyl (3-bromopropyl)carbamate (9.4 g, 39.6 mmol); potassium carbonate 
(10.9 g, 79.2 mmol); N,N-dimethylformamide (100 mL). The residue was purified by column 
chromatography (eluent: hexane/ethyl acetate: 7/3) to give 25 as a yellow solid (3.03 g, 32%). H 
(CDCl3, 500 Mz) 7.86 (d, 1H, J = 8.3 Hz, Ar-H), 7.74 (s, 1H, Ar-H), 7.70 (td, 1H, J = 8.3 Hz, 
J = 0.7 Hz, Ar-H), 4.98 (s br., 1H, NH), 4.26 (t, 2H, J = 5.9 Hz, OCH2), 3.96 (s, 3H, OCH3), 3.38 
(q, 2H, J = 5.9 Hz, CH2-NH), 2.08 (quint., 2H, J = 5.9 Hz, -CH2-), 1.44 (s, 9H, (CH3)3). 
Methyl 4-amino-3-(3-((tert-butoxycarbonyl)amino)propoxy)benzoate (26)177 
 
Using the general procedure for nitro reduction b). Methyl 3-(3-((tert-butoxycarbonyl)amino)pro-
poxy)-4-nitrobenzoate 25 (3.03 g, 8.55 mmol); methanol:ethyle acetate 1:1 (40 mL); palladium 
10% on carbon (300 mg). White solid (2.55 g, 93%). H (MeOD, 500 Mz) 7.47 (dd, 1H, J = 8.3 
Hz, J = 1.8 Hz, Ar-H), 7.41 (d, 1H, J = 1.8 Hz, Ar-H), 6.70 (d, 1H, J = 8.3 Hz, Ar-H), 4.08 (t, 2H, 
J = 5.9 Hz, OCH2), 3.82 (s, 3H, OCH3), 3.28 (t, 2H, J = 6.6 Hz, CH2-NH), 2.01 (quint., 2H, 
J = 6.4 Hz, -CH2-), 1.43 (s, 9H, (CH3)3). 
4-amino-3-(3-((tert-butoxycarbonyl)amino)propoxy)benzoic acid (27)177 
 
Using the general procedure for ester hydrolysis d). Methyl 4-amino-3-(3-((tert-butoxycarbonyl)-
amino)propoxy)benzoate 26 (2.55 g, 7.9 mmol); sodium hydroxide solution (20.0 mL, 54.0 
mmol); methanol: tetrahydrofuran (30 mL). Hygroscopic brown powder (1.76 g, 72%). H 
(CDCl3, 500 Mz) 7.64 (d, 1H, J = 8.3 Hz, Ar-H), 7.49 (s br., 1H, Ar-H), 6.69 (d, 1H, J = 8.3 Hz, 
Ar-H), 4.73 (s br., 1H, NH), 4.15 (t, 2H, J = 6.4 Hz, O-CH2) 3.38-3.34 (m, 2H, CH2-NH), 2.05 (t, 
2H, J = 6.4 Hz, -CH2-), 1.45 (s, 9H, C(CH3)3). 
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4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-((tert-butoxycarbonyl)amino)pro-
poxy)benzoic acid (28)177 
 
Using the general procedure for Fmoc protection f). 4-amino-3-(3-((tert-butoxy-
carbonyl)amino)pro-poxy)benzoic acid (1.76 g, 5.7 mmol) 27; fluorenylmethyl chloroformate 
(1.76 g, 6.8 mmol); sodium carbonate (1.50 g, 14.2 mmol); anhydrous chloroform (300 mL). The 
residue was purified by flash chromatography (eluent: dichloromethane/methanol: 10/0 to 0/10) 
to give the desired product 28 (1.87 g, 62%) as a white powder. H (CDCl3, 500 Mz) 8.14 (s br., 
1H), 7.80 (d, 2H, J = 7.6 Hz, Ar-H), 7.75 (d, 1H, J = 6.9 Hz, Ar-H), 7.66 (d, 3H, J = 7.10, Ar-H), 
7.58 (s, 1H, Ar-H), 7.44 (t, 2H, J = 7.6 Hz, Ar-H), 7.35 (t, 2H, J = 7.10 Hz, Ar-H), 4.70 (s br., 
1H, NH), 4.54 (d, 2H, J = 6.9 Hz, CH2(Fmoc)), 4.35 (t, 1H, J = 6.9 Hz, CH(Fmoc)), 4.19 (s br., 
2H, O-CH2), 3.39 (s br., 2H, CH2-NH), 2.09 (t, 2H, J = 6.2 Hz, -CH2-), 1.44 (s, 9H, C(CH3)3).  
Methyl 3-(2-(tert-butoxy)-2-oxoethoxy)-4-nitrobenzoate (29)177 
 
Using the general procedure for O-alkylation a). Methyl-4-amino-3-hydroxybenzoate 20 (3.0 g, 
15.2 mmol); tert-butylbromoacetate (3.9 mL, 26.9 mmol); potassium carbonate (7.4 g, 53.7 
mmol) N,N-dimethylformamide (60 mL). Brown solid (3.5 g, 73%). H (500 MHz, CDCl3) 7.88 
(d, 1H, 8.5 Hz, Ar-H), 7.75 (dd, 1H, J = 8.5, 1.4 Hz, Ar-H), 7.63 (s, 1H, Ar-H), 4.73 (s, 2H, 
OCH2), 3.96 (s, 3H, OCH3), 1.45 (s, 9H, OC(CH3)3). 
3-(2-(tert-butoxy)-2-oxoethoxy)-4-nitrobenzoic acid (30)177 
 
Lithium hydroxide monohydrate (418 mg, 10.0 mmol) in water (10 mL) was added to a solution 
of methyl 3-(2-(tert-butoxy)-2-oxoethoxy)-4-nitrobenzoate 29 (3.1 g, 10.0 mmol) in 
tetrahydrofuran (20 mL) and the solution was stirred at room temperature for 16 hours. The 
mixture was washed with dichloromethane (30 mL) and the organic layer was dried over 
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magnesium sulphate, filtered and evaporated under vacuum to recollect non-reacted starting 
material; the aqueous layer was adjusted to pH 4 with a 10% aqueous solution of potassium 
hydrogen sulphate and extracted with dichloromethane (2 x 30 mL). The organic layer was dried 
with magnesium sulphate, filtered, and the filtrate was evaporated under vacuum to give 30 as a 
yellow solid (548 mg, 19%). H (500 MHz, CDCl3) 7.91 (d, 1H, J = 8.3 Hz, Ar-H), 7.83 (dd, 1H, 
J = 8.3 Hz, 1.4 Hz, Ar-H), 7.70 (d, 1H, J = 1.4 Hz, Ar-H), 4.77 (s, 2H, OCH2), 1.52 (s, 9H, 
OC(CH3)3).  
4-amino-3-(2-(tert-butoxy)-2-oxoethoxy)benzoic acid (31)177 
 
Using the general procedure for nitro reduction b). 3-(2-(tert-butoxy)-2-oxoethoxy)-4-
nitrobenzoic acid 30 (649 mg, 2.2 mol); methanol (15 mL); palladium 10% on carbon (65 mg). 
Beige solid (553 mg, 95%). H (500 MHz, CDCl3) 7.67 (dd, 1H, J = 8.3 Hz, 1.4 Hz, Ar-H), 7.44 
(d, J = 1.4 Hz, Ar-H), 6.71 (d, 1H, J = 8.3 Hz), 4.40 (s, 2H, OCH2), 1.51 (s, 9H, OC(CH3)3). 
4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-(tert-butoxy)-2-oxoethoxy)benzoic 
acid (32)177 
 
Using the general procedure for Fmoc protection f). 4-amino-3-(2-(tert-butoxy)-2-oxoethoxy)-
benzoic acid 31 (533 mg, 2.1 mmol); fluorenylmethyl chloroformate (534 mg, 2.1 mmol); sodium 
hydrogen carbonate (174 mg, 2.1 mmol); anhydrous chloroform (10 mL). The residue was taken 
up with chloroform and precipitated with hexane three times and finally purified by flash 
chromatography (eluent: dichloromethane/methanol: 9.5/0.5) to give the target material 32 as a 
white solid (54 mg, 5%).H (500 MHz, MeOD) 8.05 (s broad, 1H, Ar-H), 7.86 (d, 2H, J = 7.6 
Hz, Ar-H), 7.76 (d, 2H, J = 7.6 Hz, Ar-H), 7.70 (d, 1H, J = 7.8 Hz, Ar-H), 7.57 (d, 1H, J = 1.8 
Hz, Ar-H), 7.45 (t, 2H, J = 7.6 Hz, Ar-H), 7.38 (td, 2H, J = 7.6 Hz, 1.2 Hz, Ar-H), 4.76 (s, 2H, 
OCH2), 4.57 (d, 2H, J = 6.6 Hz, CH2(Fmoc)), 4.36 (t, 1H, J = 6.6 Hz, CH(Fmoc)), 1.53 (s, 9H, 
C(CH3)3). 
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Methyl 3-(4-(tert-butoxy)-4-oxobutoxy)-4-nitrobenzoate (33) 
 
Using the general procedure for O-alkylation a). Methyl-4-amino-3-hydroxybenzoate 20 (180 mg, 
0.9 mmol); tert-butyl 4-bromobutanoate 14 (247 mg, 1.1 mmol); potassium carbonate (380 mg, 
2.76 mmol); N,N-dimethylformamide. White solid (104 mg, 33%). H (500 MHz, CDCl3) 7.84 
(d, 1H, J = 8.3 Hz, Ar-H), 7.74 (d, 2H, J = 1.5 Hz, Ar-H), 7.70 (d, 1H, J = 1.5 Hz, Ar-H), 4.24 (t, 
2H, J = 6.0, -OCH2-), 3.97 (s, 3H, -OCH3), 2.49 (t, 2H, J = 7.3 Hz, -CH2CO2(CH3)3), 2.16 (quint., 
2H, J = 6.3 Hz -CH2-), 1.46 (s, 9H, -C(CH3)3). C (125 MHz, CDCl3) 172.3, 165.2, 151.7, 142.5, 
134.8, 125.3, 121.4, 115.6, 80.6, 68.8, 52.8, 31.4, 28.1, 24.3. max/cm-1 (solid state) = 2985, 2952, 
1720 (COOMe, COOtBu), 1530, 1293 (NO2). HRMS: Calcd. [M+Na]+ (C16H21NO7) 
m/z = 362.1216. Found [M+Na]+ m/z = 362.1217. 
3-(4-(tert-butoxy)-4-oxobutoxy)-4-nitrobenzoic acid (34) 
 
Methyl 3-(4-(tert-butoxy)-4-oxobutoxy)-4-nitrobenzoate 33 (650 mg, 1.9 mmol) was dissolved 
in tetrahydrofuran (25 mL) and water (25 mL), in an ice bath. A 0.25M aqueous solution of 
sodium hydroxide was added and the mixture was stirred for 4 hours at 0°C. The mixture was 
then diluted with water (50 mL) and extracted with ethyl acetate (2 x 50 mL). The organic layer 
was washed with brine (50 mL) and the solvent was evaporated. The residue was purified by 
column chromatography (eluent: dichloromethane/methanol 10/0 to 9/1) to give the product 34 
as a pale yellow solid (406 mg, 66%). H (500 MHz, MeOD) 7.82 (d, 2H, J = 8.3 Hz, Ar-H), 7.69 
(dd, 1H, J = 1.3 Hz, 8.3 Hz, Ar-H), 4.23 (t, 2H, J = 6.0, -OCH2-), 2.47 (t, 2H, J = 7.3 
Hz, -CH2CO2(CH3)3), 2.10 (quint., 2H, J = 6.4 Hz, -CH2-), 1.44 (s, 9H, -C(CH3)3). C (125 MHz, 
MeOD) 199.3, 174.1, 152.6, 143.6, 125.6, 122.6, 116.9, 81.6, 69.9, 32.5, 28.2, 25.6 (1 x C 
missing). max/cm-1 (solid state) = 2981, 2931, 1735 (COOH, COO
tBu), 1520, 1287 (NO2). 
HRMS: Calcd. [M+Na]+ (C15H19NO7) m/z = 348.1059. Found [M+Na]+ m/z = 348.1059. 
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4-amino-3-(4-(tert-butoxy)-4-oxobutoxy)benzoic acid (35) 
 
Using the general procedure for nitro reduction b). 3-(4-(tert-butoxy)-4-oxobutoxy)-4-
nitrobenzoic acid 34 (782 mg, 2.4 mmol); methanol (20 mL); palladium 10% on carbon (78 mg). 
Brown powder (651 mg, 92%). H (500 MHz, MeOD) 7.50 (d, 2H, J = 11.4 Hz, Ar-H), 6.70 (d, 
1H, J = 8.0), 4.07 (t, 2H, J = 6.2 Hz, -OCH2-), 2.48 (t, 2H, J = 7.3 Hz, -CH2CO2C(CH3)3), 2.09 
(quint., 2H, J = 6.4 Hz, -CH2-), 1.45 (s, 9H, -C(CH3)3). C (125 MHz, DMSO-d6): 172.6, 144.6, 
124.3, 112.5, 80.1, 67.3, 31.9, 28.3, 24.9 (4 x C missing). max/cm-1 (solid state) = 3362 (NH) 
2925, 1716 (COOH, COOtBu), 1146, 751 (NH). HRMS: Calcd. [M+Na]+ (C15H21NO5) 
m/z = 318.1317. Found [M+Na]+ m/z = 318.1318. 
4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(tert-butoxy)-4-oxobutoxy)benzoic 
acid (36) 
 
Using the general procedure for Fmoc protection f). 4-amino-3-(4-(tert-butoxy)-4-oxobutoxy)-
benzoic acid 35 (1.6 g, 5.4 mmol); fluorenylmethyl chloroformate (1.4 g, 5.4 mmol), sodium 
hydrogen carbonate (498 mg, 5.9 mmol); anhydrous chloroform (50 mL). The residue was 
purified by flash chromatography (eluent: dichloromethane/methanol: 10/0 to 9/1) and the 
product 36 was collected as a white powder (1.73 g, 62%). H (500 MHz, CDCl3) 8.18 (s broad, 
1H, NH), 7.81 (d, 2H, J = 7.5 Hz, Ar-H), 7.78-7.76 (m, 1H, Ar-H(Fmoc)), 7.69 (d, 1H, J = 7.5 
Hz, Ar-H), 7.65-7.62 (m, 2H, Ar-H (Fmoc)), 7.59 (d, 1H, J = 1.5 Hz, Ar-H(Fmoc)), 7.45 (t, 2H, 
J = 7.6 Hz, Ar-H(Fmoc)), 7.37 (t, 2H, J = 7.6 Hz Ar-H(Fmoc)), 4.55 (d, 2H, J = 7.1 Hz, 
CH2(Fmoc)), 4.36 (t, 1H, J = 7.1 Hz, CH(Fmoc)), 4.20 (t, 2H, J = 6.2 Hz, -OCH2-), 2.50 (t, 2H, 
J = 7.1 Hz, -CH2CO2(CH3)3), 2.23 (quint., 2H, J = 6.6 Hz, -CH2-), 1.48 (s, 9H, CO2(CH3)3). C 
(125 MHz, CDCl3) 172.2, 171.0, 153.1, 146.3, 143.7, 141.4, 133.0, 127.9, 127.2, 125.1, 124.5, 
123.3, 120.1, 117.4, 112.1, 80.8, 68.3, 67.6, 47.1, 32.2, 28.1, 24.5. max/cm-1 (solid state) = 3426 
(NH amide), 2971, 1715 (COOH, COOtBu), 1681 (C=O amide) 1195. HRMS: Calcd. [M+Na]+ 
(C30H31NO7) m/z = 540.1998. Found [M+]+ m/z = 540.1996. 
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 N-alkylated monomers (Chapter 2) 
4-(isobutylamino)benzoic acid (38)178 
 
Using the general procedure for reductive amination e). 4-aminobenzoic acid 37 (2.0 g, 14.6 
mmol); isobutyraldehyde (1.34 mL, 14.6 mmol); picoline borane (2.8 g, 26.3 mmol); methanol 
(25 mL). The residue was then taken up with ethyl acetate and precipitated with hexane to obtain 
the target material 38 as a white solid (2.6 g, 91%). H (500 MHz, CDCl3), 7.92 (d, 2H, J = 8.7 
Hz, Ar-H), 6.56 (d, 2H, J = 8.7 Hz, Ar-H), 3.01 (d, 2H, J = 6.8 Hz, CH2CH(CH3)2), 2.76 (s, 1H, 
N-H), 1.94-1.88 (m, 1H, CH2CH(CH3)2), 1.03 (d, 6H, J = 6.8 Hz, CH2CH(CH3)2). 
4-((((9H-fluoren-9-yl)methoxy)carbonyl)(isobutyl)amino)benzoic acid (39)178 
 
Using the general procedure for Fmoc protection f). 4-(isobutylamino)benzoic acid 38 (2.5 g, 13.2 
mol); fluorenylmethyl chloroformate (4.1 g, 15.8 mmol); anhydrous chloroform (70 mL). The 
solvent was removed and the residue was taken up in chloroform and precipitated with hexane, 
and the precipitate was isolated by centrifugation, dissolved in chloroform (20 mL) and 
evaporated under vacuum to get the target 39 as an off-white foam (3.21 g, 59%). H (500 MHz, 
CDCl3) 8.04 (d, 2H, J = 8.3 Hz, Ar-H), 7.72 (d, 2H, J = 7.3 Hz, Ar-H), 7.38 (t, 2H, J = 7.3 Hz, 
Ar-H), 7.33 (d, 2H, J = 8.3 Hz, Ar-H), 7.24 (t, 2H, J = 7.3 Hz, Ar-H), 7.16 (d, 2H, J = 8.3 Hz, Ar-
H), 4.55 (d, 2H, J = 5.9 Hz, CH2(Fmoc)), 4.13 (t, 1H, J = 5.9 Hz, CH(Fmoc)), 3.47 (d, 2H, J = 7.3 
Hz, CH2CH(CH3)2), 1.70-1.62 (m, 1H, CH2CH(CH3)2), 0.79 (d, 6H, J = 6.8 Hz, CH2CH(CH3)2). 
4-((2-(tert-butoxy)-2-oxoethyl)amino)benzoic acid (40)178 
 
Using the general procedure for reductive amination e). 4-aminobenzoic acid 37 (589 mg, 
4.3 mmol); tert-butyl glyoxylate 3 (559 mg, crude, ≈3.1 mmol); picoline borane (556 mg, 5.2 
83 
 
mmol); methanol (20 mL); The residue was purified by flash chromatography (eluent: ethyl 
acetate/hexane: 0/10 to 5/5), yielding target compound 40 as a white solid (335 mg, 44%). H (500 
MHz, CDCl3) 7.95 (d, 2H, J = 8.7 Hz, Ar-H), 6.58 (d, 2H, J = 8.7 Hz, Ar-H), 4.80 (s, 1H, N-H), 
3.87 (s, 2H, N-CH2), 1.51 (s, 9H, C(CH3)3). 
4-((((9H-fluoren-9-yl)methoxy)carbonyl)(2-(tert-butoxy)-2-oxoethyl)amino)benzoic acid (41)178 
 
Using the general procedure for Fmoc protection f). 4-((2-(tert-butoxy)-2-oxoethyl)amino)-
benzoic acid 40 (268 mg, 1.1 mmol); fluorenylmethyl chloroformate (276 mg, 1.1 mmol); sodium 
hydrogen carbonate (99 mg, 1.2 mmol); anhydrous chloroform (10 mL). The solvent was removed 
and the residue was taken up in chloroform and precipitated with hexane, and the precipitate was 
isolated by centrifugation. The solid was dissolved in chloroform and evaporated under vacuum 
to give the desired product 41 as an off-white foam (263 mg, 52%). H (500 MHz, CDCl3): 8.08 
(d, 2H, J = 8.3 Hz, Ar-H), 7.74 (d, 2H, J = 7.6 Hz, Ar-H), 7.39 (t broad, 3H, J = 7.3 Hz, Ar-H) 
7.33 (m broad, 3H, Ar-H), 7.24 (m broad, 2H, Ar-H), 4.51 (d, 2H, J = 6.6 Hz, CH2(Fmoc)), 4.27 
(s, 2H, N-CH2), 4.16 (s broad, 1H, CH(Fmoc)), 1.46 (s, 9H, C(CH3)3). 
4-((4-(tert-butoxy)-4-oxobutyl)amino)benzoic acid (42) 
 
Using the general procedure for reductive amination e). 4-aminobenzoic acid 37 (2.5 g, 18.2 
mmol); tert-butyl-4-oxobutanoate 13 (2.87 g, 18.2 mmol); picoline borane (2.3 g, 21.8 mmol); 
methanol (100 mL). The obtained pink residue was filtered and washed with dichloromethane 
and the product 42 was collected as a white powder (2.58 g, 51%).H (500 MHz, MeOD) 7.78 
(d, 2H, J = 9.0 Hz, Ar-H), 6.59 (d, 2H, J = 9.0 Hz, Ar-H), 3.18 (t, 2H, J = 7.0 Hz, CO2-CH2), 2.34 
(t, 2H, J = 7.0 Hz, NH-CH2), 1.87 (quint., 2H, J = 7.0 Hz, CH2-CH2-CH2), 1.45 (s, 9H, -C(CH3)3). 
C (125 MHz, MeOD) 174.8, 170.9, 154.6, 132.9, 118.3, 112.2, 81.7, 43.4, 33.9, 28.5, 25.7. 
max/cm-1 (solid state) = 3382 (NH), 2959, 2933, 2520 (COOH, COO
tBu), 1705 (COOtBu) 1659, 
1414, 1159 (COOH). HRMS: Calcd. [M+H]+ (C15H2NO4) m/z = 280.1504. Found [M+H]+ 
m/z = 280.1547. 
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4-((((9H-fluoren-9-yl)methoxy)carbonyl)(4-(tert-butoxy)-4-oxobutyl)amino)benzoic acid (43) 
 
Using the general procedure for Fmoc protection f). 4-((4-(tert-butoxy)-4-oxobutyl)-
amino)benzoic acid 42 (2.5 g, 8.6 mol); fluorenylmethyl chloroformate (2.2 g, 8.6 mmol); sodium 
hydrogen carbonate (798 mg, 9.5 mmol); anhydrous chloroform (50 mL) The residue was purified 
by flash chromatography (eluent: dichloromethane/methanol: 10/0 to 8.5/1.5) and product 43 was 
collected as a white powder (2.6 g, 59%).H (500 MHz, CDCl3): 8.07 (d, 2H, J = 8.2 Hz Ar-H), 
7.73 (d, 2H, J = 7.6 Hz, Ar-H), 7.39-7.33 (m, 4H, Ar-H), 7.24 (t, 2H, J = 7.3 Hz, Ar-H), 7.19 (d, 
2H, J = 8.2 Hz, Ar-H), 4.56 (d, 2H, J = 5.8 Hz, CH2(Fmoc)), 4.14 (t, 1H, J = 5.5 Hz, CH(Fmoc)), 
3.65 (t, 2H, J = 7.0 Hz, CO2CH2), 2.15 (t, 2H, J = 7.0 Hz, NH-CH2), 1.74 (quint., 2H, J = 7.0 Hz, 
CH2-CH2-CH2), 1.42 (s, 9H, -C(CH3)3). C (125 MHz, CDCl3): 172.1, 170.9, 154.8, 146.5, 143.6, 
141.4, 131.1 127.7, 127.0, 126.7, 124.7, 119.9, 80.5, 67.3, 49.4, 47.2, 32.4, 28.1, 23.7 (3 x C 
missing). max/cm-1 (solid state) = 2975, 2656 (COOH, COO
tBu), 1685, 1418, 1146 (COOH). 
HRMS: Calcd. [M+Na]+ (C30H31NO6) m/z = 524.2083. Found [M+Na]+ m/z = 524.2050. 
4-((3-((tert-butoxycarbonyl)amino)propyl)amino)benzoic acid (44)178 
 
Using the general procedure for reductive amination e). 4-aminobenzoic acid 37 (792 mg, 
5.8 mmol); tert-butyl (3-oxopropyl)carbamate 19 (1.0 g, 5.8 mmol); picoline borane (74 mg, 6.9 
mmol); methanol (40 mL). The residue was precipitated from diethyl ether and water to give 44 
as a white powder (943 mg, 55%). H (500 MHz, CDCl3) 7.92 (d, 2H, J = 8.7 Hz, Ar-H), 6.59 (d, 
2H, J = 8.7 Hz, Ar-H), 4.64 (s, 1H, N-H), 3.28-3.24 (m, 4H, NCH2CH2CH2N), 1.80 (t, 2H, J = 5.9 
Hz, NCH2CH2CH2N), 1.46 (s, 9H, C(CH3)3). 
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4-((((9H-fluoren-9-yl)methoxy)carbonyl)(3-((tert-butoxycarbonyl)amino)propyl)-
amino)benzoic acid (45)178 
 
Using the general procedure for Fmoc protection f). 4-((3-((tert-butoxycarbonyl)amino)-
propyl)amino)benzoic acid 44 (202 mg, 0.7 mmol); fluorenylmethyl chloroformate (248 mg, 0.9 
mmol); sodium hydrogen carbonate (0.5g, 5.9 mmol); anhydrous chloroform (10 mL). The 
residue was taken up in chloroform and precipitated with hexane, and the precipitate was isolated 
by centrifugation, dissolved in chloroform and evaporated under vacuum to get the target 45 as a 
white foam (123 mg, 35%). H (500 MHz, CDCl3) 8.01 (d, 2H, J = 8.3 Hz, Ar-H), 7.72 (d, 2H, 
J = 7.3 Hz, Ar-H), 7.39 (t, 2H, J = 7.3 Hz, Ar-H), 7.31 (d broad, 2H, J = 5.5 Hz, Ar-H), 7.27 (t, 
2H, J = 7.8 Hz, Ar-H), 7.12 (d, 2H, J = 7.8 Hz, Ar-H), 4.85 (s, 1H, N-H), 4.58 (d, 2H, J = 5.5 Hz, 
CH2(Fmoc)), 4.12 (t, 1H, J = 5.5 Hz, CH(Fmoc)), 3.66 (t, 2H, J = 5.5 Hz CH2-N), 3.02 (t broad, 
2H, J = 6.4 Hz, CH2-N), 1.57 (m broad, 2H, NCH2CH2CH2N), 1.47 (s, 9H, C(CH3)3). 
 Alkene functionalised N-alkylated monomers (Chapter 3) 
Methyl 4-nitro-3-(prop-2-yn-1-yloxy)benzoate (65)215 
 
Using the general procedure for O-alkylation a). Methyl 3-hydroxy-4-nitrobenzoate 20 (5.0 g, 
25.4 mmol); propargyl bromide 64 (4.26 ml, 38.2 mmol); potassium carbonate (18.9 g, 136.5 
mmol); N,N-dimethylformamide (100 ml). Pale yellow solid (6.0 g, quant.). H (500 MHz, CDCl3) 
7.94 (d, 1H, J = 1.3 Hz, Ar-H), 7.89 (d, 1H, J = 8.7 Hz, Ar-H), 7.79 (dd, 1H, J = 8.7 Hz, 1.3 Hz, 
Ar-H), 4.93 (s, 2H, CH2C≡CH), 4.01 (s, 3H, OCH3), 2.64 (t, 1H, J = 2.3 Hz, CH2C≡CH). 
Methyl 4-amino-3-(prop-2-ynyloxy)benzoate (66) 215 
 
Using the general procedure for nitro reduction c). Tin (II) chloride dihydrate (28.6 g, 127.0 
mmol); methyl 4-nitro-3-(prop-2-ynyloxy)benzoate 65 (6.0 g, 25.4 mmol); ethyl acetate (300 
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mL). Orange solid (5.0 g, 96%). H (500 MHz, CDCl3) 7.62 (dd, 1H, J = 8.3, 1.8 Hz, Ar-H), 7.59 
(d, 1H, J = 1.8 Hz, Ar-H), 6.75 (d, 1H, J = 8.3 Hz, Ar-H), 4.81 (d, 2H, J = 2.3 Hz, CH2C≡CH), 
3.89 (s, 3H, CH3), 2.57 (t, 1H, J = 2.3 Hz, CH2C≡CH). 
4-amino-3-(prop-2-yn-1-yloxy)benzoic acid (67)215 
 
Using the general procedure for ester hydrolysis d). Methyl 4-amino-3-(prop-2-ynyloxy)benzoate 
66 (2.9 g, 14.1 mmol); sodium hydroxide 20% (21 mL, 42.3 mmol); methanol:tetrahydrofuran 
(100 mL). Beige solid (2.5 g, 93%). H (500 MHz, MeOD) 7.61 (d, 1H, J = 1.8 Hz, Ar-H), 7.56 
(dd, 1H, J = 8.3, 1.8 Hz Hz, Ar-H), 6.76 (d, 1H, J = 8.3 Hz, Ar-H), 4.83 (d, 2H, J = 2.5 Hz 
CH2C≡CH), 3.01 (t, 1H, J = 2.5 Hz, CH2C≡CH). 
4-[(2-methylpropyl)amino]-3-(prop-2-yn-1-yloxy)benzoic acid (68)  
 
Using the general procedure for reductive amination e). 4-Amino-3-(prop-2-yn-1-yloxy) benzoic 
acid 67 (3.92 g, 20.5 mmol); isobutyraldehyde (1.87 mL, 20.5 mmol); picoline borane (2.63 g, 
24.6 mmol); methanol (100 mL). Pale yellow solid (5.08 g, quant.). H (500 MHz, DMSO-d6) 
12.08 (s, 1H, OH) 7.47 (dd, 1H, J = 8.1 Hz, 1.7 Hz, Ar-H), 7.41 (d, 1H, J = 1.7 Hz, Ar-H), 6.56 
(d, 1H, J = 8.1 Hz, Ar-H), 5.59 (t, 1H, J = 5.9 Hz, N-H) 4.83 (d, 2H, J = 2.1 Hz, CH2C≡CH), 3.57 
(t, 1H, J = 2.1 Hz, CH2C≡CH), 2.9 (t, 2H, J = 6.4 Hz, CH2CH(CH3)2), 1.81-1.90 (m, 1H, 
CH2CH(CH3)2), 0.90 (d, 6H, J = 6.4 Hz, CH2CH(CH3)2). C (125 MHz, DMSO-d6) 167.4, 142.9, 
142.8, 125.0, 116.2, 112.2, 107.8, 79.2, 78.4, 55.9, 49.8, 27.1, 20.2, 20.0. max/cm-1 (solid 
state) = 3401 (NH), 3278 (CH alkyne), 2961 (COOH), 2122 (C≡C), 1659, 1410, 1280 (COOH). 
HRMS: Calcd. [M+H]+ (C14H17NO3) m/z = 248.1208. Found [M+H]+ m/z = 248.1283. 
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4-((((9H-fluoren-9-yl)methoxy)carbonyl)(isobutyl)amino)-3-(prop-2-yn-1-yloxy)benzoic 
acid (69) 
 
Using the general procedure for Fmoc protection f). 4-[(2-methylpropyl)amino]-3-(prop-2-yn-1-
yloxy)benzoic acid 68 (4.97 g, 20.1 mmol); fluorenylmethyl chloroformate (6.24 g, 24.1 mmol); 
anhydrous chloroform (100 ml). The residue was purified by flash chromatography (eluent: ethyl 
acetate/hexane: 0/10 to 5/5). The collected oil was taken up in chloroform and precipitated with 
hexane, and the precipitate was isolated by centrifugation, dissolved in chloroform and evaporated 
under vacuum to get 69 as an off-white foam (1.55 g, 16%). H (500 MHz, DMSO-d6) 13.09 (s, 
1H, C(O)OH) 7.78 (s broad, 2H, Ar-H), 7.68 (s, 1H, Ar-H), 7.56 (d, 1H, J = 7.7 Hz, Ar-H), 7.34 
(s broad, 2H, Ar-H), 7.21 (d, 2H, J = 8.1 Hz, Ar-H), 7.15 (s, 3H, Ar-H), 4.83 (s, 2H, CH2C≡CH), 
4.22 (s broad, 2H, CH2(Fmoc)), 4.02 (s broad, 1H, CH(Fmoc)), 3.54 (s, 2H, CH2CH(CH3)2), 1.61 
(s, 1H, CH2CH(CH3)2), 0.81 (s, 6H, CH2CH(CH3)2). c (125 MHz, DMSO-d6) 166.6, 154.7, 152.7, 
143.5, 140.6, 134.4, 130.7, 129.6, 127.4, 126.8, 124.9, 122.3, 119.9, 114.1, 79.2, 78.6, 66.7, 56.1, 
55.9, 46.4, 26.8, 19.9. max/cm-1 (solid state) = 2957, 1685, 1406, 1285 (COOH). HRMS: Calcd. 
[M+Na]+ (C14H17NO3) m/z = 492.1709. Found [M+Na]+ m/z = 492.1787. 
Methyl 4-nitro-3-(2-(2-(2-(prop-2-yn-1-yloxy)ethoxy)ethoxy)ethoxy)benzoate (78) 
 
Using the general procedure for O-alkylation a). Methyl 3-hydroxy-4-nitrobenzoate 20 (1.0 g, 
5.1 mmol); 3-(2-(2-(2-chloroethoxy)ethoxy)ethoxy)prop-1-yne 77 (4:1 Cl:Br, 1.1 g, 5.1 mmol); 
potassium carbonate (2.1 g, 15.3 mmol); N,N-dimethylformamide (50 ml). 70°C. The residue was 
purified by flash chromatography (eluent: dichloromethane/methanol 10/0 to 9/1) and 78 was 
collected as a pale oil (957 mg, 51%). H (500 MHz, CDCl3) 7.82 (d, 1H, J = 8.4 Hz, Ar-H), 7.78 
(d, 1H, J = 1.6 Hz, Ar-H), 7.70 (dd, 1H, J = 8.4, 1.6 Hz, Ar-H), 4.33 (t, 2H, J = 4.6 Hz, H5 or 6), 
4.19 (d, 2H, J = 2.3 Hz, CH2C≡CH), 3.95 (s, 3H, OCH3), 3.92 (t, 2H, J = 4.6 Hz, H5 or 6), 3.75-
3.73 (m, 2H, H1-4), 3.70-3.66 (m, 6H, H1-4), 2.43 (t, 1H, J = 2.3 Hz, CH2C≡CH). C (125 MHz, 
CDCl3) 165.2, 151.8, 142.8, 34.8, 125.3, 121.7, 116.0, 79.7, 74.5, 71.1, 70.7, 70.4, 69.9, 39.2, 
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69.1, 58.4, 52.8. max/cm-1 (solid state) = 3283 (CH alkyne), 2870 (C≡C), 1293 (COOMe), 1241 
(C-O ether). HRMS: Calcd. [M+Na]+ (C17H21NO8) m/z = 390.1165 Found [M+Na]+ 
m/z = 390.1163. 
Methyl 4-amino-3-(2-(2-(2-(prop-2-yn-1-yloxy)ethoxy)ethoxy)ethoxy)benzoate (79) 
 
Using the general procedure for nitro reduction c). Tin (II) chloride dihydrate (4.0 g, 17.9 mmol); 
methyl 4-nitro-3-(2-(2-(2-(prop-2-yn-1-yloxy)ethoxy)ethoxy)ethoxy)benzoate 78 (1.3 g, 3.6 
mmol); ethyl acetate (50 mL). The residue was purified by flash chromatography (eluent: 
dichloromethane/methanol: 9.5/0.5) to get the desired product 79 as a yellow oil (436 mg, 36%). 
H (500 MHz, CDCl3) 7.54 (dd, 1H, J = 8.1, 1.7 Hz, Ar-H), 7.49 (d, 1H, J = 1.7 Hz, Ar-H), 6.68 
(d, 1H, J = 8.1 Hz, Ar-H), 4.42 (s broad, 2H, NH2), 4.23 (q, 4H, J = 2.3 Hz, H5-6), 3.87-3.84 (m, 
2H, CH2C≡CH), 3.86 (s, 3H, OCH3), 3.75-3.67 (m, 8H, H1-4), 2.45 (t, 1H, J = 2.3 Hz, CH2C≡CH). 
C (125 MHz, CDCl3) 166.8, 144.6, 141.8, 124.3, 118.8, 113.7, 113.0, 79.2, 74.2, 70.2, 70.0, 69.2, 
68.7, 68.2, 60.0, 51.2 (1 x C missing). max/cm-1 (solid state) = 3478 (NH), 3361 (CH alkyne), 
3252, 2872 (CH), 2113 (C≡C), 1291 (COOMe), 1261 (C-O ether). HRMS: Calcd. [M+H]+ 
(C17H23NO6) m/z = 338.1559. Found [M+H]+ m/z = 338.1622. 
4-amino-3-(2-(2-(2-(prop-2-yn-1-yloxy)ethoxy)ethoxy)ethoxy)benzoic acid (80) 
 
Using the general procedure for ester hydrolysis d). Methyl 4-amino-3-(2-(2-(2-(prop-2-yn-1-
yloxy)ethoxy)ethoxy)ethoxy)benzoate 79 (400 mg, 1.2 mmol); sodium hydroxide 10% (10 mL, 
11.8 mmol); tetrahydrofuran (10 mL). Pale yellow oil (62 mg, 16%). H (500 MHz, CDCl3) 7.65 
(dd, 1H, J = 8.1, 1.7 Hz, Ar-H), 7.53 (d, 1H, J = 1.7 Hz, Ar-H), 6.69 (d, 1H, J = 8.1 Hz, Ar-H), 
4.23 (m, 4H, H5-6), 3.88 (m, 2H, CH2C≡CH), 3.70 (m, 8H, H1-4), 2.46 (t, 1H, J = 2.3 Hz, 
CH2C≡CH). c (125 MHz, CDCl3) 171.7, 144.9, 143.1, 125.7, 118.0, 114.5, 113.3, 79.6, 74.6, 
70.6, 70.6, 70.4, 69.6, 69.1, 68.6, 58.4. max/cm-1 (solid state) = 3478 (NH), 3359 (CH alkyne), 
3286, 3012 (CO2H) 2871 (CH), 2119 (C≡C), 1291 (CO2H), 1243 (C-O ether). HRMS: Calcd. 
[M+Na]+ (C16H21NO7) m/z = 346.1267. Found [M+Na]+ m/z = 346.1280. 
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4-(isobutylamino)-3-(2-(2-(2-(prop-2-yn-1-yloxy)ethoxy)ethoxy)ethoxy)benzoic acid (81) 
 
Using the general procedure for reductive amination e). 4-amino-3-(2-(2-(2-(prop-2-yn-1-
yloxy)ethoxy)ethoxy)ethoxy)benzoic acid 80 (55 mg, 0.17 mmol); isobutyraldehyde (16 L, 0.17 
mmol); picoline borane (22 mg, 0.20 mmol); methanol (2 mL). The residue was purified by flash 
chromatography (eluent: dichloromethane) to give 81 as a pale yellow oil (51 mg, 79%). H (500 
MHz, CDCl3) 7.72 (dd, 1H, J = 8.5, 1.6 Hz, Ar-H), 7.47 (d, 1H, J = 1.6 Hz, Ar-H), 6.55 (d, 1H, 
J = 8.5 Hz, Ar-H), 4.23 (t, 2H, J = 4.6 Hz, H5 or H6), 4.20 (d, 2H, J = 2.3 Hz, CH2C≡CH), 3.90 
(t, 2H, J = 4.6 Hz, H5 or H6), 3.74-3.68 (m, 8H, H1-4), 3.03 (d, 2H, 6.8 Hz, CH2CH(CH3)2), 2.44 
(t, 1H, J = 2.3 Hz, CH2C≡CH), 1.97 (quint., 1H, CH2CH(CH3)2), 1.00 (d, 6H, J = 6.6 Hz, 
CH2CH(CH3)2). c (125 MHz, CDCl3) 172.2, 144.4, 143.9, 126.2, 115.5, 112.4, 107.8, 79.6, 74.5, 
70.6, 70.6, 70.4, 69.6, 69.0, 68.2, 58.3, 50.6, 27.9, 20.4. max/cm-1 (solid state) = 3440 (NH), 3312 
(CH alkyne), 2953 (CO2H), 2874 (CH), 2061 (C≡C), 1279 (CO2H), 1245 (C-O ether). HRMS: 
Calcd. [M+Na]+ (C20H29NO6) m/z = 402.1926. Found [M+Na]+ m/z = 402.1908. 
4-((((9H-fluoren-9-yl)methoxy)carbonyl)(isobutyl)amino)-3-(2-(2-(2-(prop-2-yn-1-
yloxy)ethoxy)ethoxy)ethoxy)benzoic acid (82) 
 
Using the general procedure for Fmoc protection f). 4-(isobutylamino)-3-(2-(2-(2-(prop-2-yn-1-
yloxy)ethoxy)ethoxy)ethoxy)benzoic acid 81 (51 mg, 0.13 mmol); fluorenylmethyl 
chloroformate (35 mg, 0.13 mmol); anhydrous chloroform (1 mL). The residue was purified by 
flash chromatography (eluent: dichloromthane/methanol: 10/0 to 9.5/0.5). Product 82 was 
collected as a pale brown oil (40 mg, 51%). H (500 MHz, CDCl3) 7.72 (dd, 1H, J = 8.0, 1.6 Hz, 
Ar-H), 7.69-7.62 (m, 3H, Ar-H), 7.35 (t broad, J = 6.6 Hz, 2H, Ar-H), 7.16 (m broad, 4H, Ar-H), 
7.09 (s broad, 1H, Ar-H), 4.46 (s broad, 1H, H5 or H6), 4.29 (s broad, 1H, H5 or H6), 4.18 (d, 
J = 2.3 Hz, 2H, CH2C≡CH), 4.16-4.11 (m, 2H, H5 or H6), 4.02 (m, 2H, H5 or H6), 3.98 (s broad, 
1H, CH(Fmoc)) 3.75 (s broad, 2H, CH2(Fmoc)), 3.68-3.56 (m, 10H, CH2CH(CH3)2 and H1-4), 2.42 
(t, J = 2.4 Hz, 1H, CH2C≡CH), 1.75 (quint. broad, 1H, CH2CH(CH3)2), 0.93 (d, 6H, J = 5.5 Hz, 
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CH2CH(CH3)2). c (125 MHz, CDCl3) 170.7, 155.8, 154.5, 143.9, 141.3, 129.7, 129.3, 127.5, 
126.9, 124.9, 123.0, 120.1, 119.8, 114.1, 79.7, 74.6, 70.8, 70.6, 70.4, 69.5, 69.1, 68.1, 67.3, 58.4, 
56.8, 47.1, 27.5, 20.1. max/cm-1 (solid state) = 3247 (CH alkyne), 2924 (CO2H), 2870 (CH), 2116 
(C≡C), 1284 (CO2H). HRMS: Calcd. [M+H]+ (C35H39NO8) m/z = 602.2676. Found [M+H]+ 
m/z = 602.2668. 
 Azide synthesis (Chapter 3) 
tert-Butyl (3-azidopropyl)carbamate (70)215 
 
A solution of tert-butyl (3-bromopropyl)carbamate 16 (5.0 g, 21.0 mmol) and sodium azide (2.73 
g, 42.0 mmol) in water:dioxane 1:1 (30 mL) was refluxed for 2 hours, behind a safety screen. The 
solution was allowed to cool down to room temperature, and stirred at room temperature for 16 
hours. The mixture was diluted with dichloromethane (30 mL) and washed with water (2 x 25 
mL). The organic layer was dried over magnesium sulphate, filtered and evaporated to give 
product 70 as a pale yellow oil (2.94 g, 70%), used without further purification. H (500 MHz, 
CDCl3)  4.71 (s, 1H, NH), 3.36 (t, 2H, J = 6.64 Hz, N3CH2-), 3.21 (q, 2H, J = 6.64 Hz, -CH2NH-), 
1.79 (quint., 2H, J = 6.64 Hz, -CH2-), 1.43 (s, 9H, OC(CH3)3). 
3-chloropropylamine hydrochloride (71) 215 
 
tert-butyl (3-azidopropyl)carbamate 70 (1.0 g, 5.0 mmol) was dissolved in methanolic 
hydrochloric acid 3M and the solution was stirred at room temperature for 2 hours, behind a safety 
screen. The solvent was then evaporated to give the hydrochloric acid salt 71 as a white solid (663 
mg, 98%). H (500 MHz, MeOD):  3.35 (t, 2H, J = 6.42 Hz, N3CH2-), 3.07 (t, 2H, J = 7.33 Hz, -
CH2NH2), 1.97 (quint., 2H, J = 7.33, -CH2-). 
5-(3-(3-azidopropyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid  (73, Flu-
azide)215 
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Fluorescein isocyanate isomer I (700 mg, 1.8 mmol) was dissolved in anhydrous N,N-
dimethylformamide (60 mL). Triethylamine (5.6 mL, 4.0 mmol) and 3-chloropropylamine 
hydrochloride 71 (272 mg, 2.0 mmol) were added and the mixture was stirred for 16 hours at 
room temperature, in the dark. The solution was diluted with ethyl acetate (200 mL) and washed 
with hydrochloric acid 1M (2 x 200 mL) and brine (2 x 200 mL). The organic layer was dried 
with magnesium sulphate, filtered and the filtrate was dried under reduced pressure to afford 73 
as an orange solid (710 mg, 81%).  H (500 MHz, MeOD) 8.12 (d, 1H, J = 1.8 Hz, Ar-H2), 7.77 
(dd, 1H, J = 8.3 Hz, 2.0 Hz, Ar-H6), 7.16 (d, 1H, J = 8.25 Hz, Ar-H5), 6.68 (t, 4H, J = 2.5 Hz, Ar-
H9, 10, 17, 18), 6.55 (dd, 2H, J = 8.7, 2.3 Hz, Ar-H12, 15),  3.71 (s br, 2H, CH2N3), 3.45 (t, 2H, J = 6.6 
Hz, CH2NH), 1.94 (quint., 2H, J = 6.6 Hz, -CH2-). C (250 MHz, MeOD) 182.9, 172.8, 170.9, 
161.9, 154.0, 142.2, 132.0, 130.1, 128.8, 125.5, 119.9, 13.4, 111.3, 103.3, 50.4, 42.9, 24.0, 20.6. 
(9H-fluoren-9-yl)methyl (2-(2-(2-((3-azidopropyl)amino)-2-oxoethoxy)ethoxy)ethyl)carba-
mate (74) 
 
To a solution of 3-azidopropylamine hydrochloride 71 (1.1 g, 7.8 mmol) and 8-(Fmoc-amino)-
3,6-dioxaoctanoic acid (3.0 g, 7.8 mmol) in anhydrous acetonitrile (40 mL) were added PyBOP 
(4.9 g, 9.4 mmol) and N,N-diisopropylethylamine (4.1 mL, 23.4 mmol) and the mixture was 
stirred at room temperature for 16 hours. The mixture was diluted with ethyl acetate (2x 50 mL), 
washed with a 10%w solution of citric acid (2x 50 mL), saturated sodium hydrogen carbonate (50 
mL) and brine (50 mL). The organic layer was dried over magnesium sulphate, and the solvent 
was removed under vacuum and the desired product 74 was obtained as a yellow oil (3.0 g, 82%). 
H (500 MHz, CDCl3): 7.77 (d, 2H, J = 7.5 Hz, Ar-H19), 7.60 (d, 2H, J = 7.5 Hz, Ar-H16), 7.41 (t, 
2H, J = 7.5 Hz, Ar-H17), 7.32 (td, 2H, J = 7.5 Hz, J = 0.8 Hz, Ar-H18), 6.99 (s, 1H, NH11), 5.31 (s, 
1H, NH4), 4.42 (d, 2H, J = 6.6 Hz, H13), 4.23 (t, 1H, J = 6.6 Hz, H14), 3.98 (s, 2H, H6), 3.69-3.60 
(m, 4H, H9,10), 3.57 (d, 2H, J = 4.7 Hz, H1), 3.41 (d, 2H, J = 4.7 Hz, H3), 3.37-3.31 (m, 4H, H7,8), 
1.81 (quint., 2H, J = 6.6 Hz, H2). D (250 MHz, CDCl3):  169.8, 156.4, 143.8, 141.2, 127.6, 126.9, 
124.8, 119.9, 70.8, 70.4, 70.1, 69.9, 66.5, 49.1, 47.1, 40.7, 36.2, 28.6. max/cm-1 (solid state) = 
3041 (NH), 2885 (CH), 2093 (N3), 1663 (C=O amide), 1261 (C-O ether). HRMS: Calcd. [M+H]+ 
(C24H29N5O5) m/z = 468.2241. Found [M+H]+ m/z = 468.2272. 
2-(2-(2-aminoethoxy)ethoxy)-N-(3-azidopropyl)acetamide (75) 
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A solution of diethylamine in dichloromethane (5.4 mL, 50% volume, 26 mmol) was added to a 
solution of (9H-fluoren-9-yl)methyl (2-(2-(2-((3-azidopropyl)amino)-2-oxoethoxy)ethoxy)-
ethyl)carbamate 74 (1.2 mg, 2.6 mmol) in dichloromethane (50 mL). The reaction mixture was 
stirred for 16 hours, then the solvent was removed under vacuum and the residue was purified by 
column chromatography (eluent: dichloromethane/methanol: 8.5/1.5). Compound 75 was 
obtained as a pale yellow oil (500 mg, 78%). H (500 MHz, CDCl3) 7.18 (s, 1H, NH4), 4.83 (s br., 
2H, NH11) 4.06 (s, 2H, H6), 3.73-3.68 (m, 6H, H1,9,10), 3.41-3.37 (m, 4H, H7,8), 3.11 (t br., 2H, 
H3), 1.84 (quint., 2H, J = 6.6 Hz, H2). C (125 MHz, CDCl3) 170.3, 70.9, 70.7, 70.4, 69.6, 49.3, 
40.4, 36.5, 28.8. 
N-(2-(2-(2-((3-azidopropyl)amino)-2-oxoethoxy)ethoxy)ethyl)-5-((4S)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)pentanamide (76, Biotin-PEG-azide) 
 
N,N-Diisopropylethylamine (185 l, 1.06 mmol) and HCTU (328 mg, 0.79 mmol) were added to 
a solution of D-biotin (129 mg, 0.53 mmol) in dimethylformamide (4 mL). 2-(2-(2-
aminoethoxy)ethoxy)-N-(3-azidopropyl)acetamide 75 (130 mg, 0.53 mmol) in dimethyl-
formamide (1 mL) was added to the mixture and the solution was stirred for 16 hours at room 
temperature. The solvent was removed under vacuum and the crude product purified on a column 
(eluent: dichloromethane/methanol 10/0 to 9/1) and Biotin-PEG-Azide 76 was collected as a 
brown oil (78 mg, 31%). H (500 MHz, CDCl3) 7.11 (t, 1H, J = 5.6 Hz, H4), 6.71 (t, 1H, J = 5.6 
Hz, H11), 6.48 (s, 1H, H23), 5.69 (s, 1H, H21), 4.51-4.48 (m, 1H, H19), 4.32-4.29 (m, 1H, H18), 4.00 
(s, 2H, H6), 3.68-3.62 (m, 4H, H7,8), 3.58 (t, 2H, J = 5.3 Hz, H9), 3.45-3.42 (m, 2H, H10), 3.40-
3.36 (m, 4H, H1,3), 3.15-3.12 (m, 1H, H17), 2.92-2.88 (dd, 1H, J = 12.8 Hz, H20), 2.74 (d, 1H, J = 
12.8 Hz, H20), 2.24 (t, 2H, J = 7.5 Hz, H13), 1.85 (quint., 2H, J = 6.6 Hz, H2), 1.75-1.62 (m, 4H, 
H15,16), 1.49-1.37 (m, 4H, H14). C (250 MHz, CDCl3) 173.6, 170.2, 164.1, 70.9, 70.6, 70.0, 61.9, 
60.2, 55.6, 49.3, 40.6, 39.1, 36.5, 35.9, 28.8, 28.2, 28.1, 25.6. max/cm-1 (solid state) = 3278, 3079 
(NH), 2927, 2886 (CH), 2096 (N3), 1695, 1654 (C=O amide), 1261 (C-O ether). HRMS: Calcd. 
[M+Na]+ (C19H33N7O5S) m/z = 494.2126. Found [M+Na]+ m/z = 494.2156.  
 Trimer and dimer synthesis 
 General procedures 
g) SPPS procedure 
Glycine loaded Wang resin (0.79 mmol.g-1, 100-200 mesh; carrier: polystyrene, crosslinked with 
1% DVB; 127 mg, 0.1 mmol) was swelled in anhydrous N-methyl-2-pyrrolidone (5 mL) 15 
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minutes prior to reaction. The appropriate monomers were dissolved in anhydrous N-methyl-2-
pyrrolidone and preactivated for coupling with Ghosez’s reagent (20% in chloroform) for 1 hour 
at 50°C. The reactions were carried out on a CEM Liberty Blue® automated microwave assisted 
peptide synthesizer, under microwave heating, following the conditions detailed in Table 5.1. 
Before each coupling, standard washing and deprotection (25% piperidine solution in N-Methyl-
2-pyrrolidone) cycles were carried out on the synthesizer. The samples on resin were washed with 
dichloromethane and ether. When required, cleavage off the resin was performed manually, using 
a 50% solution of TFA in dichloromethane (2 mL). TFA was removed by bubbling the solution 
with nitrogen and the solvent was evaporated under vacuum. 
Table 5.1: Conditions for SPPS depending on the type of scaffold. 
Scaffold 
Monomer 
(mmol) 
Ghosez 
(mmol) 
NMP (mL) Method 
Coupling 
time (mins) 
Temperature 
(°C) 
N-alkylated 0.25-0.5 0.25-0.5 5 Double 20 60 
O-alkylated 0.2 0.2 4 Single 30 50 
 
h) General click-chemistry procedure 
The trimer on resin was swelled in tetrahydrofuran (1 mL). Azidobiotin 72 (0.1 mmol), water (1 
mL), copper (II) sulphate (0.01 mmol) and sodium ascorbate (0.02 mmol) were added in that 
order. The reaction was carried out on a Stuart SB2 rotator for 16 hours. Addition of more 
equivalents of reagents was sometimes required to observe the completion of the reaction. The 
resin was then washed with water, dichloromethane and ether, then the trimer was cleaved off the 
resin using a 50% solution of TFA in dichloromethane (2 mL). TFA was removed by bubbling 
the solution with nitrogen and the remaining solvent was evaporated under vacuum. 
 Numbering system 
To simplify the NMR assignment of the trimers, the following nomenclature is used. The 
monomers constituting the dimers/trimers are considered separately, numbered 1 to 2 or 3 starting 
from the N-terminus, and the glycine is numbered 3 or 4. All the monomers are numbered 
following the same standard system: the carbon bearing the carboxylic acid is C1 and the one 
bearing the amine is C4. The carbon attached to the nitrogen is Cα, and the numbering of the 
aliphatic part of the chain continues with Cβ, etc. The numbering of the protons corresponds to 
the numbering of the carbons (Figure 5.1). For clarity purposes, the monomer number is added as 
a prefix to the proton number. 
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Figure 5.1: Examples of numbering of an N-alkylated trimer 1B2iBu3AG (left) and an O-
alkylated dimer 1B2AG (right). 
To avoid confusion, in the case of O-substituted N-alkylated compounds, a first number indicates 
the monomer bearing the side chain. A second number followed by O specifies the position of the 
functionalised oxygen. The aliphatic protons are numbered Hα, Hβ, etc. Triazole protons are 
indicated as HT (Figure 5.2). 
 
Figure 5.2: Numbering system for biotin (left) and FITC (right) orthogonal groups. 
 Synthesis of dimer and trimers (Chapter 2) 
4-(2-amino-5-((2-(3-aminopropoxy)-4-((carboxymethyl)carbamoyl)phenyl)carbamoyl)-
phenoxy)butanoic acid (50) 
Using the general SPPS procedure g). 24 (107 mg, 0.2 mmol); 36 (104 
mg, 0.2 mmol). The residue was purified using semi-preparative HPLC 
(eluent: acetonitrile/water: 0.5/9.5 to 9.5/0.5) and the product was 
collected as a pale cream powder (9.3 mg, 19%). H (500 MHz, DMSO-
d6) 9.01 (s, 1H, 2-NH), 8.48 (s, 1H, 3-NH), 8.11 (d, 1H, J = 8.3 Hz, 2-
H5), 7.55 (s, 1H, 2-H2), 7.50 (d, 1H, J = 8.3 Hz, 2-H6), 7.38 (s, 1H, 
1-H6), 7.36 (s, 1H, 1-H2), 6.71 (d, 1H, J = 8.1 Hz, 1-H5), 5.43 (s broad, 
2H, NH2), 4.18 (t, 2H, J = 5.5 Hz, 2-Hα), 4.05 (t, 2H, J = 6.5 Hz, 1-
Hα), 3.79 (d, 2H, J = 4.9 Hz, 3-Hα), 2.99 (t, 2H, J = 6.6 Hz, 2-Hγ), 2.29 (t, 2H, J = 6.6 Hz, 1-Hγ), 
2.08 - 2.15 (m, 2H, 2-Hβ), 1.96 - 2.01 (m, 2H, 1-Hβ). C (125 MHz, DMSO-d6) 175.5, 175.0, 
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171.6, 165.6, 165.4, 151.1, 148.9, 144.6, 142.2, 131.2, 130.8, 129.5, 129.4, 122.7, 120.9, 120.0, 
68.2, 67.3, 32.4, 27.7, 25.0, 24.8, 24.5. HRMS: Calcd. [M+H]+ (C23H28N4O8) m/z = 489.1907. 
Found [M+H]+ m/z = 489.1902. 
 
4-(2-(4-amino-3-(3-carboxypropoxy)benzamido)-5-((carboxymethyl)carbamoyl)phenoxy)-
butanoic acid (48) 
Using the general SPPS procedure g). 36 (208 mg, 0.4 mmol). The 
residue was purified using semi-preparative HPLC (eluent: 
acetonitrile/water: 0.5/9.5 to 9.5/0.5) and the product was collected as 
a pale cream powder (4.6 mg, 9%). H (500 MHz, DMSO-d6) 1H NMR 
(500 MHz, DMSO-d6)  ppm 8.98 (s, 1H, 2-NH), 8.77 (t, 1H, J = 5.9 
Hz, 3-NH), 8.14 (d, 1H, J = 8.4 Hz, 2-H5), 7.53 (d, 1H, J = 1.7 Hz, 2-
H2), 7.50 (dd, 1H, J = 8.5, 1.7 Hz, 2-H6), 7.36 (dd, 1H, J = 8.1, 1.9 
Hz, 1-H6), 7.34 (d, 1H, J = 1.9 Hz, 1-H2), 6.68 (d, 1H, J = 8.1 Hz, 1-H5), 4.14 (t, 2H, J = 6.2 Hz, 
2-Hα), 4.04 (t, 2H, J = 6.2 Hz, 1-Hα), 3.92 (d, 2H, J = 5.8 Hz, 3-Hα), 2.44 - 2.47 (m, 4H, 1-Hγ 
and 2-Hγ), 2.05 (quint., 2H, J = 6.7 Hz, 2-Hβ), 1.99 (quint, 2H, J = 6.7 Hz, 1-Hβ). C (125 MHz, 
DMSO-d6) 175.0, 171.8, 166.2, 165.1, 164.0, 148.8, 148.4, 144.4, 141.9, 130.6, 129.2, 129.1, 
121.2, 120.8, 119.0, 110.7, 110.3, 92.2, 79.4, 78.7, 24.9, 24.1, 16.8 (1 x C missing). 
HRMS: Calcd. [M+H]+ (C24H27N3O10) m/z = 518.1696. Found [M+H]+ m/z = 518.1769. 
 
(4-(4-amino-3-(sec-butoxy)benzamido)-3-(sec-butoxy)benzoyl)glycine (57) 
Dark yellow solid, prepared by Dr Sílvia Rodriguez-Marin. δH (500 MHz, 
DMSO-d6) 8.89 (s, 1H, 2-NH), 8.74 (t, 1H, 3-NH) 8.24 (d, 1H, J = 8.3 Hz, 
2-H5), 7.56 (d, 1H, J = 1.7 Hz, 2-H2), 7.52 (dd, 1H, J = 8.4 Hz, 1.7 Hz, 2-
H6), 7.32 (t, 1H, J = 1.5 Hz, 1-H2), 7.30 (d, 1H, J = 8.2, 1.9 Hz, 1-H6), 6.72 
(d, 1H, J = 8.1 Hz, 1-H5), 5.41 (s, 2H, 1-NH2), 4.56 (quint., 1H, J = 5.9 Hz, 
2-Hα), 4.40 (quint., 1H, J = 59 Hz, 1-Hα), 3.92 (d, 2H, J = 5.9 Hz, 3-Hα), 
1.79-1.61 (m, 4H, 1-Hβ, 2-Hβ), 1.32 (dd, 3H, J = 6.1 Hz, 1.3 Hz, 2-
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CHα(CH3)), 1.28 (dd, 3H, J = 6.1 Hz, 2.3 Hz, 1-CHα(CH3)), 0.99-0.94 (m, 6H, 1-Hγ, 2-Hγ). C 
(125 MHz, DMSO-d6) 171.4, 165.8, 164.4, 147.0, 143.5, 143.2, 131.7, 128.9, 121.1, 120.9, 119.9, 
112.8, 112.2, 76.0, 75.3, 41.3, 40.4, 28.6, 28.5, 19.1, 19.0 18.9, 9.6, 9.4. HRMS: Calcd. [M+H]+ 
(C24H32N3O6) m/z = 458.2286. Found [M+H]+ m/z = 458.2298. 
 
4-(4-((3-aminopropyl)amino)-N-(4-((carboxymethyl)carbamoyl)phenyl)benzamido)buta-
noic acid (55) 
Using the general SPPS procedure g). 43 (126 mg, 0.25 mmol); 45 (129 
mg, 0.25 mmol). The residue was purified using semi-preparative HPLC 
(eluent: acetonitrile/water: 0.5/9.5 to 9.5/0.5) and the product was collected 
as a pale cream powder (2.8 mg, 6%). H (500 MHz, DMSO-d6) 8.38 (t 
broad, 1H, 3-NH), 7.73 (d, 2H, J = 8.2 Hz, 2-H2), 7.15 (d, 2H, J = 8.1 Hz, 
2-H3), 6.99 (d, 2H, J = 8.6 Hz, 1-H2), 6.33 (d, 2H, J = 8.4 Hz, 1-H3), 6.11 
(s broad, 1H, 1-NH), 3.85 (d, 2H, J = 7.4 Hz, 2-Hα), 3.74 (d, 2H, J = 5.0 
Hz, 3-Hα), 3.02 (t broad, 2H, 1-Hα), 2.78 (t broad, 2H, 1-Hγ), 2.23 (t, 
J = 7.4 Hz, 2-Hγ), 1.65 - 1.77 (m, 4H, 1-Hβ and 2-Hβ). C (125 MHz, DMSO-d6) 199.6, 174.5, 
169.6, 168.2, 146.8, 131.6, 131.5, 130.0, 128.0, 121.8, 118.2, 85.9, 54.7, 51.9, 28.1, 27.6, 23.1, 
21.5, 12.5. HRMS: Calcd. [M+H]+ (C23H28N4O6) m/z = 457.2009. Found [M+H]+ m/z = 457.2092. 
 
4-(4-(4-((3-aminopropyl)-amino)-N-isobutylbenzamido)-N-(4-((carboxymethyl)carba-
moyl)phenyl)benzamido)buta-noic acid (53) 
Using the general SPPS procedure g). 43 (251 mg, 0.5 mmol); 39 (208 mg, 0.5 mmol); 45 (258 
mg, 0.5 mmol). The residue was purified using semi-preparative HPLC (eluent: 
acetonitrile/water: 0.5/9.5 to 9.5/0.5) and the product was collected as a pale cream powder (9.3 
mg, 15%). H (500 MHz, pyr.-d5) 9.27 (s broad, 1H, 4-NH), 8.21 (d, 2H, J = 8.3 Hz, 3-H2), 7.47 
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(d, 2H, J = 8.2 Hz, 2-H2), 7.35 (d, 2H, J = 8.8 Hz, 1-H2), 7.26 (d, 2H, 
J = 8.3 Hz, 3-H3), 7.13 (d, 2H, J = 8.3 Hz, 2-H3), 6.61 (d, 2H, J = 8.8 
Hz, 1-H3), 4.56 (d, 2H, J = 4.8 Hz, 4-Hα), 4.22 (t, 2H, J = 7.2 Hz, 3-
Hα), 3.86 (d, 2H, J = 7.3 Hz, 2-Hα), 3.41 (t, 2H, J = 6.6 Hz, 1-Hα), 3.34 
(t, 2H, J = 5.7 Hz, 1-Hγ), 2.67 (t, 2H, J = 7.4 Hz, 3-Hγ), 2.18 - 2.27 (m, 
4H, 1-Hβ and 3-Hβ), 1.91 - 1.99 (m, 1H, 2-Hβ), 0.90 (d, 6H, J = 6.7 Hz, 
2-Hγ). H (500 MHz, DMSO-d6) 8.47 (t, 1H, J = 5.3 Hz, 4-NH), 7.72 (d, 
2H, J = 8.5 Hz, 3-H2), 7.18-7.16 (m, 4H, 2-H2, 3-H3), 6.96 (d, 2H, J = 
8.4 Hz, 2-H3), 6.83 (d, 2H, J = 8.5 Hz, 1-H2), 6.19 (d, 2H, J = 8.8 Hz, 
1-H3), 3.87 (t, 2H, J = 7.4 Hz, 3-Hα), 3.70 (d, 2H, J = 5.3 Hz, 4-Hα), 
3.63 (d, 2H, J = 7.4 Hz, 3-Hγ), 3.06 (t br., 2H, 1-Hα), 2.87 (t, 2H, J = 6.9 Hz, 1-Hγ), 2.27 (t, 2H, 
J = 7.5 Hz, 2-Hα), 1.83-1.78 (m, 2H, 1-Hβ), 1.75-1.67 (m, 3H, 2-Hβ, 3-Hβ), 0.80 (d, 6H, J = 6.6 
Hz, 2-Hγ). C (125 MHz, DMSO-d6) 172.7, 169.4, 168.8, 165.2, 150.1, 145.3, 145.1, 133.9, 132.2, 
130.9, 128.7, 127.8, 127.3, 126.2, 121.2, 110.0,58.3, 56.1, 48.5, 43.2, 36.2, 31.1, 26.6, 26.0, 22.8, 
20.1 (1 x C missing).  HRMS: Calcd. [M+H]+ (C34H41N5O7) m/z = 632.3006. Found [M+H]+ 
m/z = 632.2992. 
 
4-((4-((4-((3-aminopropyl)(4-((carboxymethyl)carbamoyl)phenyl)carbamoyl)phenyl)(iso-
butyl)carbamoyl)phenyl)amino)butanoic acid (54)   
Using the general SPPS procedure g). 45 (258 mg, 0.5 mmol); 39 (208 
mg, 0.5 mmol); 43 (251 mg, 0.5 mmol). The residue was purified using 
semi-preparative HPLC (eluent: acetonitrile/water: 0.5/9.5 to 9.5/0.5) and 
the product was collected as a pale cream powder (10.2 mg, 16%). H (500 
MHz, pyridin-d5) 9.13 (s broad, 1H, 4-NH), 8.20 (d, 2H, J = 8.4 Hz, 3-
H2), 7.48 (d, 2H,  J = 8.4 Hz, 2-H2), 7.35 (d, 2H, J = 8.7 Hz, 1-H2), 7.25 
(d, 2H, J = 8.6 Hz, 3-H3), 7.14 (d, 2H, J = 8.6 Hz, 2-H3), 6.60 (d, 2H, J = 
8.8 Hz, 1-H3), 4.55 (d, 2H, J = 4.9 Hz, 4-Hα), 4.22 (t, 2H, J = 7.2 Hz, 3-
Hα), 3.86 (d, 2H, J = 7.5 Hz, 2-Hα), 3.44-3.26 (m, 4H, 1-Hα and 1-Hγ), 
2.68 (t, 2H, J = 7.3 Hz, 3-Hγ), 2.26-2.15 (m, 4H, 1-Hβ, 3-Hβ), 2.01-1.90 
(m, 1H, 2-Hβ), 0.90 (d, 6H, J = 6.6 Hz, 2-Hγ). H (500 MHz, DMSO-d6) 
8.38 (t, 1H, J = 5.5 Hz, 4-NH), 7.71 (d, 2H, J = 8.5 Hz, 3-H2), 7.19-7.16 (m, 4H, 2-H2 and 3-
H3), 6.96 (d, 2H, J = 8.4 Hz, 2-H3), 6.82 (d, 2H, J = 8.4 Hz, 1-H2), 6.17 (d, 2H, J = 8.7 Hz, 1-
H3), 3.86 (t, 2H, J = 7.0 Hz, 3-Hα), 3.64 (d, 2H, J = 6.5 Hz, 4-Hα and 3-Hγ), 3.06 (t br., 2H, 1-
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Hα), 2.86 (t, 2H, J = 7.0 Hz, 1-Hγ), 2.26 (t, 2H, J = 7.5 Hz, 2-Hα), 1.84-1.79 (m, 2H, 1-Hβ), 1.75-
1.68 (m, 3H, 2-Hβ, 3-Hβ), 0.81 (d, 6H, J = 6.6 Hz, 2-Hγ). C (125 MHz, DMSO-d6) 174.1, 173.1, 
169.5, 168.6, 165.1, 150.1, 145.3, 145.0, 134.0, 132.4, 131.0, 128.7, 127.8, 127.3, 126.2, 120.9, 
109.9, 56.1, 48.5, 43.8, 36.0, 31.2, 26.6, 25.8, 22.8, 20.1 (1 x C missing). HRMS: Calcd. [M+H]+ 
(C34H41N5O7) m/z = 632.3006. Found [M+H]+ m/z = 632.2984. 
 
 Synthesis of trimers (Chapter 3) 
 (4-(N-isobutyl-4-(N-isobutyl-4 (isobutylamino)benzamido)benzamido)benzoyl)glycine (58) 
Using the general SPPS procedure g). 39 (624 mg, 1.5 mmol). The product 
was collected as a brown solid (57.9 mg, 96%). H (500 MHz, DMSO-d6) 
8.82 (t, 1H, J = 5.9 Hz, 4-NH), 7.74 (d, 2H, J = 8.7 Hz, 3-H2), 7.19 (d, 2H, 
J = 8.5 Hz, 3-H3), 7.12 (d, 2H, J = 8.3 Hz, 2-H2), 6.93 (d, 2H, J = 8.5 Hz, 
2-H3), 6.86 (d, 2H, J = 8.7 Hz, 1-H2), 6.27 (d, 2H, J = 8.7 Hz, 1-H3), 3.90 
(d, 2H, J = 5.9 Hz, 4-Hα), 3.73 (d, 2H, J = 7.3 Hz, 3-Hα), 3.59 (d, 2H, J = 
7.3 Hz, 2-Hα), 2.79 (d, 2H, J = 6.6 Hz, 1-Hα), 1.79-1.71 (m, 2H, 1-Hβ and 
3-Hβ), 1.67-1.62 (m, 1H, 2-Hβ) 0.89 (d, 6H, J = 6.6 Hz, 1-Hγ), 0.85 (d, 
6H, J = 6.6 Hz, 3-Hγ), 0.77 (d, 6H, J = 6.6 Hz, 2-Hγ). C (125 MHz, 
DMSO-d6) 171.7, 169.8, 169.7, 166.1, 150.8, 146.2, 145.9, 133.8, 131.7, 
131.1, 129.2, 128.4, 127.7, 126.7, 122.0, 110.6, 56.4, 50.7, 41.6, 31.1, 27.8, 27.2, 27.1, 20.8, 20.5, 
20.4. HRMS: Calcd. [M+H]+ (C35H44N4O5) m/z = 601.3312. Found [M+H]+ m/z = 601.3416. 
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(4-(N-isobutyl-4-(N-isobutyl-4-(isobutylamino)benzamido)-3-(prop-2-yn-1-yloxy)benz-
amido)benzoyl)glycine (Alk-58) 
Using the general SPPS procedure g). 39 (415 mg, 1.0 mmol); 68 (234 
mg, 0.5 mmol). A small amount of the sample was cleaved off the 
resin with TFA (50% in dichloromethane) to confirm the structure. 
HRMS: Calcd. [M+H]+ (C38H46N4O6) m/z = 655.3417. Found [M+H]+ 
m/z = 655.3502.  
 
(4-(N-isobutyl-4-(N-isobutyl-4-(isobutylamino)benzamido)-3-((1-(3-(4-(2-oxohexahy-dro-
1H-thieno[3,4-d]imidazol-4-yl)butanamido)propyl)-1H-1,2,3-triazol-5-yl)methoxy)-
benzamido)benzoyl)glycine (Biotin-58) 
Using the general click-chemistry 
procedure h) on Alk-58. The product 
was collected as a brown solid (59.9 mg, 
60% over 2 steps). H (500 MHz, 
DMSO-d6) 8.82 (t, 1H, J = 5.3 Hz, 4-
NH), 7.98 (s, 1H, 2-3OT), 7.87 (s br., 1H, 
4-CO2H), 7.70 (d, 2H, J = 8.1 Hz, 3-H2), 
7.17 (d, 2H, J = 7.9 Hz, 3-H3), 7.06 (s, 
1H, 2-H2), 6.90 (d, 1H, J = 7.7 Hz, 2-
H5), 6.84 (d, 2H, J = 8.1 Hz, 1-H2), 6.67 
(d, 1H, J = 7.7 Hz, 2-H6), 6.36 (d, 2H, J 
= 7.9 Hz, 1-H3), 4.93 (s broad, 1H, 2-3ONH), 4.83 (s broad, 1H, 2-3ONH), 4.36 (t broad, 2H, J = 
6.2 Hz, 2-3OHβ), 4.29 (t broad, 1H, J = 6.2 Hz, 2-3OHλ), 4.11 (t broad, 1H, J = 6.2 Hz, 2-3OHλ), 
3.89 (d, 2H, J = 5.3 Hz, 4-Hα), 3.69 (d, 2H, J = 6.6 Hz, 3-Hα), 3.55 (s broad, 2H, 2-3OHδ) 3.15 
(s, 2H, 2-3OHα), 3.08 (d, 1H, J = 4.6 Hz, 2-3oHι), 3.05 (d, 2H, J = 5.3 Hz, 2-Hα), 2.81 (d, 2H, J 
= 6.6 Hz, 1-Hα), 2.77 (dd (under previous peak), 1H, J = 4.5 Hz, , 2-3OHκ), 2.53 (d, 1H, 
J = 4.9 Hz, 2-3OHκ), 2.07-2.05 (m, 2H, 2-3OHε), 1.95-1.91 (m, 2H, 2-3OHγ), 1.81-1.74 (m, 1H, 
1-Hβ), 1.73-1.66 (m, 1H, 3-Hβ), 1.63-1.56 (m, 2H, 2-3OHθ) 1.55-1.47 (m, 4H, 2-Hβ and  2-3OHζ), 
1.34-1.24 (m, 2H, 2-3OHη), 0.89 (d, 6H, J = 6.6 Hz, 1-Hγ), 0.84 (d, 6H, J = 6.4 Hz, 3-Hγ), 0.71 
(d, 6H, J = 6.4 Hz, 2-Hγ). c (125 MHz, DMSO-d6) 172.2, 171.1, 170.2, 169.8, 169.0, 165.8, 
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152.2, 148.1, 145.6, 142.0, 135.9, 133.6, 131.2, 129.4, 128.9, 127.8, 127.1, 124.4, 120.5, 113.5, 
111.5, 61.5, 61.1, 59.6, 59.3, 55.3, 54.7, 51.2, 48.4, 47.3, 41.1, 35.6, 35.1, 30.0, 28.1, 27.9, 27.0, 
26.7, 26.5, 25.1, 20.6, 20.1, 19.9. HRMS: Calcd. [M+H]+ (C51H68N10O8S) m/z = 981.4942. Found 
[M+H]+ m/z = 981.5024. 
 
5-(3-(3-(4-((5-((4-((carboxymethyl)carbamoyl)phenyl)(isobutyl)carbamoyl)-2-(N-isobutyl-
4-(isobutylamino)benzamido)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)propyl)ureido)-2-(6-
hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (Flu-58) 
Using the general click-chemistry procedure h) on 
Alk-58. The crude product was purified by semi-
preparative HPLC (eluent: acetonitrile/ water: 
0.5/9.5 to 9.5/0.5), the fractions were evaporated 
to afford Flu-58 as a dark red solid (3.5mg, 6%). 
H (500 MHz, DMSO-d6) 8.81 (t, 1H, J = 5.8 Hz, 
4-NH), 8.21 (s broad, 2-3OH2), 7.97 (s, 1H, , 2-
3OOH), 7.75 (d, 1H (under previous peak), 2-
3OH6), 7.73 (d, 2H, J = 8.5 Hz, 3-H2), 7.21 (d, 
2H, J = 8.5 Hz, 3-H3), 7.16 (d, 1H, J = 8.3 Hz, 2-
3OH5), 7.09 (s broad, 1H, 2-H2), 6.91 (d, 1H, J = 
8.1 Hz, 2-H5), 6.81 (d, 2H, J = 8.7 Hz, 1-H2), 6.68 
(d, 1H, J = 8.1 Hz, 2-H6), 6.65 (d, 2H, J = 2.3 Hz, 
2-3OH10), 6.59 (t, 2H, J = 8.7 Hz, 2-3OH9), 6.54 (dd, 2H, J = 8.7 Hz, 2.3 Hz, 2-3OH11), 6.22 (d, 
2H, J = 8.7 Hz, 1-H3), 5.82 (s broad, 1H, 1-NH), 4.93 (s broad, 1H, 2-3ONH), 4.87 (s broad, 1H, 
2-3ONH), 4.47 (t, 2H, J = 7.0 Hz, 2-3OHδ), 3.89 (d, 2H, J = 6.0 Hz, 4-Hα), 3.71 (d, 2H, J = 7.0 
Hz, 3-Hα), 3.55 (d, 2H, J = 5.3 Hz, 2-3OHβ), 2.77 (d, 2H, J = 6.6 Hz, 1-Hα), 2.15 (quint., 2H, J = 
7.0 Hz, 2-3OHγ) 1.77-1.68 (m, 2H, 3-Hβ and 1-Hβ), 1.54-1.49 (m, 1H, 2-Hβ), 0.87 (d, 6H, J = 6.6 
Hz, 1-Hγ), 0.84 (d, 6H, J = 6.8 Hz, 3-Hγ), 0.71 (d, 6H, J = 6.8 Hz, 2-Hγ). 13C NMR could not be 
acquired (not enough material). HRMS: Calcd. [M+H]+ (C62H65N9O11S) m/z = 1144.4558. Found 
[M+H]+ m/z = 1144.4598. 
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(4-(N-(cyclohexylmethyl)-4-(N-(naphthalen-2-ylmethyl)-4-(phenethylamino)benzamido)-3-
(prop-2-yn-1-yloxy)benzamido)benzoyl)glycine (Alk-59rev) 
 Alk-59rev was prepared following the general SPPS procedure. 
The readily available monomers “cyclohexane” 83 (232 mg, 0.5 
mmol) and “2-naphtyl” 84 (277 mg, 0.5 mmol) and “ethyl-Ph” 85 
(228 mg, 0.5 mmol) were used. A small amount of the sample was 
cleaved off the resin with TFA (50% in dichloromethane) to 
confirm the structure. HRMS: Calcd. [M+H]+ (C52H50N4O6) 
m/z = 827.3764. Found [M+H]+ m/z = 827.3769.  
 
 
 
 
5-(3-(3-(4-((5-((4-((carboxymethyl)carbamoyl)phenyl)(cyclohexylmethyl)carbamoyl)-2-(N-
(naphthalen-2-ylmethyl)-4-(phenethylamino)benzamido)phenoxy)methyl)-1H-1,2,3-triazol-
1-yl)propyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (Flu-59rev) 
 Using the general click-chemistry procedure h) 
on Alk-59rev. The crude product was purified by 
semi-preparative HPLC (eluent: acetonitrile/ 
water: 0.5/9.5 to 9.5/0.5), the fractions were 
evaporated to afford a dark red solid (1.7 mg, 
3%). H (500 MHz, DMSO-d6) 10.1 (s, 2H, 
2-3ONH), 8.17 (s, 1H, 2-3OH2), 7.81-7.80 (m, 
1H, 2-3OArH), 7.77 (d, 3H, J = 8.3 Hz, 2-3OArH), 
7.71 (d, 2H, J = 8.3 Hz, 2-3OArH), 7.64 (s, 1H, 
1-NH), 7.45-7.41 (m, 2H, 1-Ph), 7.25 (d, 4H, 
J = 4.3 Hz, ArH), 7.23 (d broad, 1H, J = 8.1 Hz, 
2-H5), 7.17-7.15 (m, 3H, 1-Ph), 7.09 (d, 1H, 
J = 8.3 Hz, 2-3OH6), 6.93 (d broad, 2H, J = 8.1 Hz, 1-H2), 6.70 (d, 1H, J = 7.1 Hz, 2-Hnapht.), 6.66 
(d, 2H, J = 2.3 Hz, 2-Hnapht.), 6.58 (d, 2H, J = 8.6 Hz, 2-Hnapht.), 6.55 (dd, 2H, J = 8.6 Hz, 2.3 Hz, 
2-Hnapht.), 6.32 (d, 2H, J = 8.6 Hz, 1-H3), 5.98 (s broad, 1H, 1-NH), 4.43 (t, 2H, J = 6.4 Hz, 
2-3OHγ), 3.93 (s broad, 2H), 3.71 (s broad, 2H), 3.25 (t broad, 2H, J = 7.3 Hz, 1-Hα), 3.09 (s, 
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broad, 2H), 3.02 (t broad, 1H, J = 5.6), 2.81 (t, 2H, J = 7.3 Hz, 1-Hβ), 2.01 (t broad, 2H, J = 6.4 
Hz, 2-3OHα), 1.67-1.63 (m, 3H), 1.63-1.58 (m, 3H, 3-Hβ,γ) 1.56-1.53 (m, 2H, 3-Hδ), 1.43 (s 
broad, 2H), 1.24 (s, 2H), 1.06 (s broad, 4H, 3-Hγ,δ), 0.90 (s broad, 1H), 0.87 (t, 2H, J = 7.3 Hz, 
3-Hε). 13C NMR could not be acquired (not enough material). 
 
 NMR experiments 
The NMR experiments performed to determine the conformation of the oligomers described in 
chapter 2 were acquired on a Bruker Advance 500, at 500 MHz and 26°C, using the following 
parameters: 
NMR Number of scan (ns) Relaxation time (d1) 
1H 64 2s 
COSY 8 1s 
NOESY 64 1s 
ROESY 200 1s 
 
 Selection of the Affimers 
 Phage Display 
The Affimer library was prepared by the BioScreening Technology Group in the School of 
Molecular and Cellular Biology.122 
 Screening 
For the selection against Biotin-58 to Biotin-63, four panning rounds were performed, described 
as follows: 
First panning round  
A colony of ER2738 E. coli cells was picked into 5 ml of 2TY media with 12 μg/mL tetracycline 
and incubated overnight at 37°C, 230 rpm. Streptavidin Coated (High Binding Capacity, Thermo 
Scientific) 8-well strips (4 wells per target) were pre-blocked with 300 μL 2x Blocking Buffer 
(BB) and incubated overnight at 37°C. The wells were washed 3 times with 300 μL phosphate 
buffered saline with 0.1% tween (PBST) and 100 μL 2x BB per well was added. 5 μL of phage 
library (1012 colony-forming units/mL) were pre-panned three times, and each time incubated at 
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room temperature for 40 minutes on a platform shaker (Heidolph VIBRAMAX 100, speed 3).  
5 μL of the biotinylated target (1 mM in DMSO) was added to the panning well and incubated for 
1 hour on the platform shaker. The phage was added to the target and incubated for 2 hours at 
room temperature on the platform shaker, while the overnight ER2738 culture was diluted 15 
times with 2TY media with 12 μg/mL tetracycline and incubated for 1 hour at 37°C, 230 rpm. 
The panning wells were washed 6 times with 300 μL of PBST and eluted with 100 μL of glycine 
(0.2 mM, pH 2.2) for 10 min, neutralised with 15 μL of Tris-HCl (1M, pH 9.1), further eluted 
with 100 μL of triethylamine (100 mM in PBS) for 6 minutes at room temperature, and neutralised 
with 50 μL of Tris–HCl (1 M, pH 7). The eluted phage were incubated with ER2738 for 1 hour 
at 37°C and 90 rpm and plated onto LB agar plates with 100 μg/mL carbenicillin (carb) and grown 
overnight. Colonies were scraped with 2TY media containing 100 μg/mL carbenicillin (2TYcarb) 
(5 mL then 2 mL), diluted to get a 8 mL solution with an absorbance at 600 nm of 0.2, and 
incubated for 1 hour at 37°C, 230 rpm. 0.32 μL of M13K07 helper phage (1014/mL) was added 
and the cells were incubated for 30 minutes at 37°C, 90 rpm. 16 μL of kanamycin (25 mg/mL) 
was added and the cells were incubated overnight at 25°C, 170 rpm. The phage were precipitated 
with 2 mL of polyethylene glycol (20% (w/v) PEG 8000, 2.5 M NaCl), incubated overnight at 
4°C, and re-suspended with 320 l of TE buffer (10 mM Tris, pH 8.0, 1 mM EDTA). 
Second panning round 
A colony of ER2738 E. coli cells was picked into 5 mL of 2TY media with 12 μg/mL tetracycline 
and incubated overnight at 37°C, 230 rpm. 20 μL of streptavidin beads (Dynabeads® MyOne™ 
Streptavidin T1, 10 mg/mL) were pre-blocked in 100 μL of 2x BB and incubated overnight at 
room temperature and 20 rpm. 
KingFisher Flex (Thermo Scientific) plate were pre-blocked: 
1 panning deep well 96 plate: 1 mL per well of 2x BB 
2 elution well 96 plates: 300 μL per well of 2x BB 
4 washing deep well 96 plates: 950 μL per well of 2x BB 
After 2 hours at 37°C, the buffer was removed from the panning and the elution plates. 100 μL 
per well of glycine (0.2 M, pH 2.2) was added to one elution plate and 100 μL per well of 
triethylamine (100 mM in PBS) was added to the other. The Streptavidin beads were centrifuged 
for 1 min at 800 xg, the buffer was removed, and the beads were re-suspended in 100 μL of fresh 
2x BB. 5 μL of the phage from the first panning round were pre-panned with 245 μL of 2x BB 
and 25 μL of pre-blocked Streptavidin beads. After incubating for 1 hour at room temperature at 
20 rpm, the phage were centrifuged at 800 xg for 1 minute and the supernatant was collected and 
pre-panned as previously. 15 μL of the biotinylated target (1 mM in DMSO) was bound to 50 μL 
of pre-blocked Streptavidin beads in 200 μL of 2x BB and incubated for 1 hour at room 
104 
 
temperature on the rotator (20 rpm). The biotinylated target was centrifuged for 1 minute at 
800 xg, and washed 3 times with 500 μL of 2x BB. The pre-panned phage were centrifuged for 1 
minute at 800 xg and the supernatant was transferred to the biotinylated targets, re-suspended, 
and transferred to the pre-blocked deep well plate. The beads were washed 4 times with 950 μL 
of PBST and eluted as previously on an automated KingFisher robotic platform (ThermoFisher). 
The eluted phage were neutralised, amplified and precipitated following the same procedure as 
for the first panning round. 
Third panning round 
A colony of ER2738 E. coli cells was picked into 5 ml of 2TY media with 12 μg/mL tetracycline 
and incubated overnight at 37°C, 230 rpm. Neutravidin Coated (High Binding Capacity, Thermo 
Scientific) 8-well strips (5 wells per target) were pre-blocked with 300 μL of 2x BB  and incubated 
overnight at 37°C. The wells were washed 3 times with 300 μL of PBST and 100 μl of 2x BB was 
added. 8 μL of the phage library from the previous round was pre-panned four times, and each 
time incubated at room temperature for 1 hour on a platform shaker. 10 μL of the biotinylated 
target (1 mM in DMSO) was added to the panning well, incubated for 1 hour on the platform 
shaker, and washed three times with PBST. The phage was then incubated with the target for 45 
minutes at room temperature on the platform shaker. The panning wells were washed 27 times 
with 300 μL of PBST and eluted with 100 μL of glycine (0.2 mM, pH 2.2) for 10 min, neutralised 
with 15 μL of Tris-HCl (1M, pH 9.1), further eluted with 100 μL of triethylamine (100 mM in 
PBS) for 6 minutes at room temperature, and neutralised with 50 μL Tris–HCl (1 M, pH 7). The 
phage were eluted, neutralised, amplified and precipitated following the same procedure as for 
the first panning round. 
Fourth panning round 
A colony of ER2738 E. coli cells was picked into 5 mL of 2TY media with 12 μg/ml tetracycline 
and incubated overnight in an orbital incubator at 37°C, 230 rpm. Streptavidin Coated (High 
Binding Capacity, Thermo Scientific) 8-well strips (6 wells per target) were pre-blocked were 
filled with 300 μl of 2x BB and incubated overnight at 37°C. The wells were washed 3 times with 
300 μL of PBST and 100 μl of 2x BB was added. 8 μL of the phage library from the previous 
round was pre-panned four times, and each time incubated at room temperature for 1 hour on a 
platform shaker. 10 μL of the biotinylated target (1 mM in DMSO) was added to the panning 
well, incubated for 1 hour on the platform shaker, and washed three times with 300 μL of PBST. 
The last well (blank) was washed with 300 μl of PBST. Half of the phage (100 μL) was transferred 
to the target and the other half (100 μL) transferred to the control well, and both were incubated 
for 45 minutes at room temperature on the platform shaker. The panning wells were washed 27 
times with 300 μL of PBST and the phage were eluted, neutralised, and amplified following the 
same procedure as for the first panning round. 
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 Phage ELISA 
50 L of Streptavidin (5 g/ml in PBS) was placed in a F96 Maxisorp Nunc-Immuno Plate 
(Thermo Scientific) and incubated for 4 hours at room temperature. The plates were blocked with 
200 µL of 2x BB, incubated overnight at 37°C, and washed with 300 μL of PBST. 50 μL of the 
biotinylated targets (1 M in of 2x BB) was placed in the 6 fist columns of the streptavidin-coated 
wells, and negative control wells were prepared in the 6 last columns with 50 μL of 2x BB. The 
plate was incubated for 1 hour at room temperature on a platform shaker and washed with 300 μL 
of PBST. 
48 individual colonies from the final panning round of the phage display were picked, inoculated 
into 96 well V bottom deep filled with 200 L of 2TYcarb, and incubated for six hours at 37°C, 
1050 rpm. 25 L of the cultures were transferred into a 96 well V bottom deep well plate with 
200 L of 2TY carb and incubated for 1 hour at 37°C, 1050 rpm. 10 L of a 1011/mL solution of 
M13K07 helper phage in 2TY carb was added to the freshly grown cultures and incubated for 30 
minutes at room temperature. 10 L of a kanamycin solution in 2TY carb (1.25 mg/mL) was 
added to the cultures and incubated overnight at room temperature, 750 rpm. The cultures were 
centrifuged at 3,500 xg for 10 minutes and 40 μL of the phage-containing supernatant was 
transferred to the previously prepared streptavidin-coated 96-well plates with 10 μL of 10x BB. 
The plate was incubated for 1 hour at room temperature on a platform shaker and washed with 
300 μL of PBST. 50 μl Anti-Fd-Bacteriophage-HRP (Seramun, diluted 1000 times in 2x BB from 
the commercial bottle) was added to the wells, the plate was incubated for 1 hour at room 
temperature on a vibrating platform shaker and washed 10 times with 300 μL of PBST. 50 μL of 
TMB (SeramunBlau® fast TMB/substrate solution) was added to the wells and allowed to 
develop for 3 minutes and the absorbance was measured at 620 nm on a Thermo Multiskan Ascent 
plate reader. The reading of the phage ELISA plates are shown below. 
 Sequencing 
When sequencing was required, the plasmid DNA was extracted from selected hits using a 
QIAprep Spin Miniprep Kit (QIAGEN), the plasmids were eluted with water (50 L) and an 
aliquot of DNA (15 L, 100 ng/l) was sent to Beckman Coulter Genomics for sequencing using 
a T7P primer. 
 Subcloning of the Affimers 
Preparation of the vector DNA 
20 µg of pET11a plasmid, 50 µL of CutSmart™ Buffer, 20 µg of NheI-HF™ and 20 µg of NotI-
HF™ were mixed together and sterile deionised water was added to a total volume of 500 µL. 
The mixture was incubated overnight at 37°C, and divided into 4 tubes of 125 µL each. 14 µL of 
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Antartic Phosphatase Reaction Buffer (10x) and 1 µL of Antartic Phosphatase were added to each 
tube which was then mixed and incubated for 15 minutes at 37°C. The Antartic Phosphatase was 
heat inactivated by incubating for 5 minutes at 65°C, and the resulting digested vector was 
purified on a 0.7% agarose gel (80 V), using 14 µL of 10x Orange G Loading Dye for each tube. 
The purified vector was extracted from the gel using a Gel Extraction kit (QIAGEN) and stored 
at -20°C for later use. 
PCR Amplification of the Affimer DNA sequence from the Phagemid Vector 
For each Affimer, one 0.2 mL PCR tube was set up, containing: 13.8 µL of sterile water, 5 µL of 
5X Phusion HF Buffer, 0.2 µL of dNTP Mix (25 nM), 0.75 µL of DMSO, 2 µL of forward primer 
(5’ – ATGGCTAGCAACTCCCTGGAAATCGAAG, 10 µM), 2 µL of reverse primer (5’ – 
TACCCTAGTGGTGATGATGGTGATGC, 10 µM), 0.25 µL of Phusion DNA Polymerase, and 
1 µL of Template DNA. 
The following PCR cycle were conducted: 
Initial denaturation: 98°C, 30 seconds; 1 cycle 
Denaturation: 98°C, 20 seconds; Annealing: 54°C, 20 seconds; Extension: 72°C, 20 seconds; 30 
cycles 
Final extension: 72°C, 10 minutes, 1 cycle 
0.5 µL of DpnI was added to the PCR mixture and incubated for 1 hour at 37°C. The amplified 
DNA was purified on a 2% agarose gel with 1 µL of 10x Orange G Loading Dye, and the purified 
DNA was extracted from the gel using a Gel Extraction kit (QIAGEN), and eluted with 15 µL of 
sterile water. 
Digestion of the PCR-amplified Affimer sequence with NheI and NotI Restriction Enzymes 
3 µL of sterile water, 6 µL of CutSmart™ Buffer, 0.5 µL of NheI-HF™ and 0.5 µL of NotI-HF™ 
were added to each PCR product, mixed and incubated overnight at 37°C. The digested products 
were purified using a PCR Clean-up kit (QIAGEN) and eluted with 50 µL of sterile water. 
Ligation of the NheI-NotI digested inserts into the pET11a vector 
2 L of 10X T4 DNA Ligase Buffer, 75 ng (0.4 L) of Vector DNA, 25 ng (0.5 L) of Insert 
DNA and 0.5 L of T4 DNA Ligase were mixed, with 3 L of sterile water. The mixture was 
incubated overnight at room temperature. 
Transformation of ligations into E.coli 
1 L of the ligation mix was added to 10 L of Agilent Technologies XL1-Blue supercompetent 
cells and the resulting mixture was incubated on ice for 30 minutes, heat shocked in at 42°C for 
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45 seconds, and incubated on ice for 2 further minutes. 190 L of Recovery Media was added 
and the mixture was incubated at 37°C for 1 hour with shaking at 225 – 250 rpm. 100 L of this 
transformation mixture was plated onto LB agar plates containing 100 g/mL of carenicilin (LB 
carb plates) and incubated overnight at 37°C. 
Purification of the subcloned plasmid DNA 
Two single colonies were picked for each subcloning, and grew overnight in 4 mL of 2TY carb 
at 37°C, 230 rpm. The plasmid DNA was then extracted using a QIAprep Spin Miniprep Kit 
(QIAGEN), eluted with water (50 l) and an aliquot of DNA (15 L, 100 ng/L) was sent to 
Beckman Coulter Genomics for sequencing using a T7P primer. 
 Expression and purification of the Affimers 
Transformation of Adhion-pET11a Plasmid into BL21Star (DE3) E.Coli 
0.5 L of DNA was aliquoted into 50 L of BL21 Star cells on ice, and incubated for 30 minutes 
on ice. The tubes were heat shocked in a 42°C water bath for 45 secods and further incubated 2 
minutes on ice. 200 L of Recovery Media was added and the mixture was incubated at 37°C for 
1 hour with shaking (230 rpm). 10 L of the transformation mixture was plated with 100 L of 
Recovery Media on LB carb plates and incubated overnight at 37°C. 
IPTG-induced Expression of the Affimer 
One transformant was picked from the overnight culture and grown in 2 mL of 2TY carb + 1% 
glucose overnight at 37°C, 230 rpm. 1 mL of this culture was added to 50 mL of LB carb and 
grown to an OD of 0.8 (3 hours). 25 L of 1M IPTG was added, and the culture was incubated 
for an additional 6 hours at 30°C, 150 rpm. The cells were harvested by centrifugation at 4,816 xg 
for 15 minutes and the supernatant was poured off. 
Extraction and purification of the Affimer 
The pellets were resuspended in the following buffer: 100 L of BugBuster 10X Protein 
Extraction Reagent (Novagen), 0.4 L of Benzonase Nuclease 25 U/l (Novagen), 10 L of Halt 
Protease Inhibitor Cocktail 100X (ThermoScientific), and 889.6 L of Lysis Buffer. The mixture 
was incubated for 20 minutes at room temperature on a rotator (Stuart SB2), then incubated for 
20 minutes in a 50°C water bath, and centrifuged at 16,000 xg for 20 minutes. 
300 L of Amintra Ni-NTA resin (Expedeon) was resuspended in 1 mL of Lysis Buffer and 
centrifuged at 1,000 xg for 1 minute and the buffer was aspirated off. The previous supernatant 
containing soluble proteins were added to the resin and incubated at room temperature for 2 hours 
on a rotator (Stuart SB2). The resin was centrifuged at 1,000 xg for 1 minute and the supernatant 
containing unbound proteins was collected and stored at -20°C. The resin was transferred to a 
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Pierce Centrifuge Column (ThermoScientific) and washed with Wash Buffer (50 mM NaH2PO4, 
500 mM NaCl, 20 mM imidazole, pH 7.4) by gravity filtration until the concentration of the 
exiting Wash Buffer was consistently below 0.09 mg/mL (approx. 20 mL). The resin was then 
eluted by incubating for 10 minutes with 500 L of Elution Buffer (50 mM NaH2PO4, 500 mM 
NaCl, 300 mM imidazole, 20% glycerol, pH 7.4) and the eluted Affimer was collected. 
 Purity assessment of the Affimers 
A 15% SDS-PAGE gel was performed to check the purity of the proteins: 
 
HRMS traces were recorded: 
58-AF8 Calcd. 12259.78. Found: 12259.0982. 
 
58-AF17: Calcd. 12727.33 Found. 12726.3642. 
 
109 
 
58-AF26: Calcd. 12283.89. Found. 12283.2020. 
 
59-AF1: Calcd. 12109.68. Found. 12109.1284. 
 
59-AF23: Calcd. 12285.86. Found. 12285.1838. 
 
59-AF25: Calcd. 12252.94. Found. 12252.2021. 
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The conformational analyses by molecular modelling of O-1B2BG (47), O-1B2AG (49) and 
N-1A2BG (56) are shown in Figure A1. The anti conformation is observed for O-1B2BG (47), 
which was stabilised by H-bond between the amine group and the carboxylic acid from the glycine 
at the bottom, and the oxygen from the O-alkylation at the top (Figure A1a). For O-1B2AG (49), 
a syn conformation was preferred, stabilised by side-chain/side-chain H-bonding (Figure A1b). 
Finally, N-1A2BG (56) adopted a trans conformation, thanks to side-chain/side-chain interactions 
(Figure A1c). 
 
Figure A1: Conformational analyses of a) O-1B2BG (47), b) O-1B2AG (49) and c) N-1A2BG (56). 
 
The self-assembly was also studied by modelling the interactions between pairs of oligoamides: 
 
Figure A2: Self-assembly of O-alkylated dimers: a) O-1B2BG (47) with O-1A2AG (48), 
b) O-1B2AG (49) with itself, and O-1B2AG (49) with O-1A2BG (50). 
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O-1B2BG(1) – O-1A2AG(2) (Figure A2a): amine of residue 1 of dimer 1 (O-1B2BG(1)) bound to 
both carboxylic acids of dimer 2 (O-1A2AG(2)). The amine on residue 2 of dimer 1 (O-1B2BG(1)) 
bound to the carboxylic acids from the glycine of both dimers (O-1B2BG(1) and O-1A2AG(2)). 
The carboxylic acid of residue 2 on dimer 2 (O-1A2AG(2)) acid also bound to the middle amide 
on dimer 1 (O-1B-CONH-2BG(1)). 
O-1B2AG(1) – O-1B2AG(2) (Figure A2b): the complex was symmetrical: the amine on residue 1 
of dimer 1 (O-1B2AG(1)) bound to the carboxylic acid side chain from the same dimer, on residue 
2 (O-1B2AG(1)) and the middle amide group of dimer 1 (O-1B-CONH-2AG(1)), as well as both 
the glycine and the bottom amide of dimer 2 (O-1B2A-CONH-G(2)). 
O-1B2AG(1) – O-1A2BG(2) (Figure A2c): the carboxylic acid on residue 1 of dimer 2 (O-
1A2BG(2)) bound to the amine on residue 2 of the same dimer (O-1A2BG(2)), which bound to both 
the carboxylic acid of residue 2 and the glycine of dimer 1 (O-1B2AG(1)). The carboxylic acid of 
residue 2 on dimer 1 also bound to the middle amide of dimer 2 (O-1A-CONH-2BG(2)). The amine 
of residue 1 on dimer 1 (O-1B2AG(1)) bound to the glycine and bottom amide of dimer 2 (O-1A2B-
CONH-G(2)). 
 
Figure A3: Self-assembly of N-alkylated dimers: a) N-1B2AG (55) with N-1A2BG (56) and b) N-
1A2BG (56) with itself. 
N-1B2AG(1) – N-1A2BG(2) (Figure A3a): the amine of residue 1 on dimer 1 (N-1B2AG(1)) bridged 
between the carboxylic acid of residue 2 on dimer 1 (N-1B2AG(1)) and glycine on dimer 2 
(N-1A2BG(2)). The amine of residue 2 on dimer 2 (N-1A2BG(2)) bridged between the carboxylic 
acid on residue 1 of dimer 2 (N-1A2BG(2)) and the carboxylic acid of residue 2 on dimer 1 
(N-1B2AG(1)). Finally, the carboxylic acid of residue 1 on dimer 2 (N-1A2BG(2)) also bound to 
the bottom glycine amide bond on dimer 1 (N-1B2A-CONH-G(1)). 
N-1A2BG(1) – N-1A2BG(2) (Figure A3b): two conformation were observed, both symmetrical. In 
both cases, the carboxylic acid of residue 1 on dimer 1 (N-1A2BG(1)) bound to the amine of residue 
121 
 
2 on both dimers (N-1A2BG(1) and N-1A2BG(2)). In one case, the glycine was not involved; 
otherwise, the glycine of dimer 1 (N-1A2BG(1)) bound to the top aniline of dimer 2 
(N-1-NH-A2BG(2)). 
The summary of all interactions observed by molecular modelling is presented in Table A1. 
Table A1: Summary of all interactions observed in molecular modelling. The group involved in 
an interactions are denoted in bold, → symbolises a H-bond, & means “binds to both”. 
Complex Interactions 
O-1B2BG(1) – 
O-1A2AG(2) 
O-1B2BG(1) → O-1A2AG(2); 
O-1B2BG(1) → O-1B2BG(1) → O-1A2AG(2); 
O-1A2AG(2) → O-1B-CONH-2BG(1). 
O-1B2AG(1) – 
O-1B2AG(2) 
O-1B2AG(1) → O-1B2AG(1) → O-1B-CONH-2AG(1) & O-1B2A-CONH-G(2); 
O-1B2AG(2) → O-1B2AG(2) → O-1B-CONH-2AG(2) & O-1B2A-CONH-G(1). 
O-1B2AG(1) – 
O-1A2BG(2) 
O-1A2BG(2) → O-1A2BG(2) → O-1B2AG(1); 
O-1B2AG(1) → O-1A-CONH-2BG(2); 
O-1B2AG(1) → O-1A2B-CONH-G(2). 
N-1B2AG(1) – 
N-1A2BG(2) 
N-1B2A-CONH-G(1) → N-1A2BG(2) → N-1A2BG(2) → N-1B2AG(1) → N-
1B2AG(1) → N-1A2BG(2)). 
N-1A2BG(1) –
N-1A2BG(2) 1 
N-1A2BG(1) → N-1A2BG(1) → N-1A2BG(2) → N-1A2BG(2). 
N-1A2BG(1) –
N-1A2BG(2) 2 
N-1A2BG(1) → N-1A2BG(1) → N-1A2BG(2) → N-1A2BG(2); 
N-1A2BG(1) → N-1-NH-A2BG(2) 
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The full NOESY spectra of N-1A2iBu3BG (54) and N-1B2iBu2AG (53) in pyridine are shown in 
Figure A4 and Figure A6. The observed correlations suggest the cis conformation (purple circle), 
and no indication of the presence of trans conformation is observed (orange), showing the 
compounds are fully cis. The full NOESY spectra of N-1A2iBu3BG (54) and N-1B2iBu2AG (53) in 
DMSO are shown in Figure A5 and Figure A7, confirming the cis conformation (purple circle) – 
the correlation or absence of correlation between 1-H2 and 2-Hα, or 2-H2 and 3-Hα could not be 
observed due to the superimposition of 2-H2 and 3-H3 in the 1H spectra. 
 
Figure A4: NOESY of N-1A2iBu3BG (54) in pyr-d5, 16 mM, 500 MHz. 
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Figure A5: NOESY of N-1A2iBu3BG (54) in DMSO-d6, 40 mM, 500 MHz. 
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Figure A6: NOESY of N-1B2iBu3AG (53) in pyr-d5, 16 mM, 500 MHz. 
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Figure A7: NOESY of N-1B2iBu2AG (53) in DMSO-d6, 40 mM, 500 MHz. 
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Bottom: N-1A2iBu2BG (54), top: N-1B2iBu2AG (53), middle: 1:1 mixture of both; 16 mM, 500 MHz, 
pyr-d5. 
 
Figure A8: 1H NMR of  N-1A2iBu2BG (53, top), N-1B2iBu2AG (54, bottom) and their 1:1 mixture 
(middle) in pyr-d5, 16 mM, 500 MHz. 
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Figure A9: NOESY NMR of O-1sBu2sBuG (57), highlighting the two conformation syn (orange 
circle) and anti (purple circle). 
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Figure A10: NMR dilutions of O-1sBu2sBuG (57) from 40 to 1 mM, DMSO-d6, 500 MHz. 
